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Abstract
Dysregulation of blood glucose (BG) levels can occur due to either the influence of stress hormones
and external drugs in the critical care setting or a developed resistance/impairment to glucose
regulation as seen in Type 1 and 2 diabetes. In both situations, external intervention to assist in
regulating BG levels has shown reductions in morbidity and mortality. A method that has proven
effective in the Intensive Care Unit (ICU) is the Stochastic TARgeted (STAR) model-based Glycemic
Control (GC) protocol, which uses a combination of population-based stochastic models and Model
Predictive Control (MPC) to provide safe and effective GC. Therefore, this type of GC may prove
effective for out-patient type 2 diabetics. However, STAR is developed for the ICU setting and
more specifically the model used, the Intensive Control Insulin Nutrition Glucose (ICING) model,
is developed based on ICU patient characteristics and is not necessarily suitable for the out-patient
setting.
This research attempts to develop the STAR protocol and associated ICING model for better
suitability of out-patient GC. In-silico and clinical data sets are used to review and develop control
methodologies and technologies, and their impact on GC and outcomes. In addition, a clinical trial
is designed to better understand the metabolic behaviour of type 2 diabetes, and enable improved,
safer control of this cohort.
The representation and use of the ICING model-based insulin sensitivity (SI) is investigated and
validated in the ICU setting. Linear interpolation of sparse BG measurements was proven to give
the best estimate of intermediate BG dynamics (mean RMSE 0.39 mmol/L). Minutely resampling
of the interpolated BG measurements is shown to give the best representation of GC performance
characteristics when GC protocol’s measurement frequency and sparsity varied. The stochastic
model currently used by the STAR controller was shown to represent both the Christchurch, New
Zealand (NZ) and Gyula, Hungary ICUs well, with the SI variability being within the controllers
current stochastic model bounds consistently equal to or greater than 90% of the time. Piece-wise
polynomial approximations of the stochastic models were shown to represent the currently used
bounds well (All R2 values > 0.96) and provide approximately equal GC performance (% time in
ii
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BG band 4.4-8.0 mmol/L, 87.9% vs. 87.5%, P=0.67) and safety (BG measurements < 2.22 mmol/L,
9 vs. 8 measurements, P=1.0) in virtual trials. Continuous 2nd order B-spline basis function (BF)
were shown to provide a much more physiologically realistic representation of SI , providing a more
realistic fit of point of care (PoC) measurement error compared to the currently used stepwise
constant BFs (fitting error variance, 2.4% current zeroth order B-spline BF and 6.0% 2nd order
B-spline BF vs. 6.0% published glucometer error).
The STAR GC protocol’s clinical data was reviewed and areas of improvement investigated. Clinical
data from STAR in Christchurch Hospital ICU, NZ and Kálmán Pándy Hospital ICU, Gyula,
Hungary since 2011 was reviewed in terms of GC performance and safety. STAR was shown to
provide approximately equally effective GC performance (86.6% and 87.1% time BG 4.4-8.0 mmol/L,
respectively) and safety (patients with BG < 2.22 mmol/L, 4/292 Christchurch, and 2/47 Gyula) in
both cohorts. These results were confirmed by the high data entry compliance of information entered
into the STAR tablets, with the lowest compliance being in the feed related interventions (86.5%
enteral nutrition (EN), and 88.2% parenteral nutrition (PN) interventions). STAR was also shown
to be able to provide higher or equivalent feed rates than the best unit surveyed in an international
survey of 150 ICUs over 20 different countries, while still providing safe and effective GC. Stepped by
day feeding protocols were shown to provide a promising alternative to the currently used variable
feeding regime used by STAR, significantly reducing workload (19.8% reduction) while maintaining
GC performance and safety. A new STAR framework was developed, Stochastic Model Predictive
(STOMP) control, that evaluated interventions based on a series of cost functions with longer 6
hour prediction horizon, improving clinical flexibility and allowing for longer 4 hour measurement
intervals. All of these outcomes serve to validate and the modelling and control methods for GC in
less acute wards and eventually the out-patient setting.
The type 2 diabetic and pre-diabetic out-patient was investigated to develop our understanding of
their metabolic characteristics. An clinical trial was designed assess the effects of exogenous basal
insulin on endogenous insulin production of type 2 diabetic and pre-diabetic out-patients, and collect
data related to their metabolic characteristics. The initial results of this trial are presented and the
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trial logistics discussed. No major concerns of patient discomfort and safety arose from the initial 2
patients. These results are a first step towards addressing type 2 diabetes using model-based basal
insulin support early in treatment.
Overall, the research performed in this thesis was designed to develop the STAR protocol and
associated ICING model for GC of out-patients with pre-diabetes and type 2 diabetes. Linearly
interpolation of sparse raw BG measurements allows for more accurate identification of model-based
SI and minutely or hourly resampling provides a fairer assessment of GC protocol performance.
The stochastic models used by STAR capture patient SI variability well, while being approximately
generalizable across independent cohorts, and can be approximated with piece-wise polynomial
functions for easier use. A considerably more physiologically realistic representation of the ICING
model’s SI was created, better representing BG measurements and the associated error. The
developed representation of SI would more optimally interpolate sparse, variable data and could
be easily applied to sparser out-patient data. The STAR GC protocol was simplified and made
more clinically flexible, while maintaining GC performance and safety, through the introduction
of piece-wise polynomial stochastic models, a minimal workload stepped feeding protocol, and cost
function control methodology (STOMP). Ultimately, these analyses better validate and incrementally
simplify STAR for the out-patient setting. Finally, a clinical trial was designed and implemented to
investigate basal insulin therapy for out-patients with pre-diabetes or type 2 diabetes, and develop
our understanding of this cohort’s metabolic characteristics.
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Chapter 1
Introduction
Multiple organs and physiological processes are involved in the regulation of BG. Dysregulation of BG
levels occur whenever there are irregularities in the function of any key metabolic regulatory organs
and/or hormones. It has been shown, in a range of clinical settings, that this BG dysregulation is
associated with increased morbidity and mortality.
These irregularities may be due to either the influence of stress hormones and external drugs in
the critical care setting or a developed resistance/impairment to glucose regulation as seen in type
2 diabetes. In both situations, external intervention to assist in regulating BG levels has shown
benefit. A method that has proven effective in the ICU is the STAR model-based GC protocol.
The ICU GC protocol STAR is unique in the respect that it is a tablet-based protocol which uses
a combination of population based stochastic models and MPC to provide safe and effective GC.
This type of GC has not been attempted before in the out-patient setting. STAR is developed for
the ICU setting and more specifically, the model used, the ICING model, is based on ICU patient
characteristics. Therefore, for the STAR GC protocol to be used in an out-patient setting the model
and GC methodology needs to be adapted.
This research attempts to develop the STAR protocol and associated ICING model for better
suitability of out-patient GC. In-silico and clinical data sets are used to review and develop control
1
CHAPTER 1. INTRODUCTION 2
methodologies and technologies, and their impact on GC and outcomes. In addition, a clinical trial
is designed to better understand the metabolic behaviour of type 2 diabetes, and enable improved,
and safer control of this cohort.
1.1 The Glucose Regulatory System
Energy for cellular function in the body is created by the food in which we consume. The majority
of the cells within the body are able to source this energy from fats, proteins, and carbohydrates.
However, the brain is only able to source energy from glucose (carbohydrates). Thus, the accessibility
of glucose is critical to brain functionality. This section discusses the how the body processes and
regulates glucose, and the reasons why BG levels are strictly regulated.
1.1.1 Metabolic Energy
The majority of functions performed by a cell require energy (free energy) to create a chemical
equilibrium shift and favour a forward reaction. A cell generates free energy by hydrolysing Adenosine
Tri-phosphate (ATP), stores of free energy [1]. The body can source ATP from either fats, proteins
or carbohydrates. However, the Central Nervous System (CNS) requires the majority of its energy to
come from glucose (Carbohydrates) [2]–[4] as protein and fat oxidisation into ATP is not as efficient
[5]. ATP created from carbohydrates is commonly created by the oxidation of glucose in the cytosol
of a cell (Glycolysis), where each molecule of glucose creates 36 molecules of ATP [1], [5].
Carbohydrates commonly found in food can be either simple sugars (monosaccharides), such as
glucose, fructose, and galactose, double sugars (disaccharides), such as sucrose, lactose, and maltose
or sugar stores (polysaccharides), such as glycogen and starch. However, all disaccharides and
polysaccharides are eventually broken down into monosaccharides before being used to create energy
[1]. As carbohydrates make up approximately 45% to 65% of a typical individuals diet [4], [6], they
provide the most common source of glucose used by a cell in the generation of ATP.
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1.1.2 Glucose Transportation
Carbohydrates consumed by a person are typically absorbed through the small intestine. Monosaccharides
can be absorbed directly, whereas polysaccharides need to be broken down by the mouth and stomach
digestive enzymes, and disaccharides are broken down by enzymes on the luminal wall of the small
intestine [7]. Once absorbed through the small intestine, monosaccharides then enter the blood
stream to be distributed throughout the body and capillary beds for cellular energy usage and
storage in the CNS, liver (glycogen stores), muscles, adipose tissue and kidneys [8]–[11].
Glucose diffuses into the interstitial fluid through small spaces between endothelial cells, lining the
capillary beds, with changes in hydrostatic and osmotic pressure [12]–[14]. However, in the brain
the endothelial cells are joined by tight junctions and thus glucose is unable to easily diffuse through
(Blood brain barrier), and are instead actively moved by transport proteins (GLUT-1) inside the
endothelial cells, into the brain interstitial fluid [15], [16]. Once glucose is within an interstitial fluid,
it is actively transported into cells by the means of 1 of 4 different glucose transport proteins, GLUT
1-4 [17], [18].
1.1.3 Glucose Regulation
As the availability of glucose in the blood is critical to brain and body functionality, complications
occur if the BG levels are too low (Hypoglycaemia) [19]–[21] or too high (Hyperglycaemia) [22]–[24].
Hypoglycaemia is associated with increased risk of micro- and macro- vascular events, coronary
events [25], [26], and mortality [27], [28] in individuals with diabetes, and increased morbidity
[29], length of stay [30], organ dysfunction [30], [31], and mortality [29], [30], [32]–[36] in critically
ill individuals. In addition, hyperglycaemia or very high BG levels are associated with increased
morbidity [37]–[39], and mortality [40] in individuals with diabetes, and increased morbidity [29],
[41]–[47], length of stay [44], [46], and mortality [41]–[45], [47]–[51] in critically ill individuals.
If hyperglycaemia occurs, the body’s natural response is the release of insulin, a peptide hormone
secreted by the Islets of Langerhans within the Beta cells of the pancreas [52]. Insulin binds to
a surface receptor of a cell, signalling a complex cascade of inter-cellular events, activating the
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GLUT4 transport protein to move to the plasma membrane and facilitating glucose uptake [53].
Insulin activates glucose uptake in adipose tissue, the liver (hepatic tissue), and muscle cells and its
conversion into glycogen stores (glycogenesis) [17], [18]. In addition, the release of insulin suppresses
the endogenous production of glucose by the liver and/or, to a lesser extent, the kidneys [54], [55].
The body’s natural response to hypoglycaemia is the production and release of glucose into the
blood stream. This endogenous glucose production is facilitated in 2 ways, by gluconeogenesis
and/or glycogenolysis. Gluconeogenesis is the creation of glucose from non-glucose substrates,
predominantly lactate, glutamine and alanine, and glycogenolysis is the breakdown of glycogen
stores into glucose [56]. Gluconeogenesis occurs in both the liver and the kidneys, and is triggered
by the release of hormones, such as adrenaline, by the brain [9]. Whereas, glycogenolysis has only
been seen to occur in the liver and is triggered by the release of glucagon by the pancreas [57], [58].
There is currently much debate over the body’s ’natural’ BG level, and it is likely patient-specific
[59]. From birth, BG has been seen to be naturally regulated between 3.5-5.5 mmol/L [59]. However,
this level tends to increase with age [60]. In addition, regulating BG between 4.4 and 8.0 mmol/L
has shown associated benefits for non-diabetes ICU patients [61]–[63]. These results imply healthy
individuals have a ’natural’ BG level around these reported ranges. In contrast, an individual
with diabetes can have a higher ’normal’ BG level specific to the glycaemic thresholds they have
developed over time and exposure [59], [62], [64], although a lower glycated haemoglobin (HbA1c)
of 7% (approximately 8.3 mmol/L BG average [65]) results in improved outcomes for individuals
with diabetes [66]. A summary diagram of the body’s natural BG regulation process can be seen in
Fig. 1.1.
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Figure 1.1: Summary of blood glucose regulation processes.
The ability for insulin to bind to cellular receptors and the presence of the many important signalling
molecules involved in activating the GLUT4 transport protein significantly contributes to an individual’s
SI SI , also known as insulin resistance [53], [67], [68]. An individual’s overall SI is determined by
the ability to uptake glucose, given an amount of insulin. The current gold standard measure of SI
is the hyper-insulinemic, euglycaemic clamp test [69]. However, various other simpler model-based
tests have been developed to approximate SI [70]–[72].
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1.2 Glycaemic Control in the Intensive Care Unit
In the ICU a patient’s body is under considerable stress as it attempts to recover from severe injury
and/or infection. The body’s stress response during this period can be broken up into 2 key stages,
the ebb and flow phase [73]. Each stage results in a variation of hormones present, and metabolic
responses. This section discusses how glucose regulation is effected by this stress response and
clinical treatment in an ICU patient’s recovery, and how external intervention can be used to assist
in BG regulation.
1.2.1 Hyperglycaemia in the Critical Care
The ebb phase typically lasts around 12-24 hours after injury [73], during which a large release
of noradrenaline, adrenaline, and cortisol [74]–[77] causes significant changes in metabolic responses
[39], [74], [77], [78]. High levels of these stress hormones stimulate hepatic and muscle glycogenolysis,
and hepatic gluconeogenesis [79]–[81]. They also depress glycogenesis [82], [83] and inhibit insulin
secretion [74], [84]. The combined effects result in ’stress-induced’ hyperglycaemia [39], [85]–[88].
The flow phase occurs immediately after the ebb phase, and typically peaks around 3-5 days
post-injury, subsiding by 7-10 days [39], [89]. During this period metabolism and catabolism is
increased, resulting in increased glucose turnover and gluconeogenesis unresponsive to hyperglycaemia
[90], [91]. In addition, the cortisol levels, a stress hormone, can remain relatively high during this
phase [39], [92], [93].
In addition to body’s the stress response, factors such as undiagnosed diabetes [94], commonly
used metabolism modifying drugs [39], [95]–[97], and excessive feeding of high glucose content
nutrition [98]–[100] can also increase the prevalence of hyperglycaemia in the ICU. There is also
a significant amount of inter- and intra- patient variability in the influence of these factors. As a
result, ’stress-induced’ hyperglycaemia is commonplace in the ICU [41], [51], [86].
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1.2.2 Glycaemic Control Benefits and Limitations
The observed relationship between hyperglycaemia morbidity and mortality outcomes in the ICU
[29], [41]–[51] has led to GC protocols being regularly employed in the ICU. Studies have shown that
safe, effective GC that modulates exogenous insulin and/or nutrition, significantly reduces mortality
and morbidity [29], [30], [51], [101], [102], organ failure [31] and cost of care [103], [104]. However,
due to the variability in a patient’s response [103], [105]–[111], some GC protocols have failed to
provide consistently safe and effective outcomes, resulting in an uncertainty of the benefits of GC
[103], [109], [112]–[117].
Two common characteristics of ineffective GC protocols are hypoglycaemia and glucose variability.
Both outcomes are independently associated with increased mortality [34]–[36], [118]–[120]. This
failure of GC is usually a result of the GC protocol’s inability to handle the highly complex, variable
and dynamic stress response of an ICU patient. Specifically, the intra- and inter- patient variability
[121]–[125]. These variabilities are the fundamental reason why safe, effective GC is difficult.
1.2.3 Glycaemic Control Protocols
ICU GC protocols are commonly in the form of either a flowchart or model-based prediction software
(MPC), which recommend insulin treatments to clinical staff. The simplest example of a flowchart
GC protocol is the sliding scale protocol in [29], which recommends an insulin dose based on difference
between the patients current BG and target BG level. Since this early sliding scale, many more
complex flowchart algorithms have been developed, which also consider factors, such as the of rate
of change of BG and previous interventions given [101], [109], [126], [127].
In contrast, MPC GC protocols use a physiological model and clinical measurements to define patient
specific metabolic behaviour. This information is then used to choose the intervention resulting in
the optimum future BG [128]–[130]. In addition, some GC protocols also modify the amount of
exogenous nutrition given to a patient in addition to the insulin dose administered [101], [128].
However, the implications of this added control input are still unknown and it is currently heavily
debated as to whether lowering an ICU patient’s caloric intake is beneficial [131]–[136].
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For a GC protocol to be effective in the ICU it needs to:
1. Effectively lower or eliminate mild and moderate hyperglycaemia (BG > 8.0 mmol/L, BG >
10.0 mmol/L).
2. Have a low occurrence of mild and severe hypoglycaemia (BG < 4.0 mmol/L, BG < 2.2
mmol/L) [137].
3. Have a low workload and compliant protocol [137]–[141]. Often assessed by BG measurement
rates.
A GC protocol which best meets these characteristics should provide the best time in the intermediate
BG band of 4.0-8.0 mmol/L and have the best chance of improved patient outcomes [61], [142],
[143], as seen previously in [29]. These characteristics are compared for 7 different GC protocols in
Table 1.1. As the statistics reported in literature are inconsistent, Table 1.1, direct comparison of the
GC protocols is difficult. However, as the distribution of BG is typically log-normal [144]–[146] an
estimate of the GC protocol’s CDF can be made by fitting a log-normal distribution to the statistics
published. The estimated log-normal CDF of BG for each protocol can be seen in Fig. 1.2.
Note these fitted log-normal CDF’s only approximate study performance and can vary due to a
small changes in the reported statistics. In addition, the results reported for the LOGIC-1 protocol
[130] were intention to treat, and thus are positively biased when directly compared to only treated
patients in other GC protocols. Moreover, only the mean and standard deviation was able to be used
for fitting from the very limited statistics presented in the NICE-SUGAR study and appendices[126].
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Figure 1.2: Comparison of the estimated log-normal CDF for each GC protocol based on the
respective statistics reported in literature.
Table 1.1: Comparison of 7 different Glycemic Control (GC) protocols found in literature in terms of performance, safety and workload using the
respective statistics published.
Protocol STAR [128] LOGIC [130] SGC (eMPC) [129] SPRINT [101] NICE-SUGAR [126] GLUCONTROL [109] Comp. Guideline [127]
Type MPC MPC MPC Flowchart Flowchart Flowchart Flowchart
# Patients 10 149 20 371 3016 536 66
Per-patient Performance
BG Mean (mmol/L) 6 5.9 6.8 6 6.39 6.5 6.5
BG SD (mmol/L) 0.93 0.5 0.4 1.3 1 2 1.2
% Time >10 2.48 - - - - - -
% TIB 4.4-8.0 89.4 - 83.4 - - - -
% TIB 4.4-6.1 - 68.6 - 53.9 - 39.3 -
% Time <4.4 2.48 - 2.13 9 - 5.1 -
% Time <2.2 0 - 0 0.1 - 2.4 -
Safety
% Patients <3.9 - 32.2% - - 87.1% - -
% Patients <3.3 - 14.1% 20.0% - - - -
% Patients <2.2 0.0% 0.0% - 5.2% 6.8% 8.7% 0.0%
Workload
Meas. Int. (Hours) 1.8 (-) 2.2 (0.4) 2.0 (0.4) 1.6 (0.3) - - -
*Model Predictive Control (MPC) blood glucose (BG), standard deviation (SD), time in band (TIB). Data presented in Mean (standard deviation (SD))
where appropriate.
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As seen in Fig. 1.2 and Table 1.1, in general, MPC is more effective and safer GC compared
to flowchart based GC protocols, spending more time in the targeted region while reducing the
occurrence of hypoglycaemia. The rates of hypoglycaemia (BG < 2.22 mmol/L) reported by
SPRINT, NICE-SUGAR and GLUCONTROL although low, are relatively high compared to the
other GC protocols. In addition, the estimated percentage of hyperglycaemia (BG > 10.0 mmol/L)
from Fig. 1.2 is relatively high for both the Space GlucoseControl and Computerized Guideline,
showing that they are not as effective in lowering a patients BG compared to the other GC protocols.
As mentioned earlier, the results presented in LOGIC-1 were based on the intention to treat [130],
therefore the reported statistics and estimated BG distribution could be heavily biased by "stable"
patients with normal glycaemia. Thus, STAR provides the most promising ICU GC protocol of the
protocols reviewed. However, deeper investigation into the STAR GC performance is required before
improvements can be made. In addition, the very low number of patients (N = 10) on the STAR
protocol limit the validity of the results presented.
1.2.4 Stochastic Targeted (STAR) Glycaemic Control
The tablet-computer-based STAR GC protocol provides patient-specific GC [128], [147] by using a
clinically evaluated pharmaco-kinetic and pharmaco-dynamic model of the insulin-glucose system
(ICING) [31], [148] and a cohort based model of SI variability [145], [149] to compute optimal insulin
and nutrition interventions. STAR aims to maximise time in the targeted band (4.4-8.0 mmol/L)
and nutrition, while maintaining a maximum 5% risk of BG < 4.4 mmol/L [128], [147]. STAR offers
1-3 hourly BG measurement frequencies to allow nurses to manage workload [150], [151]. STAR
has been the standard of care in Christchurch Hospital ICU, Christchurch, New Zealand and in
the Kálmán Pándy Hospital ICU, Gyula, Hungary since 2011. Note the predecessor of STAR in
Christchurch was the paper-based, model-derived [152], SPRINT GC protocol [31], [101].
Starting criteria for STAR is two successive BG measurements over 8.0 mmol/L within a 4-h
period. After 2 measurements are taken, integral based parameter fitting [153] is used to identify
a model-based SI , Eq. (1.1) [31], [148], [154]. This value is used with a stochastic model, based on
historical data [128], [145], [149], [155], to find the 5th and 95th percentile potential future SI values.
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These 5th and 95th percentile SI values and a potential insulin and nutrition intervention are then
used to forward-simulate the likely resulting 5th and 95th percentile BG values for that intervention.
This process is iterated over many possible interventions to find the intervention with 5% risk of BG
< 4.4-4.6 mmol/L and the maximum likely time in the targeted 4.4-8.0 mmol/L band [128], [147].
STAR modifies nutrition rate depending on the bounds of predicted potential behaviour, with a
preference to increase insulin before reducing nutrition, and to raise nutrition whenever possible [128],
[147]. STAR modulates this nutrition rate between 30-100% of the caloric goal, with a maximum
step change of ±30% caloric goal per hour [128]. American College of Chest Physicians (ACCP)
guidelines are used to determine patient-specific daily caloric goal intake of 25 kcal/kg/day [156].
STAR is a risk-based MPC GC protocol. It is the only GC protocol to use an estimated future
variability, and thus risk, in dosing. It thus doses to an outcome BG range, rather than an outcome
target BG level.
The ability for the ICINGmodel to capture metabolic physiology directly determines the physiological
representation, and inter- and intra- patient variability of SI . Prior iterations of the ICINGmodel-based
SI were shown to correlate well with clamp measurements [72], [157]. However, as the physiological
model has developed, the modelled representation of SI and it’s variability will have changed and
consequently influenced the GC performance of the STAR protocol. Therefore, improving the
modelled representation of SI is the best route to improving GC performance, and safety.
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1.2.4.1 ICING Model
The current model used by STAR is a variant of the Intensive Control Insulin Nutrition Glucose
(ICING) model [148], [158], defined:
Ġ(t) = −pGG(t)− SI(t)G(t)
Q(t)
1 + αGQ(t)
+ P (t) + EGP − CNS
VG
(1.1)














P (t) = min(d2P2, Pmax) + PN(t) (1.4)
Ṗ1(t) = −d1P1 + EN(t) (1.5)
Ṗ2(t) = −min(d2P2, Pmax) + d1P1 (1.6)
uen(G) = min(max(umin, k1G(t) + k2), umax) (1.7)
Where the key variables are described in Table 1.2, and the remaining model parameters, rates and
constants are described in [122], [148].
Table 1.2: Key variables of the ICING model.
Variable Unit Description
G(t) mmol/L Blood glucose concentration
I(t) mU/L Plasma insulin concentration
Q(t) mU/L Interstitial insulin concentration
P (t) mmol/min Glucose appearance in plasma from dextrose intake
SI(t) L/(mU.min) Insulin sensitivity
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1.2.4.2 Insulin Sensitivity (SI)
For an out-patient, under steady state conditions, SI is considered to be relatively constant. Due to
an ICU patient’s hormonal stress response and/or the drugs given, SI can fluctuate significantly over
short periods of time [31], [112], [122], [145]. Therefore, a dynamic interpretation of SI is required
to model a patient’s behaviour in the ICU.
A key characteristic of the STAR GC protocol, and main contributor to its performance, is its
ability to capture inter- and intra- patient variability through hour to hour changes in a patient’s
SI . However, as SI is fitted hourly, step-wise, to historical data it may also erratically change to
best fit the historical BG data, capturing BG, as well as any non-modelled dynamics. Therefore,
again, an improvement in the ICING model could reduce erratic, non-physiological SI fluctuations,
narrow the bands of the stochastic model, and, ultimately, improve the GC performance and safety
of STAR.
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1.3 Glycaemic Control in Out-patients with type 2 Diabetes
The prevalence of diabetes mellitus in the world has dramatically increased over the past decade. In
NZ alone, prevalence has increased from 3.8% to 5.5% (approximately 193,000 People) [159], with
approximately 800 people dying from it each year (92% having type 2 diabetes) [159], [160]. This
section discusses diabetes and how type 2 diabetes is currently managed in NZ.
1.3.1 Type 1 and 2 Diabetes
Type 1 diabetes, is commonly the result of autoimmune destruction of the insulin producing cells
in the pancreas (Beta cells in Islets of Langerhans) as a result of a genetic or other disorder
[161]. The rate of destruction of Beta cells varies between individuals, but ultimately results in
little-to no endogenous insulin production [162]. This loss results in the need for exogenous insulin
administration to mimic normal insulin secretion behaviour and lower BG levels.
In contrast, type 2 diabetes is more commonly the result of poor health, sedentary lifestyles, and
diet, leading to both insulin resistance and deficient insulin secretion. Consequently, BG levels
are not able to be lowered to euglycaemia via normal physiological mechanisms [162]. As type 2
diabetes is a progressive condition, treatment depends on an individual’s specific progression. This
issue complicates treatment of type 2 diabetes due to the unknown and variable ability someone
with type 2 diabetes has to control their own BG levels with normal physiology, before requiring
insulin or other drugs.
Prolonged hyperglycaemia, resulting from untreated diabetes can lead to blindness (Retinopathy),
amputation (Neuropathy), cardiovascular disease, stroke and renal disease [163]–[167]. Moreover, it
has been shown that a significant reduction in a diabetic individual’s morbidity and mortality can
be achieved if euglycaemia can be maintained [165], [168]. However, because this level of control
has proven very difficult, the tangible costs of type 2 diabetes alone in NZ are estimated to be over
$1.3 billion and to rise to $1.7 billion by 2021 [169], [170], approximately 0.5% of GDP [171] and
approximately 10% of the total health care budget [172]. This cost is unsustainable and must be
reduced.
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Currently in NZ, diagnosis of type 2 diabetes is based on an HbA1c ≥ 6.7% (50 mmol/mol) or a
fasting BG ≥ 7.0 mmol/L or one BG measurement ≥ 11.1 mmol/L [173]. An HbA1c measurement
provides a weighted measure of the mean BG over the previous 120 days [174]. However, as
these tests are only typically performed when there is a suspicion of diabetes, it is estimated
that approximately 25% of people with diabetes are undiagnosed [175]. It has been shown if type
2 diabetes is treated early and ’effectively’, its progression can be stopped and normo-glycaemia
maintained [176]–[178], reducing the associated long term health care costs. However, if not treated
effectively their condition completely degrades, secreting only negligible amounts of endogenous
insulin. At this point their condition becomes very similar to an individual with type 1 diabetes in
terms of treatment [179]–[181]. However, such treatment is difficult, costly and often not robust.
Hence, as the progression of type 2 diabetes can be slowed or stopped, preventative treatment is the
focus of this research. A simplified summary of the progression of type 2 diabetes, based on similar
figures in [176], [178], [182]–[185], can be seen in Fig. 1.3. The goal of this research is to intervene
as early as possible in this figure at the beginning of impaired glucose tolerance (IGT), rather than
later in the type 2 diabetes region.
Figure 1.3: Simplification of the changes in glucose regulatory factors throughout the progression
of type 2 diabetes, including normal glucose tolerance (NGT) and impaired glucose tolerance
(IGT), and its current relationship to the treatments offered based on data published in [176],
[178], [182]–[184]
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1.3.2 Current type 2 Diabetes Treatment
After the initial diagnosis of type 2 diabetes, the first treatment option suggested is generally a
significant change in lifestyle (Diet and exercise) to try and lower the individual’s HbA1c [162], [181].
If the targeted HbA1c is not met after 3 months assistive oral medication is recommended. Currently
in NZ, the initial recommended medication for type 2 diabetes is Metformin (Apotex NZ Ltd., New
Zealand) [186]. Metformin acts by increasing the biological efficiency of available insulin, increasing
glucose uptake and effectively increasing a patient’s sensitivity to insulin [181], [187] and has been
proven effective in improving patient outcomes [188]. If the individual’s condition still deteriorates
they are prescribed Sulphonylurea [186], which acts as a steroid to increase pancreatic insulin output
(endogenous insulin secretion) [181], [189]. However, it has been shown that 9 years after the
prescription of sulphonylurea, approximately 80% of patients will still require insulin treatment [25],
[190], where insulin is the last available treatment option [183], [186], [191]. The approximate timing
of suggested treatments in relation to the progression of diabetes can be seen in Fig. 1.3.
Insulin therapy for type 2 diabetes usually begins with basal insulin support [179]–[181], where basal
insulin is a subcutaneous long acting analogue of insulin which is designed to be released slowly and
steadily into the blood stream over a long period of time (Typically 16+ hours). The most common
commercially available forms of long acting insulin are Glargine and Detemir. Basal insulin support is
designed to mimic the normal basal insulin production of the pancreas [179]–[181], [183], leaving the
pancreas free to act around meals. The most common dosing regime is a sliding scale proportional to
the individual’s morning fasted BG week long average [180], [192], [193]. However, if an individual’s
condition deteriorates even further they are prescribed both basal and rapid acting insulin to try and
mimic the entire functionality of the pancreas [179]–[181], [183], similar to type 1 diabetes treatment
[183], [194].
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1.3.3 Basal Insulin Therapy
Many studies have discussed and compared the treatment options for type 2 diabetes, specifically
with regard to GC and beta cell degradation (endogenous insulin secretion). It has been shown in
many cases that insulin treatment is more effective in preserving beta cells [25], [168], [195], [196],
improving lipid metabolism [197]–[200], and achieving GC targets [25], [164], [190], [201] compared
to other offered treatments. This result may be due to those receiving oral medication still requiring
relatively high endogenous insulin secretion rates from the pancreas, leading to the eventual ’fatigue’
of the pancreas [161], [202]–[205]. Therefore, treating type 2 diabetes with basal insulin, much earlier,
may allow the pancreas to ’rest’, reducing endogenous insulin secretion [206], [207], in between meals
and thus allowing it to act more appropriately during meals [208]. Ultimately, this approach suggests
basal insulin therapy may improve GC and reduce the degradation of an individual’s pancreatic
functionality.
However, basal insulin therapy is usually only offered after an individual with type 2 diabetes
condition has substantially progressed, and beta cell endogenous insulin production is likely significantly
depleted Fig. 1.3 [176]. This is largely due to the perceived risks associated with insulin therapy
[64], [66], [164], [180], [201], [209]–[211]. Therefore, starting basal insulin therapy this late in the
progression of type 2 diabetes may not allow the potential benefits of insulin therapy to be best
utilised. One study in particular looked at prescribing people age 50 and over, with evidence of
cardiovascular disease and newly detected or established diabetes (pre-diabetes or early stage type
2 diabetes), with standard practice diabetes treatment or one daily injection of Glargine (Basal
insulin) for 6 years [212]. The primary outcomes were in regard to cardiovascular events, and no
conclusive outcome was found. However, a 41% reduction in the number of people with newly
diagnosed diabetes was seen in the group which used basal insulin therapy compared to those who
were receiving standard treatment [193], despite having significant numbers who quit this therapy
or were not fully compliant. This outcome strongly emphasises the potential benefits of early basal
insulin therapy, which is otherwise not used clinically.
Although basal insulin therapy may have potential benefits, it increases the risk of hypoglycaemia
19 1.3. GLYCAEMIC CONTROL IN OUT-PATIENTS WITH TYPE 2 DIABETES
if not taken correctly [64], [66], [164], [180], [201], [209]–[211]. It thus is avoided clinically for this
reason [191], [201]. In addition, there is also a negative stigma around starting insulin therapy, as
individuals and the physician feel they have failed [183]. Therefore, before early basal insulin therapy
can be offered, a very safe and effective dosing protocol needs to be developed. Only then can the
potential benefits of early basal insulin therapy be realized.
As seen by the GC offered in the ICU (Section 1.2.3) one of the best ways to ensure a safe
dosing regime, is by using a MPC GC protocol, preferably in this case, a risk-based protocol. To
allow a MPC GC protocol to be formed, an effective model needs to be developed which includes
subcutaneous insulin action and any other added relevant dynamics. Facilitating the prediction of
glucose trends in type 2 diabetes and the expected endogenous insulin response to exogenous insulin
are particularly important needs, not already available for this model or any other.
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1.4 Summary
Glucose is found in carbohydrates and is essential to body and brain functionality as it is the most
common and efficient source of ATP energy for cellular function. Thus, the body naturally regulates
BG with the pancreas, liver, and kidneys to a likely patient-specific BG level. If an individual’s
BG level is too low or high (hypo- and hyper- glycaemia, respectively) complications arise, which
have been shown to be associated with increased morbidity and mortality in both diabetes and
critically illness. Hyperglycaemia is common place in the ICU, and significant benefits have been
shown if BG levels are controlled to ’normal’ levels. Model-based GC techniques have been shown
to provide effective GC, with the STAR framework performing particularly well. However, a more
comprehensive review of the STAR GC is first required to understand the strengths and weaknesses
of the GC protocol. In addition, improvements in the physiological resemblance of the ICING
model’s interpretation of SI could improve STAR’s GC and applicability to ward and out-patient
GC. Therefore, the first part of this research is focused on reviewing and developing the STAR GC
protocol, and updating the modelled representation of SI with the future expectation of providing
GC to the wards and out-patients.
Finally, it is commonplace for an individual with type 2 diabetes condition to degrade on oral
medication and insulin treatment is typically only offered after significant damage to the pancreas
has occurred. This choice is made almost exclusively due to the risks of hypoglycaemia associated
with insulin therapy. However, potential benefits may exist if insulin is used as an initial treatment
option for GC. Therefore, the second part of this research is focused on gathering the required
information to be able to safely use basal insulin therapy as the initial treatment option for type 2
diabetes in the wards.
Part I:
Improving the validity and
representation of Insulin
Sensitivity





Interpretation of Retrospective BG
Measurements
2.1 Background
ICU GC protocols use a range of different BG measurement intervals (0.5 – 4 hours), which may vary
during treatment depending on a patient’s condition [101], [109], [129], [213]–[215]. In particular,
most GC protocols measure more frequently when out of their targeted band and less frequently
when patients are ’stable’ [101], [109], [129], [213]–[215]. Therefore, the BG information recorded by
each GC protocol has varying degrees of sparsity, with raw BG measurements commonly being more
dense in areas of poor control. This variability and skewness of the raw BG measurements make
fair assessment and comparison of GC protocol performance difficult, particularly when one key GC
performance criteria is percentage of time within, above, and below the targeted BG range [137].
A common method to improve assessment fairness is to interpolate between BG measurements and
sample the interpolated trace [101], [129], [214], [215]. However, the best interpolation technique
and sample rate is still unknown.
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Similarly, many insulin-glucose models use parameter identification techniques that require a similar
approximation of the continuous BG dynamics [112], [216]–[221], which can significantly skew model
fit and ‘accuracy’. Many models and identification methods use linear interpolation between BG
measurements as a first approach [148], [219]. However, the accuracy of linear interpolation in
comparison to other interpolation techniques has not been assessed.
This chapter investigates the accuracy of 5 different BG interpolation methods over clinically typical
2, 3 and 4 hour measurement intervals. The effect of various sampling rates on the interpolated BG
trace is also assessed in relation to the outcome of key GC performance statistics.
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2.2 Methods
2.2.1 Patient Data
Patient data from patients treated with SPRINT and STAR in Christchurch Hospital ICU, NZ
between 2005-2016 is used [101], [147], [215]. The Upper South Regional Ethics Committee, NZ
granted approval for the retrospective audit, analysis and publication of the Christchurch Hospital
patient data.
SPRINT is a paper based GC protocol which offers 1-2 hour measurement intervals and allows the
time of BG measurements to be recorded to an hourly resolution [101]. In contrast, STAR is a
tablet-based GC protocol which offers 1-3 hours measurement intervals and allows the time of BG
measurements to be recorded to a resolution in minutes [147], [215]. To assess which interpolation
technique best captures the intermediate BG dynamics a representative sample of the densely
measured SPRINT cohort data is used [101]. The effect of sampling rate on GC performance
statistics is assessed using the more sparsely measured STAR cohort data.
2.2.2 Interpolation techniques
Five interpolation techniques are investigated, separated into 2 types of interpolation:
1. Piece-wise interpolation: The interpolated trace goes through all of the measurement points.
2. Fitted interpolation: The interpolated trace is a combination of BF, best fit to the measured
data points, as a whole, but can miss any individual point.
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2.2.2.1 Piece-wise interpolation
Three Piece-wise interpolation techniques are investigated; linear, spline and cubic interpolation.
Linear interpolation: Data between BGmeasurements is assumed to be a linear line. Thus, continuous
BG data is represented by a piece-wise 1st order polynomial.
Spline interpolation: Data between BG measurements is assumed to follow a spline using not-a-knot
end conditions, continuous in both 1st and 2nd derivative. Thus, continuous BG data is represented
by cubic interpolation of the spline.
Cubic interpolation: Data between BGmeasurements is assumed to be a cubic relationship, continuous
in only the 1st derivative. Thus, continuous BG data is represented by a piece-wise cubic polynomial.
Figure 2.1: Example of the Piece-wise interpolation techniques being investigated.
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2.2.2.2 Fitted interpolation
Two fitted interpolation techniques are investigated, each using 1st and 2nd Order B-spline BF
fitting. Fitted interpolation is used to incorporate an approximation of the measurement error,
and restrict over fitting rapid changes in the interpolated BG trace due to measurement error and
outliers. BF widths were varied to investigate the best fit with this criteria. The interpolated BG
trace, G(t), is identified as the linear combination of BFs, Φn(t), minimizing the error between the
identified and clinically measured BG:

Φ1(t1) Φ2(t1) · · · Φn(t1)































Where: Φn = basis function n, γn = fitted basis function coefficient n,
BGmeas(tm) = BG measurement at time tm, n = number of basis functions,
m = number of BG measurements, Ginterp(t) = interpolated BG trace
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1st Order B-spline BFs: The BG interpolation trace is made from a linear combination of 1st Order
B-spline BFs. 1st Order B-spline BFs are based on the piece-wise function defined in [222]. When




KW KW × i < t < KW × (i+ 1)
1− t−KW ×(i+1)KW KW × (i+ 1) < t < KW × (i+ 2)
0 Otherwise
(2.3)
Where: Φi = basis function i, KW = knot width, i = basis function number
2nd Order B-spline BFs: The BG interpolation trace is made from a linear combination of 2nd
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Φi(t) = 1 ∀t (2.5)
Where: Φi = basis function i, KW = knot width, i = basis function number
n = number of basis functions
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The B-spline BFs are in fixed locations, occurring every instance of the chosen KW, and overlap.
The inherent property of the B-spline BFs in Eq. (2.5) ensures no underlying waveform can be
induced into the fitted data and a constant value can also be represented. An illustrative example
of the fitted interpolation techniques can be seen in Fig. 2.2.
Figure 2.2: Example of the fitted interpolation techniques (1st and 2nd Order B-spline BFs) being
investigated.
2.2.3 Interpolation Analysis
To assess which interpolation technique best represents the overall BG dynamics, both the fit
to the measured and intermediate BG dynamics needs to be considered. To achieve this goal, a
proportion of BG measurements are removed from the dense SPRINT BG measurement sets before
interpolation. The removed BG measurements are then compared to the post-interpolation BG
estimate for independent validation. Clinical patient BG data was thinned to create 2, 3 and 4 hour
periods between measurements, similar to what would be expected clinically from STAR [215] and
many other protocols [101], [109], [129], [213], [214].
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Removed BGmeasurements are referred to as ‘hidden’ measurements, and the remaining measurements
’observed’ measurements. For a BG measurement to be removed it must meet the following criteria:
1. Can be removed without causing a gap between the neighbouring measurements greater than
the measurement period being investigated (2, 3 and 4 hours).
2. The interventions (nutrition and insulin) given to the patient over this period are constant.
Intervention changes would only be able to be captured by a model and would not usually
occur without a prior BG measurement.
An example of this removal process is shown in Fig. 2.3, and Table 2.1 summarises the resulting
sparse SPRINT BG data.
Figure 2.3: Example of BG measurement removal from patient data to maximize 2 hour BG
measurement intervals.
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Table 2.1: Thinned patient data sets for each measurement interval to be used for evaluation of
techniques.
Measurement interval 2 hr 3 hr 4 hr
No. Patients 29 31 34
No. Observed Meas. 3296 2922 1862
No. Hidden Meas. (% Total) 853 (20.6%) 1404 (32.5%) 2512 (57.4%)
All interpolation techniques are investigated in regard to goodness of fit of both the observed
and hidden data. A range of BF KWs are used for the fitted interpolation techniques, based on
Eq. (2.3) and Eq. (2.4). Goodness of fit is assessed by using Root Mean Square Error (RMSE)
between the interpolated trace and the observed and/or hidden measurements. There is no observed
measurement error for the piece-wise interpolation techniques as the piece-wise functions start and
end at the observed measurements, so the hidden measurements are the sole form of validation.
For fitted interpolation, hidden measurement RMSE is expected to be larger than the observed
measurement RMSE as observed measurements are used in the identification process. The error for
hidden measurements validates the ability of the interpolation technique to capture the intermediate
BG dynamics over time intervals relevant to GC protocols. The RMSE for both the observed and
hidden measurements are then compared to the error expected from the point of care measurement
device used in the SPRINT study, Arkray Super-GlucocardTM II glucometer (Arkray, Minnesota,




To assess which sampling rate of the pre-determined interpolated BG trace best captures GC
performance, key GC performance statistics are compared with various sampling intervals (1 and 60
minute, and original clinical measurement intervals). The statistics compared are:
• BG mean, median and standard deviation.
• Percentage of time in the targeted range (4.4-8.0 mmol/L).
• Percentage of time BG < 2.2 mmol/L, BG < 4.4 mmol/L, and BG > 10 mmol/L.
The percentage of time above, below or in band statistics can only approximated with the provided
data as the percentage of raw or resampled measurements with in a certain range. All sampling of the
interpolated BG trace starts from the first BG measurement and is therefore heavily dependent on
the interpolation technique used. Non-parametric statistics are used exclusively due to the typically
skewed distributions of BG data. P-values were computed using the Mann-Whitney rank-sum test
for all continuous data. P-values <0.025 are considered statistically significant after Bonferroni
correction [224] for multiple comparisons.
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2.3 Results
2.3.1 Piece-wise interpolation
Fig. 2.4 shows the cohort hidden RMSE for the 3 piece-wise interpolation techniques (Linear, Spline
and Cubic). Linear interpolation gave the best estimate of the hidden measurements, having a mean
RMSE of 0.39 mmol/L across the 3 intervals investigated. As expected, the longer the measurement
interval interpolated, the further the interpolated trace deviated from the hidden BG measurements.
Figure 2.4: Piece-wise interpolation hidden measurement RMSE.
2.3.2 Fitted interpolation
Fig. 2.5 and Fig. 2.6 presents the cohort RMSE, for both hidden and observed measurements of the
1st and 2nd order B-spline BFs, respectively. In both figures, as the KW is increased the observed
measurement RMSE is shown to increase, while the hidden measurement RMSE decreases.
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Figure 2.5: 1st Order B-spline BFs fitted interpolation RMSE of observed and hidden
measurements. The black line provides reference to the upper limit of Fig. 2.4
Figure 2.6: 2nd Order B-spline BFs fitted interpolation RMSE of observed and hidden
measurements. The black line provides reference to the upper limit of Fig. 2.4
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Figure 2.7: Example of the two fitted interpolation techniques fitted to patient data. The linear
piece-wise interpolation technique is also provided for comparison
Figure 2.8: Example of the influence of KW on the fitted interpolation fit.
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2.3.3 Sampling interval
The prior analysis shows linear interpolation provided the best estimate of the intermediate BG
dynamics post measurement. Using linear interpolation, the effect of sampling rate on the STAR
cohort GC statistics was investigated. Table 2.2 shows the results are significantly skewed if
re-sampling is not used. This is likely a result of the raw measurements having different measurement
intervals in and out of the targeted 4.4-8.0 mmol/L, as per the STAR protocol. In addition, a slight
variation in some statistics are observed if the interpolated BG trace is sampled more frequently.
Table 2.2: GC performance statistics of the STAR GC protocol using different sampling intervals
on a linearly interpolated BG trace.
Sampling Interval Raw Measurements Hourly Minutely
P-Values
Raw vs. Hourly vs.
Hourly Minutely
Number patients 221 221 221 - -
Cohort Statistics
BG Mean 6.92 6.73 6.71 - -
BG Median [IQR] 6.80 [5.90 - 7.90] 6.61 [5.96 - 7.40] 6.60 [5.95 - 7.38] - -
BG SD 1.29 1.23 1.23 - -
% time <2.2 mmol/L 0.04328 0.00456 0.00941 - -
% time <4.4 mmol/L 2.62 1.35 1.32 - -
% TIB 4.4-8.0 mmol/L 74.32 83.30 83.78 - -
% time >10 mmol/L 7.13 4.10 3.88 - -
Per-patient Statistics
BG Mean 6.84 [6.50 - 7.42] 6.66 [6.36 - 7.21] 6.64 [6.31 - 7.14] 0.001 0.38
BG Median 6.70 [6.30 - 7.20] 6.50 [6.14 - 6.90] 6.49 [6.14 - 6.87] 0.001 0.80
BG SD 1.43 [1.08 - 1.98] 1.17 [0.85 - 1.65] 1.07 [0.79 - 1.51] <0.001 0.08
% time <2.2 mmol/L 0.00 [0.00 - 0.00] 0.00 [0.00 - 0.00] 0.00 [0.00 - 0.00] 0.18 0.18
% time <4.4 mmol/L 0.00 [0.00 - 5.34] 0.00 [0.00 - 1.79] 0.00 [0.00 - 1.49] <0.001 0.09
% TIB 4.4-8.0 mmol/L 81.50 [66.67 - 90.00] 88.42 [77.42 - 94.44] 88.80 [77.89 - 95.52] <0.001 0.37
% time >10 mmol/L 2.78 [0.00 - 8.70] 1.22 [0.00 - 5.56] 0.78 [0.00 - 4.48] 0.04 0.56
*blood glucose (BG), standard deviation (SD), inter-quartile range (IQR), time in band (TIB).
Data presented in Median [inter-quartile range (IQR)] where appropriate.
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Fig. 2.9 shows how the various resampling techniques influence the interpretation of results. The
raw measurements can be seen to be dense at the beginning when the patient is out of the target
band slightly sparser within the target band. Hourly resampling can be seen to more fairly capture
the underlying BG trace. However, as seen at hour 29, hourly resampling can still miss key peaks
in BG, dynamics that could only be captured with minutely resampling.
Figure 2.9: Example of the influence of resampling on time in band statistics.
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2.4 Discussion
2.4.1 Piece-wise interpolation performance
Fig. 2.4 shows all the piece-wise interpolation techniques performed extremely well in capturing
intermediate BG dynamics. Linear interpolation performed the best with an average RMSE of
0.39 mmol/L, over all the measurement intervals assessed. As the measurement interval assessed
increased, so did the hidden RMSE. This result is likely due to the greater time for the intermediate
BG dynamics to deviate from the interpolated trace.
2.4.2 Fitted interpolation performance
Fig. 2.5 and Fig. 2.6 show a trade-off of error to the the hidden and observed measurements for
the fitted interpolated trace. As the KW is increased, the RMSE of the observed measurements
is increased, while the RMSE of the hidden measurements is decreased. This is due to fitted
interpolation techniques becoming less erratic as the BG KW increases, as shown in Fig. 2.8. The
KW BF which provided the most similar magnitude hidden and observed RMSE was chosen as the
optimal, equally representing both hidden and observed measurements. The 150 minute KW 1st
order B-spline BF provided the best compromise of fit to the observed (mean RMSE 1.07 mmol/L)
and hidden (mean RMSE 0.80 mmol/L) measurements. Similarly, the 150 minute KW 2nd order
B-spline BF also provided the best compromise of fit to the observed (mean RMSE 1.06 mmol/L)
and hidden (mean RMSE 0.64 mmol/L) measurements. Note as the variability BG levels increased
the fitted interpolation techniques struggled to capture the erratic dynamics as seen in Fig. 2.7. The
restrictive nature of fitting wide knot-width basis functions is shown by the increase in observed
measurement error. Overall, the 2nd order B-spline BF interpolation provided the best fit to both
the observed and hidden measurements.
2.4.3 Optimal Interpolation
Although the piece-wise interpolation techniques are very prone to erroneous measurements compared
to the fitted interpolation techniques, which are designed to incorporate measurement error, they still
provided a better estimation of the hidden measurements. The trade-off of fit between observed and
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hidden measurements resulted in a much larger RMSE overall for the fitted interpolation techniques
compared to the piece-wise interpolation techniques. In addition, the SPRINT BG values were
measured using a Super Glucocard II (Arkray, Minnesota, USA), which has a measurement error
SD ranging from 0.15–0.56 mmol/L depending on the BG value [223]. Only the linear and cubic
piece-wise interpolation techniques provided a RMSE within this measurement error, providing
a further independent validation that the piece-wise interpolation techniques provided the best
estimation of the intermediate BG dynamics.
2.4.4 Sampling Analysis
Table 2.2 clearly shows there are significant differences in key GC statistics when using raw measure
-ments compared to a sampled interpolated BG trace, for both cohort and per-patient statistics.
The largest impact was seen in the median per-patient percentage of time statistics; 81.5% vs 88%
BG within 4.4-8.0 mmol/L, P < 0.001; 2.78% vs approximately 1.0% BG > 10.0 mmol/L, P = 0.04.
A significant difference can also be seen in the per-patient BG mean and median (mean BG of 6.84
vs 6.65 mmol/L, P = 0.001, and median BG of 6.7 vs 6.49 mmol/L, P = 0.001). This discrepancy
is most likely due to the varying measurement frequency in and out of band for the STAR GC
protocol, inherently causing higher numbers of raw measurements to occur outside of the targeted
band than within. This behaviour is common in GC protocols [101], [109], [129], [213], [214] and
would result in ’poor’ measurements being over-represented, skewing statistics.
Only a small benefit is observed from sampling the interpolated BG trace minutely compared to
hourly. The largest difference occurring in the per-patient median percentage of time BG > 10
mmol/L measurements (0.78% vs 1.22%, P = 0.56 Table 2.2). This result is most likely due to the
hourly sampling of the interpolated BG trace not capturing the peaks in BG seen with minutely
sampling. This outcome is especially important when considering the number of patients within the
hyper- and hypo- glycaemic regions (BG > 10.0 mmol/L and BG < 4.4 mmol/L). In regard to the
other statistics, a negligible difference in BG mean, and median was seen, Table 2.2. However, a
slight difference could be seen in the per-patient standard deviation of BG between sampling rates
(1.17 vs 1.07, P = 0.08). Again,this result is likely due to the hourly sampling rate not capturing
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the full spread of the BG trace. Overall, minutely sampling had limited effect on central tendency
statistics, and a greater impact on outlying events or surges, as expected.
2.4.5 Limitations
The SPRINT protocol has measurement intervals of 1-2 hours [101]. Thus, as per protocol, the
SPRINT BG data is denser in regions where a patient is variable and/or out of the targeted band.
Therefore, the measurements removed (hidden measurements) to make the data sparse are more
likely to be removed from the more variable and out of band BG regions (BG < 4.4 mmol/L and
BG > 6.1 mmol/L). Hence, the hidden measurement error is a stronger validation test, but will
likely have higher associated BG measurement error than if more stable periods were included. The
results are thus a conservative estimate.
The number of observed and hidden BG measurement varies as the measurement interval assessed
is increased due to the SPRINT data needing to be denser to assess smaller measurement intervals.
However, there is still a significant amount (20.6%) of data for assessment of the 2 hour measurement
interval to provide a fair assessment of the BG interpolation techniques.
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2.5 Summary
Overall the linear piece-wise performed the best of all interpolation techniques investigated (mean
RMSE 0.39 mmol/L), providing the best estimate of the intermediate BG dynamics. The fitted
interpolation techniques failed to capture the hidden BG measurements without providing a poor fit
to the observed measurements. Thus, linear interpolation provides the best estimate of intermediate
BG dynamics and should be used when approximations are required in modelling.
There is a significant difference in key GC performance statistics when comparing raw to resampled
interpolated BG measurements, especially when the GC protocols being investigated have varying
measurement intervals depending on the BG value. Therefore, for fair comparison of a GC protocol’s
performance, minutely resampled linear interpolation of BG results is the best option.
Chapter 3
Evaluation and simplification of STAR’s
stochastic model
3.1 Background
A feature of the STAR GC protocol is its ability to account for inter- and intra- patient variability
of hour-to-hour changes in patient specific SI . STAR captures this variability by using a cohort
based stochastic model [145], [149] of 1, 2, and 3 hourly changes in the ICING model-based SI [148]
to compute optimal insulin and nutrition interventions. The cohort based stochastic model enables
STAR to generate/predict a 90% range of BG outcome for a given intervention [128], [147]. STAR
uses this risk-based MPC technique to maximise time in the targeted band (4.4-8.0 mmol/L), and
concomitantly maximise nutrition delivered, while maintaining a maximum 5% risk of BG < 4.4
mmol/L [128], [147].
The insulin and nutrition treatments given by STAR are thus clearly dependent on the predicted
5th and 95th percentile SI bounds given by the stochastic model [128], [147]. As a result, the
stochastic model bounds directly determine STAR’s ability to provide safe and effective GC. If the
stochastic bounds are too wide, STAR over estimates patient variability, and, as a result, provides
1G. M. Shaw, K. W. Stewart, J. Dickson, C. Pretty, and J. G. Chase, “THE SECRET TO SAFE, EFFECTIVE
AND SUCCESSFUL INSULIN DOSING,” in 41st ANZICS/ACCM INTENSIVE CARE ASM, 2016, p. 281.
2K. W. Stewart, J. Dickson, C. Pretty, G. Shaw, and J. G. Chase, “Variability is a constant! Insulin sensitivity
and its variability in 4 ICU Cohorts.,” in 16th Annual Diabetes Technology Meeting, 2016.
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too conservative and thus less or ineffective GC. Alternatively, if the stochastic bounds are too
narrow, STAR under estimates patient variability, and, as a result, provides too aggressive and thus
unsafe GC. Hence, a balance exists in which the stochastic model provides equally effective and safe
GC for every patient.
The original controller stochastic model used by STAR [145] was developed using the ICING
model published by Lin et al. [148] and a selection of 120 patients from the SPRINT cohort
[101]. The stochastic model was built using two dimensional kernel density estimation. SI was
bounded to physiological limits of 1.0×10−5 and 1.0×10−3 L/(mU.min) [225], [226], which is at
the low end of values reported for healthy and pre-diabetic individuals (1.4×10−4 - 4.0×10−3
L/(mU.min) [72], [227]). The variance of each point was determined by the local data density in a
centred, ortho-normalised space [145]. However, since the creation of this stochastic model further
unpublished iterations have been made expanding the limits of the controller stochastic model to
1.0×10−7 - 2.8×10−3 L/(mU.min) to account for patients with a much higher or lower [72], [227]
and possibly more variable SI [125], [228].
Since the development of the original stochastic model, the physiological model used to describe SI
has progressed (Section 1.2.4.1 ICING Model) and an order of magnitude more patient data has been
collected across differing demographics and clinical practices. Therefore, to ensure STAR’s controller
stochastic model captures the required patient variability, and is thus able to provide generalizable
safe and effective GC, the currently used controller stochastic model requires comparison to the
patient variability seen across differing cohort demographics and clinical practices.
In addition, the ’variability’ in the defined stochastic model bounds appear to be very specific to
the cohort of data used to create the stochastic model. Therefore, simplification of the controller
stochastic model in the form of a piece-wise polynomial may better approximate the underlying
population stochastic bounds. However, validation of the piece-wise polynomials used is required to
ensure patient GC performance and safety is not compromised.
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The aim of this chapter is to compare the stochastic model currently used by STAR to that
of 3 different STAR cohorts, from differing demographics and clinical practices. In addition, a
simple piece-wise polynomial approximation of STAR’s currently used controller stochastic model is
proposed and its GC performance and safety investigated in virtual trials.
3.2 Methods
3.2.1 Insulin Sensitivity identification
A variant of the clinically evaluated ICING model [31], [148] is used to describe glucose-insulin
metabolic system dynamics, Section 1.2.4.1 ICING Model. The model-based SI represents the whole
body balance of insulin and glucose from all sources, where SI is identified through integral-based
identification [148], [153]. Note, considering that SI is mathematically identified to best fit the BG
measurements, any measurement error or discrepancies in the given and STAR recorded interventions
can lead to excessively high or erratic SI values. The minimum value of SI is limited to 1×10−7
L/(mU.min), approximately 1,000x lower than the SI identified for healthy and pre-diabetic subjects
[72], [227].
3.2.2 Stochastic model generalizability
To validate the 5th and 95th percentile bounds of the stochastic model currently used by STAR, the
bounds are compared to the 5th and 95th percentile bounds of 3 different STAR cohort’s stochastic
models. The ability for the current stochastic model to capture each cohort’s SI variability is
assessed via a histogram of the percentage of SI values within the current STAR 5th and 95th
percentile bounds, ideally 90%. Each of the STAR cohort stochastic models are formed using the
same methodology as described by Lin et al. [145]. Note, only the 1 hour stochastic model is
compared as this model has the largest influence on control, and models of the other intervals are
similar. Also, only the 5th and 95th percentile values are compared, as these are what are used in
STAR’s GC algorithm.
Each of the cohort’s absolute SI value CDFs are also compared. Due to the large number of SI values
identified, most statistical tests comparing the cohorts values (Wilcoxon rank-sum or Kruskal-Wallis
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test) will return a very small P value, regardless of actual similarity or differences. Therefore, only
visual inspect is used to compare each of the cohorts CDFs.
3.2.2.1 Patient Data
Clinical data from 3 cohorts treated with the STAR protocol [128], [229] in Christchurch Hospital
ICU, Christchurch, NZ, Kálmán Pándy Hospital ICU, Gyula, Hungary, and the International Medical
University Medical Centre, Kuantan, Malaysia from 2011 to present were used for stochastic model
comparison. Details of these patients are shown in Table 3.1. The Upper South Regional Ethics
Committee, New Zealand granted approval for the audit, analysis and publication of the Christchurch
Hospital ICU data. According to the local ethical codes in Hungary and Malaysia, the retrospective
study is considered a clinical data audit, and only required depersonalization of data without the
need for individual patient consent to analyse or publish the anonymized data.
Table 3.1: Patient Demographics for the 3 STAR cohorts being used for comparison of stochastic
models. Note, not all data is available for all cohorts.
Cohort STAR Gyula STAR Christchurch STAR Kuantan
Number Patients 47 426 36
Age 66 [58 - 71] 65 [55 - 72] 62 [55 - 68]
Percent male 61.7 63.6 61.1
Length of ICU Stay (Days) 14.0 [8.0 : 20.5] 4.6 [2.0 - 11.6] -
Mean Days on protocol 5.3 3.8 3.9
APACHE II Score 32.0 [28.0 : 36.0] 20.00 [15.00 - 25.00] -
ICU Mortality (%) 38.3 20.9 -
Percent T2DM 0.0 - 63.9
*Intensive Care Unit (ICU), Acute Physiology And Chronic Health Evaluation (APACHE), Type 2
Diabetic (T2DM). Data presented in Median [inter-quartile range (IQR)] where appropriate.
3.2.3 Stochastic model simplification
Each of the 1, 2 and 3 hour STAR controller stochastic models are approximated by piece-wise
polynomials. The mathematical approximations of the stochastic model bounds were chosen to be
as simple as possible, while still being representative of the stochastic model trends. Due to 99%
of SI values being less than 1.8×10−3, any stochastic model characteristics above this value were
considered to be unrepresentative of the underlying population trends. In addition, the mathematical
approximations were desired to follow the previous stochastic model trends where data density was
high. Therefore, 2nd order piece-wise polynomials were used to the represent the 5th and 95th
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percentile bounds. The correlation coefficients of the piece-wise polynomial approximations to the
current stochastic model bounds below 1.8×10−3 are used to assess representation of currently used
stochastic model bounds. A comparison of the piece-wise polynomials and the the current controller
stochastic models are shown in Figures 3.1 to 3.3. Note, the piece-wise polynomial stochastic models
have no upper bound, unlike the currently used stochastic models which saturate SI values at their
upper bound (2.8×10−3).
The ability for the piece-wise polynomials to capture the patient variability is investigated through
virtual trials [154], [230]. Clinical data from the 426 patients treated with STAR in Christchurch,
Table 3.1, were used to generate virtual patients. Virtual patients were created from the patient-specific
time varying model-based SI profiles [153]. This model-based SI can be used as a critical marker
of a patient’s metabolic state [145], [230]. These virtual patients allow robust protocols to be
safely designed and rigorously tested prior to clinical implementation, improving patient safety and
minimising the need for protocol alterations post-implementation [154], [230]. The virtual patients
were simulated with the stochastic models of interest, the STAR GC protocol, and the ICING model.
From the virtual trial results of the two sets of stochastic models, currently used and piece-wise
polynomial approximation, the GC safety and performance is compared.
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3.2.3.1 1 hour stochastic model
The polynomials are defined:
SI,n+1 5th perc =

1× 10−7 SI,n < 6× 10−5
−150.8× SI,n2 + 0.7459× SI,n − 2.915× 10−5 6× 10−5 ≤ SI,n ≤ 2.5× 10−3
0.89× 10−3 2.5× 10−3 < SI,n
(3.1)
SI,n+1 95th perc =

2.8× 10−4 SI,n < 1× 10−4
401.1× SI,n2 + 0.8108× SI,n + 1.98× 10−4 1× 10−4 ≤ SI,n
(3.2)
Figure 3.1: A comparison of the 1 hour controller stochastic model and piece-wise polynomial
approximation.
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3.2.3.2 2 hour stochastic model
The polynomials are defined:
SI,n+2 5th perc =

1× 10−7 SI,n < 6× 10−5
−158.2× SI,n2 + 0.7459× SI,n − 2.915× 10−5 6× 10−5 ≤ SI,n ≤ 2.2× 10−3
0.84× 10−3 2.2× 10−3 < SI,n
(3.3)
SI,n+2 95th perc =

2.8× 10−4 SI,n < 1× 10−4
474.5× SI,n2 + 0.8108× SI,n + 1.98× 10−4 1× 10−4 ≤ SI,n
(3.4)
Figure 3.2: A comparison of the 2 hour controller stochastic model and piece-wise polynomial
approximation.
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3.2.3.3 3 hour stochastic model
The polynomials are defined:
SI,n+3 5th perc =

1× 10−7 SI,n < 6× 10−5
−167.5× SI,n2 + 0.7459× SI,n − 2.915× 10−5 6× 10−5 ≤ SI,n ≤ 2.2× 10−3
0.8× 10−3 2.2× 10−3 < SI,n
(3.5)
SI,n+3 95th perc =

2.8× 10−4 SI,n < 1× 10−4
557.9× SI,n2 + 0.8108× SI,n + 1.98× 10−4 1× 10−4 ≤ SI,n
(3.6)
Figure 3.3: A comparison of the 3 hour controller stochastic model and piece-wise polynomial
approximation.
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3.2.3.4 Analysis and Statistics
Due to irregular sampling intervals, patient episode BG data were analysed after linear interpolation
at 60 min intervals, see Chapter 2 Interpretation of Retrospective BG Measurements. Note, minutely
sampling was not used as this analysis was preformed before the prior chapter’s analysis had been
performed. Mean hourly nutrition rates of glucose are reported, but exclude hours in which patients
were not fed, as occasionally patients could not be fed due to clinical reasons irrespective of the GC
protocol.
Non-parametric statistics are used exclusively for all the comparative tests due to the typically
skewed distributions of BG, insulin dose and other data. P-values were computed using the Mann
-Whitney rank-sum test for all continuous data and the chi-squared test for categorical data. P-values
<0.05 are considered statistically significant.
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3.3 Results
3.3.1 Stochastic model generalizability
Fig. 3.4 shows the SI CDFs for all 3 of the STAR cohorts are very different. The median values range
from approximately 2.7e×10−4 L/(mU.min) for Christchurch and Kuantan to 4.2×10−4 L/(mU.min)
for Gyula. In addition, each cohort has varying amounts of saturation occurring (SI = 1×10−7),
with levels of 0.3%, 2.3%, and 9.5% for Gyula, Christchurch and Kuantan, respectively. This result
may indicate variability in the ICING model’s ability to capture metabolic dynamics across cohorts.
These results all also show the absolute SI differences possible between cohorts.
(a) Overall CDFs. (b) Zoomed in to the 99th percentile SI value
(1.8×10−3).
Figure 3.4: The cumulative distribution function (CDF) of insulin sensitivity (SI) for the 3 STAR
cohorts investigated.
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Figs. 3.5 and 3.6 shows the controller stochastic model to capture the majority of patient SI
variability (shaded 5th-95th percentile region) in both Gyula and Christchurch. Equally, the percentage
of identified SI values within the controller stochastic model’s 5th-95th percentile bounds are consistently
equal to or greater than 90%, where data is dense (SI < 1.0×10−3). In contrast, the Kuantan
cohort’s shaded 5th-95th percentile region, Fig. 3.7 can be seen to well exceed those of the controller
stochastic model bounds. In addition, the percentage of identified SI values within the controller
stochastic model’s 5th-95th percentile bounds are consistently below 90%, where data is dense (SI <
1.0×10−3). Thus, suggesting the variability seen in the Kuantan cohort is much larger than STAR
currently accounts for.
Figure 3.5: (Top) Comparison of the STAR controller and STAR Gyula stochastic model.
(Bottom) Histogram of percentage of SI within the STAR controller 5th-95th percentile bounds.
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Figure 3.6: (Top) Comparison of the STAR controller and STAR Christchurch stochastic model.
(Bottom) Histogram of percentage of SI within the STAR controller 5th-95th percentile bounds.
Figure 3.7: (Top) Comparison of the STAR controller and STAR Kuantan stochastic model.
(Bottom) Histogram of percentage of SI within the STAR controller 5th-95th percentile bounds.
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3.3.2 Stochastic model simplification
Table 3.2 shows the correlation coefficients of the piece-wise polynomial approximations to the
current stochastic model bounds (SI < 1.8×10−3). All of the piece-wise polynomial approximations
of the stochastic bounds are shown to have an R2 value > 0.96. Overall indicating the simple
piece-wise polynomials captured the data and underlying trends in percentiles very well.
Table 3.2: Correlation coefficients (R2) of the piece-wise polynomial approximations to the
currently used stochastic model bounds, when SI < 1.8×10−3.
Stochastic model
1 Hour 2 Hour 3 Hour
5th percentile approx. R2 0.988 0.984 0.978
95th percentile approx. R2 0.990 0.983 0.969
The GC performance and safety of STAR using the current controller stochastic models and the
proposed piece-wise polynomial approximate stochastic models is shown in Table 3.3. The piece-wise
polynomial stochastic models provided very similar GC performance to the current-controller stochastic
models, with similar time in the targeted 4.4-8.0 mmol/L BG band (87.9% vs. 87.5%, P=0.67) and
reduction of hyperglycaemia (% time BG > 10.0 mmol/L, 1.6% vs. 1.7%, P=0.91). Equally, the
safety provided by both sets of stochastic models was similar, both having similar numbers of severe
hypoglycaemia measurements (BG < 2.22 mmol/L, 9 vs. 8 measurements, P=1.0). Interestingly,
the piece-wise polynomial stochastic models slightly improved safety having 19 less measurements of
mild hypoglycaemia (BG < 4.0 mmol/L), P = 0.2. The hourly resampled BG CDFs for each set of
stochastic models are plotted in Fig. 3.8. Both sets of stochastic models resulted in very similar BG
CDFs, again emphasising the approximately equivalent control able to be offered with the piece-wise
polynomial stochastic models.
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Table 3.3: Comparison of the per-patient virtual trial GC performance and safety results for the
STAR controller with the current and proposed piece-wise polynomial stochastic models.
STAR Controller STAR Piece-wise Poly P-Value
Num Patients 426 426 -
Total hours 38833 38835 -
Num BG measurements 22485 22393 -
Measures/day (Per-Patient) 14.2 [11.4 - 24.5] 14.3 [11.4 - 24.5] 0.92
GC Performance
BG median (mmol/L) 6.2 [5.9 - 7.0] 6.4 [5.9 - 7.1] 0.04
BG mean (mmol/L) 6.4 [6.1 - 7.3] 6.6 [6.1 - 7.4] 0.08
BG SD (mmol/L) 1.3 [1.0 - 1.7] 1.2 [0.9 - 1.7] 0.59
% BG >10.0 mmol/L 1.6 [0.0 - 7.7] 1.7 [0.0 - 7.7] 0.91
% BG within 4.0-8.0 mmol/L 87.9 [69.2 - 95.1] 87.5 [70.6 - 94.6] 0.67
% BG <4.4 mmol/L 0.0 [0.0 - 4.8] 0.0 [0.0 - 4.1] 0.33
% BG <2.22 mmol/L 0.0 [0.0 - 0.0] 0.0 [0.0 - 0.0] 0.81
Mean hourly insulin rate (U/hr) 3.7 [2.6 - 5.0] 3.6 [2.5 - 4.8] 0.09
Mean hourly feed rate (g/hour) 4.6 [3.8 - 5.5] 4.8 [4.0 - 5.6] 0.25
Safety
Num measures <4.0 mmol/L 141 122 0.20
Num measures <2.22 mmol/L 9 8 1
*Glycemic Control (GC), blood glucose (BG), standard deviation (SD). Data presented in Median
[inter-quartile range (IQR)] where appropriate.
Figure 3.8: Resampled hourly BG cumulative distribution function (CDF) for STAR using the
current controller stochastic models and the proposed piece-wise polynomial stochastic models.
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3.4 Discussion
3.4.1 Stochastic model generalizability
The SI values identified across all of the cohorts investigated were very different in absolute value,
as shown by Fig. 3.4. Notably, the Kuantan cohort had the largest spread of SI values and the
highest percentage of SI saturated values (9.5%), which may be the result of 63.9% of the cohort
being type 2 diabetic, as seen in Table 3.1. Overall, the differences in SI values may be a result of
the patient demographics and/or clinical practice resulting in a different identified SI value.
The currently used 1-hour STAR controller stochastic model’s 5th and 95th percentile bounds
captured approximately all of the SI variability seen in the STAR Gyula and Christchurch cohorts
where data was dense (SI < 1.0×10−3), as seen in Figs. 3.5 and 3.6. This shows, within the
STAR Christchurch cohort especially where the patient’s diabetic status was unknown, the current
stochastic model was able to robustly capture the unknown patient variability. In addition, the
controller stochastic bounds were observed to actually be over conservative in many cases capturing
considerably more than 90% of the identified SI values, as seen in the histograms of Figs. 3.5 and 3.6.
Hence, revealing a potential area of improvement for future iterations of the stochastic model. Note,
as the data density decreases (SI > 1.0×10−3) the cohort stochastic model bounds can be observed
to become more variable and the controller stochastic model become less representative of this less
dense SI region.
The Kuantan cohort 1-hour stochastic model appeared very different to the STAR controller stochastic
model, as seen in Fig. 3.7. At all SI values, the Kuantan cohort stochastic bounds were wider than
the currently used STAR controller stochastic bounds. This is further emphasised by the percentage
of identified SI values within the controller stochastic model’s 5th-95th percentile bounds being
consistently below 90%, having mean of approximately 65% where data was dense (SI < 1.0×10−3).
This again may be a result of 63.9% of the cohort being type 2 diabetic, Table 3.1, providing a
much more metabolically variable cohort. Consequently, when STAR is used in Kuantan it may
offer treatment options that are too aggressive for this cohort’s typical behaviour. However, STAR
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has only been implemented in Kuantan since 2017 on limited patients [231], and, thus, as a result,
this data may be very prone to data entry errors or non-compliance.
In addition, as seen in a publication currently under review, adherence to the GC protocol was seen
to be very low (approximately 60% at best) due clinical staff not following any recommendations in
several cases. Therefore, the recorded interventions of STAR may differ to what was given clinically
and, as a result, a much more variable SI trace is identified. Thus, only once compliance is improved
in Kuantan can the stochastic bounds be robustly evaluated.
Given that the STAR controller stochastic model captures both the Gyula and Christchurch cohort
well, each from differing clinical practices and demographics, it provides a good basis for the STAR
controller in Kuantan until compliance is improved and the ’true’ patient characteristics be better
captured. However, compliance in Christchurch was shown to be very high (>86% Chapter 6).
Thus, the confidence in the Christchurch data used is very high.
3.4.2 Stochastic model simplification
Table 3.2 showed the piece-wise polynomial stochastic models to give a good representation of
the currently used stochastic model bounds (All R2 values > 0.96). In addition, these piece-wise
polynomials were not influenced by the variability in the stochastic model bounds due to low data
density, as discussed earlier. Overall indicating the simple piece-wise polynomials captured the
current stochastic model bounds well and the underlying trends in percentiles were held at all values
of SI .
The piece-wise polynomial stochastic models provided approximately equal GC performance to the
currently used controller stochastic models. Both sets of stochastic models provided a very high time
in the targeted 4.4-8.0 mmol/L BG band (87.9% vs. 87.5%, P=0.67 Table 3.3) and effectively reduced
hyperglycaemia (% time BG < 10 mmol/L, 1.6% vs. 1.7%, P=0.91 Table 3.3). The approximately
equivalent GC performance can also be seen by the very similar BG CDFs in Fig. 3.8. In addition,
the piece-wise polynomial stochastic models were able to provide slightly safer GC, reducing the
incidence of mild hypoglycaemia (BG < 4.0 mmol/L, 141 vs. 122, P=0.2 Table 3.3) and providing
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approximately equal occurrences of severe hypoglycaemia (BG < 2.22 mmol/L) measurements (9
vs. 8 measurements, P=1.0 Table 3.3). Overall, these results suggest that the piece-wise polynomial
approximation of the controller stochastic models provides a viable alternative without compromising
in GC performance or safety.
The reduced number of mild hypoglycaemic cases offered by the piece-wise polynomial stochastic
models may be due to capturing the underlying trend in the stochastic model bounds. In particular,
the variability in the stochastic model bound, specific to the cohort used to create the stochastic
model, is removed and the underlying trend captured. This may have resulted in more representative,
and potentially more conservative percentile bounds being provided, reducing the occurrences of mild
hypoglycaemia (BG < 4.0 mmol/L) for some patients, Table 3.3.
In addition, since the implementation of STAR, although rare, model-based SI values of 10.0×10−3
L/(mU.min) and upwards have been identified, significantly higher than the bounds of what was first
implemented (1.0×10−3 L/(mU.min)) and what is currently implemented in the STAR controller
(2.8×10−3 L/(mU.min)). Currently, STAR saturates SI values at the bounds of the stochastic model
which may result in under estimating the 5th and 95th percentile bounds. However, the piece-wise
polynomial stochastic models do not saturate. Therefore, the predicted percentiles, particularly the
95th percentile bound, which corresponds to the lower 5th percentile BG, will not be under estimated.
This may also account for the slight reduction in mild hypoglycaemia seen in Table 3.3.
The piece-wise polynomial stochastic models provide a simple alternative to the currently used STAR
controller stochastic model look up tables. In addition, approximating the the 5th and 95th percentile
stochastic bounds with piece-wise polynomials allows stochastic bounds to be better predicted in
areas where data density is low, causing the previously formed stochastic to have erratic 5th and 95th
percentile bounds. Hence, the piece-wise polynomials offer a means to better extend these model’s
functionality.
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3.4.3 Limitations
Due to SI being mathematically identified to best fit the BG measurements and clinical data, any
measurement error or discrepancies between the interventions given and recorded in STAR could
lead to excessively high SI values. Therefore, the identified SI value may not be physiologically
representative, and is very specific to the model used to identify it. Thus, comparison to other
published SI values, which use different physiological models, has limited validity, and should only
be used as guide. However, regardless of the identification process, STAR needs to be able to act
appropriately if it is provided very unlikely high SI value.
The 95th percentile piece-wise polynomials are represented by a quadratic in all of the stochastic
models, when SI > 1.0×10−4 L/(mU.min). Therefore, the approximated 95th percentile will grow to
excessively high SI values when the currently identified SI value is high, which is likely due erroneous
data input. As a result, the 5th percentile BG value calculated for any intervention offered by STAR
will be very low, and, thus, the intervention recommended by STAR will maximise BG in any way
possible. Thus, providing the safest treatment option possible when the identified SI value is likely
erroneous. The improvement in safety with the unbounded piece-wise polynomial stochastic models
can be attributed to this safer behaviour at high SI values. Note, all other approximations of the
percentiles are saturated at some value before and after the quadratic used.
As noted, if iterations to the insulin-glucose model used to describe a patient’s SI are made, the
stochastic model bounds need to be re-evaluated for the updated model. Thus, the piece-wise




The treatment options offered by STAR are very dependent on the 5th and 95th percentile SI bounds
defined in the stochastic model used. The currently-used stochastic model has been used with STAR
in 3 different countries around the world. However, the stochastic bounds in relation to each cohort’s
stochastic model have not been evaluated. This chapter compared each of the cohort’s 1 hour SI
stochastic model to the currently used STAR controller stochastic model.
The SI variability seen in both Gyula and Christchurch were well captured by the currently used 1
hour STAR controller stochastic model, with the percentage of identified SI values being consistently
equal to or greater than 90% within the controllers current stochastic model bounds. The SI
variability in the Kuantan cohort was seen to be much larger than the what was in the currently used
STAR controller stochastic model, with the percentage of identified SI values being approximately
equal 65% within the controllers current stochastic model bounds. However, this discrepancy is likely
due to the large non-compliance of data entry in Kuantan and a re-evaluation of the stochastic model
is required once compliance is improved.
Piece-wise polynomials were used to approximate the currently used controller stochastic models.
The piece-wise polynomial stochastic models were shown to give a good representation of the
currently used stochastic model bounds (All R2 values > 0.96). GC performance and safety was
compared with virtual trials using the STAR Christchurch cohort. The piece-wise polynomials
provide approximately equal GC performance and slightly improved safety, having 19 less cases
of mild hypoglycaemia (BG < 4.0 mmol/L). Overall, the piece-wise polynomial stochastic models
provide a promising alternative to the currently used stochastic model.
Chapter 4
Improving the identification of
model-based Insulin Sensitivity
4.1 Background
Some of the most effective and safe GC techniques used currently are model-based [215], [232]–[235],
where treatment decisions are based on model identified physiological markers and forward prediction
of insulin-glucose response to care. A model that has worked particularly well in guiding GC
is the ICING model [148], [158], which is used in the STAR framework [128], [147], [215], [229].
The STAR model-based framework is able to provide patient-specific, safe control using models of
time-varying patient metabolic dynamics [145], [149], with discrete, hourly-identified stepwise jumps
of model-based SI values [153], effectively representing SI with 60 minute KW zeroth order B-spline
BF. However, the current identification of SI has multiple limitations:
• Constant, hourly stepwise jumps in SI are not strictly physiologically accurate. As BG and
thus SI is a physiological signal, changes should be continuous and smooth [236]–[243], even
if rapid, and not discrete step wise jumps.
• Frequent (Hourly) SI changes require assumed intermediate BG dynamics to be identifiable
[244], [245]. As the median patient, mean measurement interval, for STAR is 1.8 hours [215],
1Stewart, K. W. , Pretty, C. G., Shaw, G. M. and Chase, J. G. (2017) ‘Creating Smooth SI. B-spline Basis
function representations of insulin sensitivity’, Biomedical Signal Processing and Control. (Under Review)
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and 2 BG measurements (1 Change in BG per equation) are required to identify each step
in SI , linear interpolation is used to assume extra data points required [246], see Chapter 2
Interpretation of Retrospective BG Measurements.
• The identified SI is very susceptible to noise, capturing both measurement noise and modelling
error [153]. Rapid SI changes, caused by large errors, overwhelm relevant model dynamics and
thus capture all of the measurement noise.
Therefore, representing SI with a continuous, identifiable function, which is less susceptible to
measurement noise, would significantly improve the physiological representation of this parameter
in this already clinically proven model [31], [128], [147], [215].
In many physiological models, the use of orthogonal BFs have proven effective in reproducing
physiological signals [247]–[249]. In particular, B-spline BFs have been shown to represent many
time varying natural phenomena [250], [251]. Hence, B-spline BFs offer a means of parametrizing
a time-varying signal like SI in a more physiologically relevant and continuous manner, without
adding significant complexity to their identification from data [244], [245].
This chapter investigates the identification of the current, zeroth order B-spline BF and an alternative
2nd order B-spline BF in modelling patient-specific time-varying SI . The BFs are compared in terms
of physiological relevance, identifiability, and susceptibility to noise and error. The goal is a more
physiologically relevant and less ’over fitted’ SI function that also provides potential for greater
physiological insight into metabolic dynamics.
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4.2 Methods
4.2.1 Identification of insulin sensitivity (SI)
A variant of the clinically evaluated ICING model [31], [148] is used to describe glucose-insulin
metabolic system dynamics, Section 1.2.4.1 ICING Model. The model-based insulin sensitivity,
SI(t), see Eq. (4.1), represents the whole body balance of insulin and glucose from all sources. SI(t)
can be identified through the rearrangement and integration of Eq. (4.1) [148], [153], as shown below.
Ġ(t) = −pGG(t)− SI(t)G(t)
Q(t)
1 + αGQ(t)


































P (t) + EGP − CNS
VG
dt− (Gmeas(tn)−Gmeas(t0))
The equation becomes: ∫ tn
t0
SI(t)× f1 dt = f2 (4.2)
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In this study, SI(t) is identified as the linear combination of BFs, Φi(t), defined:
[









Combining Eqs. (4.2) and (4.3), the BF coefficients, γi, can be solved for using least squares. Overall,
minimizing the error between f1 and f2, and thus, the modelled G(t) and clinically measured BG,


















Where: γi = basis function fitted coefficient i
The modelled BG solution, G(t), can then be simulated using the ICING model, Equations (1.1)
to (1.7), with the identified SI(t) trace and same clinical interventions. The resultant simulated
BG trace can be used for assessment of model fit. Depending on the shape of the chosen BF, the
dynamics of the identified SI trace are restricted accordingly. As a result, the modelled BG, G(t),
goodness-of-fit to the clinical BG data is a function of BF shape.
Given the nature of SI within the ICINGmodel, a minimum of 2 BGmeasurements per BF (1 Change
in BG per equation) are required to identify each BF. A new BF occurs every KW. Therefore, to
ensure identifiability, 2 BG measurements per KW are needed. As the measurement intervals offered
by STAR are 1-3 hours [128], [147], a KW greater than or equal to 180 minutes (3 hours) is required
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to ensure BF identifiability without having to assume intermediate BG measurements, as is done
currently with the 60 minute KW zeroth order B-spline BFs.
4.2.2 Physiological Representation
In non-critically ill patients, under steady state conditions, SI is considered to be relatively constant
[252], [253]. However, within critically ill patients the stress-heightened state and/or the drugs
given after insult can result in a highly dynamic counter-regulatory hormone and cytokine response,
inducing frequent changes in BG [236]–[238], [240] and thus effective SI [31], [112], [145], [228], [254],
[255]. In addition, SI is generally considered to occur in a continuous manner as it is a physiological
signal. Thus, a 2nd order B-spline BF is chosen to represent SI as a smooth continuous trace.
4.2.3 Basis Functions
4.2.3.1 B-spline BFs
B-spline BF are defined by the equations below [222]:
When k = 0: Φi(t) =

1 ti ≤ t < ti+1
0 Otherwise
(4.5)







Where: Φ = basis function, k = basis function order, i = basis function # ti = knot-width location
The range of ti ≤ t < ti+1 defines the KW of the given BF.
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4.2.3.2 Zeroth order B-spline BFs (Current Technique)




1 KW × (i− 1) < t < KW × (i)
0 Otherwise
(4.7)
Where: Φi = basis function i, KW = knot width, i = basis function #
This BF holds a constant value over the period of the KW. The current BF used to fit the
ICING model uses a 60 minute KW, zeroth order B-spline BF [153], as shown in Fig. 4.1. It
thus requires interpolated measurements every 60 minutes between any more widely spread clinical
BG measurements.
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4.2.3.3 2nd order B-spline BFs





2×KW 2 KW × i < t < KW × (i+ 1)
−1
KW 2 (KW × (i+
3
2 )− t)
2 + 34 KW × (i+ 1) < t < KW × (i+ 2)
(KW ×(i+3)−t)2





Φi(t) = 1 ∀t (4.9)
Where: Φi = basis function i, KW = knot width, i = basis function #,
n = number of basis functions
In contrast to Eq. (4.7), these BFs overlap each other, as shown in Fig. 4.1. The inherent properties
of B-spline BFs in Eq. (4.9) ensure no assumed or underlying waveform is induced into the identified
solution, and a constant value can also be represented.
A smooth 2nd order polynomial BF ensures continuous differentiability of two orders. Physiologically,
SI thus varies smoothly and continually. Equally, the first derivative of SI may provide significant
physiological insight not currently available using non-differentiable, discontinuous zeroth order BFs.
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Figure 4.1: Comparison of the basis function (BF) being investigated. (Top) BG measurement
data used to identify insulin sensitivity (SI). (Middle) Zeroth order 60 minute knot-width (KW)
B-spline BFs, current fitting technique. (Bottom) 2nd order 170 minute KW B-spline BFs.
4.2.4 Clinical data
Clinical data for validation analysis was obtained from a published 20 patient benchmark cohort
[101] and a 72 patient sub-cohort of the STAR cohort [215]. The cohorts were specifically chosen for
validation analysis as they used glucometers of considerably different precision. STAR patients were
selected if they started GC after 2014, ensuring they were using a different, lower error, glucometer
to that used in the benchmark cohort. The Upper South Regional Ethics Committee, New Zealand
granted ethics approval for the audit, analysis, and publication of these data. Each cohorts clinical
GC performance results are presented in Table 4.1 for reference.
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Table 4.1: Clinical GC performance statistics of the benchmark and STAR sub-cohort.
Benchmark cohort STAR sub-cohort
Num Patients 20 72
Total hours 6918 6386
Num BG measurements: 4482 3089
Measures/day (Per-Patient) 15.4 [13.5 - 17.3] 11.5 [10.6 - 13.7]
BG median (mmol/L) 5.7 [5.3 - 6.0] 6.6 [6.3 - 7.1]
BG mean (mmol/L) 5.9 [5.5 - 6.2] 6.7 [6.5 - 7.2]
BG SD (mmol/L) 0.9 [0.8 - 1.3] 1.0 [0.8 - 1.4]
% BG <2.22 mmol/L 0.0 [0.0 - 0.0] 0.0 [0.0 - 0.0]
% BG <4.4 mmol/L 5.2 [2.4 - 10.0] 0.0 [0.0 - 0.0]
% BG within 4.0-8.0 mmol/L 95.1 [90.2 - 97.7] 90.1 [78.4 - 93.9]
% BG >10.0 mmol/L 0.0 [0.0 - 0.6] 0.7 [0.0 - 4.1]
*blood glucose (BG), standard deviation (SD). Data presented in Median [inter-quartile range
(IQR)] where appropriate.
4.2.5 Basis Function Fit Analysis
Zeroth order B-spline BFs (KW = 60) are compared to 2nd order B-spline BFs in terms of fit
and susceptibility to noise. Four 2nd order B-spline BF KWs are assessed, ranging from 180 to
300 minutes. The most appropriate KW will be determined by which BF best represents the SI
dynamics.
4.2.5.1 Fit Assessment
In all modelled systems there are both modelling and measurement errors, both contributing to the
overall fitting error. If a model is ‘over fit’ to measured data there is low overall fitting error, as
the identified model dynamics also capture measurement error. However, in a ‘good fit’ to measured
data, measurement error is still observed in the overall fitting error.
As identified SI dynamics depend on the BF used to represent it, the resulting ICING model fitting
error is also a function of the BF used. Therefore, modelling error can be minimized by choosing an
appropriate BF. However, to avoid over fitting, the overall fitting error should not be less than the
expected measurement error of the BG meter used, indicating minimal model error without ’over
fitting’.
The overall fitting error (Goodness-of-fit) of each of the BFs is assessed by the relative difference
between the resultant model BG solution and clinical BG measurements, on both the benchmark
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cohort and STAR sub-cohort. The relative difference error distribution characteristics are compared
to error metrics for the point of care (PoC) measurement device used with each cohort. The
benchmark cohort used the Arkray Super-GlucocardTM II glucometer (Arkray, Minnesota, USA).
However, independent published glucometer error data for the Arkray Super-GlucocardTM II could
not be found, so the similar Glucocard X Meter (Arkray, Inc., Kyoto, Japan) published in [256],
[257] is used (Mean = 0%, SD = 9.35%). The STAR cohort used the Roche Accu-Chek Inform II (F.
Hoffmann-La Roche Ltd, Basel, Switzerland), with glucometer error metrics in [258], [259] (Mean =
0%, SD = 6.0%).
4.2.5.2 Sensitivity to added erroneous BG measurements
To further illustrate the reduction in ’over fitting’, or susceptibility of the BF to measurement noise,
the current zeroth order B-spline BF and best 2nd order B-spline BF are used to identify the SI trace
on 2 patients in which erroneous BG measurements are added. The erroneous BG measurements
are added in addition to the ‘real’ clinical BG measurements and put at extremely unlikely levels
relative to the clinical BG data based on what is seen clinically. The identified SI trace and resulting
modelled BG of the two different BFs are compared in terms of susceptibility to the added erroneous
BG measurements.
To work out the maximum expected change in BG, the initial BG and proceeding change in BG,
over an hour, was used to form a stochastic model. From this stochastic model the most likely
change above and below the current can be determined. Data from 221 patients treated with the
STAR protocol in Christchurch Hospital ICU, NZ was used to create the stochastic model seen in
Fig. 4.2.
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Figure 4.2: Stochastic model of hourly changes in blood glucose (BG) given the initial BG level,
based on data from the STAR Christchurch Hospital, New Zealand (NZ) cohort.
From Fig. 4.2 it can be seen that a change in BG of 2.0 mmol/(L.hr) is very unlikely at all BG
levels, especially below 10.0 mmol/L. Above 13 mmol/L and below 3.5 mmol/L the bounds are very
wide due to low numbers of measurements in this region, Table 4.1. Therefore, the erroneous BG




The 2nd order B-spline BF is shown to have a considerably more physiologically representative
signal compared to the current zeroth order B-spline BF technique, Fig. 4.3 and Fig. 4.4. This
interpretation is especially apparent around hour 30 in Fig. 4.3 and hour 6 in Fig. 4.4, where the
2nd order B-spline BF provides a smooth solution to SI without the excessive variation seen in the
zeroth order B-spline BF. In general, the 2nd order B-spline BF provides a very plausible solution
to the patient-specific time varying SI .
Figure 4.3: Example patient 1. Comparison of the physiological representation for current zeroth
order 60 minute knot-width (KW) B-spline basis function (BF), and the 2nd order 180 minute KW
B-spline BF. Top Panel: Measured BG and the resulting modelled G(t). Bottom Panel: insulin
sensitivity (SI) representation over time.
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Figure 4.4: Example patient 2. Comparison of the physiological representation for current zeroth
order 60 minute knot-width (KW) B-spline basis function (BF), and the 2nd order 180 minute KW
B-spline BF. Top Panel: Measured BG and the resulting modelled G(t). Bottom Panel: insulin
sensitivity (SI) representation over time.
4.3.2 Basis Function Fit Analysis
4.3.2.1 Fit Assessment
Tables 4.2 and 4.3 show the relative fitting error characteristics and expected error of the glucometers
used for the benchmark cohort and STAR sub-cohort, respectively, for each BF considered. The
zeroth order B-spline BF has considerably less fitting error, in both cohorts than what would
be expected from the BG meter. In contrast, all of the 2nd order B-spline BFs have an error
approximately equal to or greater than what would be expected from the relevant BG meter,
increasing with KW. In addition, the relative fitting error decreases between the benchmark cohort
and STAR sub-cohort, as the sensor precision improves, as would be expected, but only for the 2nd
order B-spline BFs. Overall, the 180 minute KW BF gives the closest fitting error to the BG meter
used in both cohorts.
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Table 4.2: Characteristics of the relative fitting error of the various basis function (BF) being
investigated on the benchmark cohort.
B-spline BF Zeroth order B-spline 2nd order B-spline PoC BG Meter [256], [257]
Knot Width (KW) 60 180 240 300 -
Mean Rel. BG Error (%) 0.7 1.2 1.4 1.6 0
SD Rel. BG Error (%) 1.0 8.7 10.0 11.0 9.35
*blood glucose (BG), standard deviation (SD), point of care (PoC).
Table 4.3: Characteristics of the relative fitting error of the various basis function (BF) being
investigated on the STAR sub-cohort.
B-spline BF Zeroth order B-spline 2nd order B-spline PoC BG Meter [258], [259]
Knot Width (KW) 60 180 240 300 -
Mean Rel. BG Error (%) 0.7 1.2 1.3 1.3 0
SD Rel. BG Error (%) 2.4 6.0 7.4 8.2 6.0
*blood glucose (BG), standard deviation (SD), point of care (PoC).
4.3.2.2 Sensitivity to added erroneous BG measurements
The current zeroth order B-spline BF and the 180 minute KW 2nd order B-spline BF are identified on
two patients in which highly erroneous and very unlikely erroneous BG measurements are introduced
to test robustness to error. Note, these patients are different from the patients used in Fig. 4.3 and
Fig. 4.4. The difference in the identified SI trace and resulting modelled BG of the Zeroth order
B-spline BF solution can be directly compared in Fig. 4.5 and Fig. 4.6. The 2nd order B-spline BF
solution is smoother and less sensitive to the erroneous measures, where the zeroth order B-spline
BF over fits the erroneous measures via physiologically unrealistic changes in SI .
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Figure 4.5: erroneous blood glucose (BG) measurement example 1. Comparing the influence of
erroneous BG measurements on the identified BG and insulin sensitivity (SI) solution for the
current zeroth order B-spline (knot-width (KW)=60) and 2nd order B-spline (KW=180) basis
function (BF). Top Panel: Measured BG and the resulting modelled G(t). Bottom Panel: insulin
sensitivity (SI) representation over time.
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Figure 4.6: erroneous blood glucose (BG) measurement example 2. Comparing the influence of
erroneous BG measurements on the identified BG and insulin sensitivity (SI) solution for the
current zeroth order B-spline (knot-width (KW)=60) and 2nd order B-spline (KW=180) basis
function (BF). Top Panel: Measured BG and the resulting modelled G(t). Bottom Panel: insulin
sensitivity (SI) representation over time.
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4.4 Discussion
4.4.1 Physiological Representation and Identifiability
Representing SI with a smooth continuous 2nd order B-spline BF results in a considerably more
realistic identified SI trace, as very few things in reality are truly represented by a piece-wise
constant, non-continuous signal. As seen in Figs. 4.3 and 4.4, the previous BF discrete step wise
jumps in SI are now represented as smooth gradual changes. The 2nd order B-spline BF behaves like
a low pass filter, reducing the effects of rapid changes in BG, and taking a mean value approximation
to high frequency BG changes. This behaviour is especially prominent in the first 10 hours of Fig. 4.4.
In addition, the 180 minute KW of the 2nd order B-spline BF requires no assumed intermediate BG
measurements to identify SI . Therefore, the modelled BG trace will be more model dependent, less
sensitive to errors, and thus more physiologically representative of the measured data and clinical
inputs.
4.4.2 Basis Function Fit Analysis
4.4.2.1 Fit Assessment
The relative fitting error of the 2nd order B-spline BFs decreased as KW decreased, as seen in
Tables 4.2 and 4.3. For both the benchmark cohort and STAR sub-cohort, only the 2nd order
B-spline BFs provided a ‘realistic’ fitting error variance approximately equal to that of the BG meter
(benchmark cohort: 8.7-11.0% vs. 9.35% [256], [257], Table 4.2 and STAR sub-cohort: 6.0-8.2%
vs. 6.0% [258], [259], Table 4.3). In contrast, in both cohorts, the zeroth order B-spline BF had
considerably less fitting error variance than the BG meter (Benchmark 1.0% vs. 9.35%, Table 4.2
and STAR sub-cohort 2.4% vs. 6.0%, Table 4.3). This latter result suggests the identified current
BF SI , and resultant BG trace may be ‘over fitted’ to the clinical BG measurements. As a result,
physiological changes in SI occurring from treatment may be swamped by rapid changes in SI driven
by BG measurement errors, as well-illustrated in Figs. 4.5 and 4.6.
The relative fitting error shown by the 180 minute KW 2nd order B-spline BF provided the most
plausible solution having a variance very similar to that expected from the BG meter used in each
77 4.4. DISCUSSION
cohort. In addition, the 180 minute KW 2nd order B-spline BFs decreased fitting error variance
when BG meter precision improved (8.7% -> 6.0%, Tables 4.2 and 4.3), where the current zeroth
order B-spline BF increased (1.0 -> 2.4%,Tables 4.2 and 4.3). Overall, these results show the 180
minute KW 2nd order B-spline BF results in a much more ’realistic’ modelled BG fit to the clinical
BG measurements than the current BF technique.
4.4.2.2 Sensitivity to added erroneous BG measurements
The 180 minute KW 2nd order B-spline BF was considerably less influenced by erroneous or highly
erroneous BG measurements than the current zeroth order B-spline BF, as seen in Figs. 4.5 and 4.6.
This outcome is again due to the 2nd order B-spline BF being essentially a low-pass filter, reducing
the effect of any rapid changes in BG, and effectively taking a moving average of the BG data,
reducing the effect of individual outliers. It is important to note the 2nd order B-spline BFs can still
accommodate the vast majority of physiologically rapid changes in BG seen in Fig. 4.2. However,
the clinical erroneous measurements that occur well outside these bounds are ignored. Thus, this
choice of BF reduces the impact of outliers without imposing restrictions on large, physiologically
realistic responses.
As the introduced 180 minute KW continuous 2nd order B-spline BF has more restricted SI
dynamics, some of the outlying hour-to-hour changes used in the stochastic model [145], as seen
in Chapter 3 Evaluation and simplification of STAR’s stochastic model, of the STAR GC algorithm
[128], [147] will be significantly reduced. As a result, significant treatment changes, offered previously
in response to a large step change in SI , will now be reduced in numbers, as STAR doses insulin
on risk using these stochastic models [128], [147], [149].. For example, at hour 25 of Fig. 4.6 the
erroneous BG measurement results in a very low SI value. Due to the newly measured BG being
out of the 4.4-8.0 mmol/L targeted band STAR would raise insulin to try and rapidly lower their
BG. However, as this measurement is erroneous, the calculated SI is much lower than what they are
likely to be at. As a result, the patient’s risk of hypoglycaemia is increased. Therefore, as the SI
changes are less prone to erroneous measurements and more restricted, STAR’s GC patient safety
and effectiveness should be improved.
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Overall, the 180 minute KW continuous 2nd order B-spline BFs allow more information to be
captured about patient-specific SI dynamics. Thus, many new continuous time analyses could be
undertaken, such as frequency analyses, and analysing the 1st and 2nd derivative of SI for clinical
information on its rate of change. These characteristics have already been shown to be related to
physiologically observed events, such as the onset of sepsis and cardiac events, which each induce
rapid SI changes [220] and could be more easily detected or diagnosed with this rate of change
information. None of these capabilities or potential capabilities are available form any model used
today. Future work in these areas provides promising potential improvements for GC. In addition,
as rapid changes in BG can now not be captured by rapid SI changes, areas of improvement in
ICING model are more apparent, and thus can be specifically addressed.
Before this technique of SI fitting can employed directly into a GC algorithm such as STAR several
areas need to be addressed. Currently, the BF coefficients are identified by assessing the entire
patient’s data set. However, in the clinical setting the BF coefficients will only be able to be
identified up to the current BG measurement. Therefore, when a new BG measurement is taken,
and SI identified, the previously identified BF coefficients, and, as a result, SI trace may change to
better fit the new BG measurement. As the previous SI value may change in the process of getting
the current SI value, the current stochastic prediction method used by STAR, predicting future SI
based on current SI , is not possible. Therefore, before this technique can be used for stochastic
prediction of future SI a better understanding of the variability in SI value, before and after a BG
measurement is added, needs to be assessed.
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4.5 Summary
This chapter investigated 2nd order B-spline BFs as an alternative to the current non-physiologically
representative zeroth order B-spline (KW = 60) BFs, used for SI identification in the ICING model.
Various KW 2nd order B-spline BFs were investigated and compared to the current zeroth order
B-spline BF. The BFs were compared in terms physiological relevance, identifiability, robustness to
erroneous measurements, and susceptibility to noise. 2nd order B-spline BFs were shown to result in
a considerably more physiologically representative SI trace. The 180 minute KW 2nd order B-spline
BF provided the most physiologically realistic fit to the BG measurements, in both the benchmark
cohort and STAR sub-cohort, having very similar fitting error variances to that of the respective
BG meter used, whilst showing significantly less susceptibility to erroneous BG measurements.
Overall, the 180 minute KW 2nd order B-spline BFs results in a more physiologically representative,
identifiable SI and a more realistic resulting BG solution. In addition, the smooth and continuous
characteristic of the 2nd order B-spline BF opens up several new potential continuous time analyses
of metabolic dynamics, and allows areas for improvements in modelling to be more easily identified.
However, the ability for this technique to be directly employed in GC needs further investigation
before direct use in the clinical setting.
Part II:
Assessment of the Stochastic
TARgeted model-based glycaemic
controller
It is a mistake to think you can solve any major




Clinical performance review of the STAR
Glycaemic Control protocol
5.1 Background
There is currently much debate about whether or not GC is beneficial for an ICU patient, with several
studies showing evidence both for [29], [30], [51], [101], [102] and against [103], [109], [112]–[117] its
use. However, the ability to provide safe, effective control across patients and clinical practices is a
necessary requirement before being able to assess the impact of GC on clinical outcomes [260]. Safe
and effective GC is an area many of these studies have failed to address [103], [105], [107], [108],
[110], [111], [213], and, as a result, have significantly increased the risk of hypoglycaemia (6.8% - 29%
of patients experienced BG < 2.2 mmol/L), which is associated with increased mortality [34]–[36],
[261]. Hindering the ability to observe any benefits of GC.
The stress response a critically ill patient experiences is highly complex, variable, and dynamic [122],
making safe, effective control of BG difficult. In particular, large changes in a patient’s SI over short
periods of time [122], [123], [254], particularly in the first 48 hours [262] where hypoglycaemia has a
1K. W. Stewart, C. G. Pretty, H. Tomlinson, F. L. Thomas, J. Homlok, S. N. Noémi, A. Illyés, G. M. Shaw, B.
Benyó, and J. G. Chase, “Safety, efficacy and clinical generalization of the STAR protocol: a retrospective analysis,”
Ann. Intensive Care, vol. 6, no. 1, p. 24, 2016.
2 K. Stewart, C. G. Pretty, F. Thomas, G. M. Shaw, T. Desaive, B. Benyo, J. Homlok, A. Illyes, N. S. Nemedi,
and J. G. Chase, “Generalizability of a Nonlinear Model-based Glycemic Controller,” in 4th IFAC International
Conference on Intelligent Control and Automation Sciences (ICONS), 2016, vol. 49, no. 5, pp. 212–217.
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stronger association to mortality [34], make achieving safe GC difficult. Therefore, a patient-specific
approach which accounts for this variability is needed.
In general, previous studies failed to achieve safe consistent GC due to the GC protocols not being
able to observe or identify individual patient-specific dynamics, and instead providing GC based on
an absolute or change in BG value, without reference to the causative treatment. These protocols
also often lack knowledge of nutrition inputs to place the measured BG value in context. Thus, a
more patient-specific approach to GC is needed to successfully manage such significant inter- and
intra- patient variability [123], [124].
The STARGC protocol appeared the most promising of the ICU GC protocols reviewed in Section 1.2.3
Glycaemic Control Protocols. However, the reviewed results were based on a clinical pilot trial
(N=10) [128]. Since this pilot trial STAR has been the standard of care in Christchurch Hospital
ICU, Christchurch, NZ and in the Kálmán Pándy Hospital ICU, Gyula, Hungary from 2011 to
present (N = approximately 800). Therefore, a deeper investigation into the STAR GC performance
is required to confirm the preliminary results of clinical pilot trial. Note the predecessor of STAR
in Christchurch was the paper-based, model-derived [152], SPRINT GC protocol [31], [101], which
is used for comparison in this analysis, as it achieved tight GC while reducing hypoglycaemia, and
also morbidity and mortality [142], [143].
This chapter provides a dual-centre retrospective analysis of the STAR GC protocol, demonstrating
that patient-specific, safe, effective GC is possible with the STAR protocol and that it is also
generalizable across/over different units and clinical practices. From this review future areas of




This dual-centre retrospective analysis provides 2 comparisons to assess:
1. Performance and Safety: STAR is compared to SPRINT in Christchurch to provide a comparison
between patient protocols in the same unit and clinical practice, and demonstrate equivalent
or better performance and safety of STAR to a successful protocol [101].
2. Generalizability: STAR Christchurch is compared to STAR Gyula to test generalizability of
safety and performance over significantly different clinical practice cultures and approaches.
Repeatability across clinical practices is a necessity for widespread uptake and achieving the
benefits of GC [260].
The metrics compared are:
• Performance: Percentage of time in BG band (4.4-8.0 mmol/L) [61].
• Safety: Number of severe hypoglycaemic cases (BG < 2.2 mmol/L) [35].
• Safety: Number of moderate hypoglycaemic cases (BG < 4.0 mmol/L) [34].
5.2.2 Patients
5.2.2.1 Cohorts
This study compares clinical data from 3 cohorts:
I Patients treated using STAR in Christchurch Hospital ICU, Christchurch, NZ, from
June 2011 – May 2015.
II Patients treated using STAR in Kálmán Pándy Hospital ICU, Gyula, Hungary, from
December 2011 – May 2015.
III Patients treated using SPRINT in Christchurch Hospital ICU, Christchurch, NZ, from
July 2005 – May 2007.
Patients in these 3 cohorts exclude those who spent less than 10 hours on protocol, and were fed on
average greater than 120% of their Society of Critical Care Medicine (SCCM)/ACCP caloric target
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[156]. Patients who spent less than 10 hours on protocol were excluded as they were considered to not
have a significant amount of time on protocol to fairly assess the performance or be clinically affected
by good GC. Patients who were fed greater than 120% of their calorific target were excluded as this
nutrition level is well outside the recommendations of STAR and SPRINT, as well as well-accepted
clinical, guidelines [156] and typical practice [263]. The number of patient episodes excluded due to
each of these filtering criteria can be seen in Table 5.1.
STAR also allows a different target band to be specified in some clinical cases. For this analysis
the most common target (The default 4.4-8.0 mmol/L target) in both Christchurch and Gyula was
chosen so the largest number of patients were available to compare the ‘matched treatment options’.
Therefore, patients on the STAR protocol who did not target the 4.4-8.0 mmol/L BG band were
excluded. These were commonly diabetic patients who were treated with a 5.0-10.0 mmol/L target
BG band to minimise the effect of relative hypoglycaemia [264]. Thus, all STAR patients compared
used the STAR framework in the same manner with respect to BG and nutrition targets. It should
be noted that all SPRINT patients targeted the 4.0-6.1 mmol/L BG band as the SPRINT protocol
was not flexible to different targets [265].
Table 5.1: Episode filtering statistics.
Number of episodes (%) SPRINT Christchurch STAR Christchurch STAR Gyula
Initial Number 487 625 68
Different GC target to protocol 0 (0.0%) 225 (36.0%) 11 (16.2%)
Episode length < 10 hours 58 (11.9%) 49 (7.8%) 6 (8.8%)
Fed over 120% Target 74 (15.2%) 15 (2.4%) 4 (5.9%)
Remaining for analysis 355 (72.9%) 336 (53.8%) 47 (69.1%)
Demographic data for these cohorts are presented in Tables 5.2 and 5.3, aligned with the two main
comparisons. Some data is unavailable for the STAR Gyula cohort in Table 5.3 due to differences
in the typical data collected. The missing data does not impact the assessment of generalizability
of the safety and performance of STAR.
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Table 5.2: Patient Demographics for the STAR and SPRINT Christchurch cohorts.
Cohort Characteristics SPRINT Christchurch STAR Christchurch P-Value
Total patients 292 267
Age 63 [48 : 73] 65 [55 : 72] 0.28
Percent male 62.7 65.5 0.48
Length of ICU Stay (Days) 6.2 [2.7 : 13.0] 5.7 [2.5 : 13.4] 0.7
% Operative 38.7 34.8 0.38
APACHE II Score 19.0 [15.0 : 24.5] 21.0 [16.0 : 25] 0.05
APACHE II RoD (%) 29.0 [16.0 : 51.0] 33.0 [15.0 : 53.0] 0.41
ICU Mortality (%) 18.2 24.3 0.08
Hospital Mortality (%) 26 30 0.35
Hospital SMR 0.76 0.86 -
Mortality on GC Protocol (%) 5.5 6.4 0.72
*Intensive Care Unit (ICU), Acute Physiology And Chronic Health Evaluation (APACHE),
standardized mortality ratio (SMR), Risk of Death (RoD). Data presented in Median
[inter-quartile range (IQR)] where appropriate.
Table 5.3: Patient Demographics for the STAR Christchurch and Gyula cohorts.
Cohort Characteristics STAR Gyula STAR Christchurch P-Value
Total patients 47 267
Age 66 [58 : 71] 65 [55 : 72] 0.72
Percent male 61.7 65.5 0.62
Length of ICU Stay (Days) 14.0 [8.0 : 20.5] 5.7 [2.5 : 13.4] <0.001
APACHE II Score 32.0 [28.0 : 36.0] 21.0 [16.0 : 25] <0.001
ICU Mortality (%) 38.3 24.3 0.05
Mortality on GC Protocol (%) 0 6.4 0.09
*Intensive Care Unit (ICU), Acute Physiology And Chronic Health Evaluation (APACHE). Data
presented in Median [inter-quartile range (IQR)] where appropriate.
5.2.2.2 Ethics, consent and permissions
The Upper South Regional Ethics Committee, NZ granted approval for the retrospective audit,
analysis and publication of the Christchurch patient data. According to the local ethical codes in
Hungary, the retrospective study of the Gyula cohort was considered a clinical data audit, and only
required depersonalization of data without the need for individual patient consent to analyse or
publish the anonymized data.
CHAPTER 5. CLINICAL PERFORMANCE REVIEW OF THE STAR GLYCAEMIC
CONTROL PROTOCOL 86
5.2.2.3 Episodes of GC
As a single patient may be treated by a protocol on several distinct occasions separated by significant
breaks. Therefore, a distinction is made between a patient and an episode of GC. A patient is
considered to be a person with the same ICU admission number, and an episode is considered to be
a period of contiguous treatment by GC. Therefore, there can be multiple episodes per patient.
An episode was defined as a period of GC (10 hours or more) in which there are no breaks in BG
measurements longer than 5 hours. If a gap in data exceeded 5 hours, it was considered that GC
had been stopped and restarted. Considering the maximum measurement interval on STAR is 3
hours, this choice accounts for reasonable variance in measurement intervals.
5.2.3 Clinical Practices and Implementation
5.2.3.1 Christchurch Hospital ICU, New Zealand
STAR has been the standard of care in the Christchurch Hospital ICU since June 2011. This
facility is a mixed medical, tertiary affiliated ICU. Starting criteria for STAR in Christchurch is
two successive BG measurements over 8 mmol/L within a 4-hour period. intravenous (IV) insulin
is delivered in hourly bolus form, with added background infusions of up to 3U/hour when insulin
requirements are high and sustained [128], [147]. Blood for BG measurement was typically taken
directly from an arterial line, and measured using an Arkray Super GlucocardTM II glucometer
(Arkray, Minnesota, USA), (2011-2012) or a Roche Accu-Chek Inform II (F. Hoffmann-La Roche
Ltd, Basel, Switzerland), (2012-2015).
SPRINT, the predecessor to STAR, used the same entry criteria as STAR and used the same insulin
delivery procedures [101]. Blood for BG measurement was also typically taken directly from an
arterial line, and measured using an Arkray Super GlucocardTM II glucometer (Arkray, Minnesota,
USA). Both SPRINT and STAR rely on closely-related models of the glucose-insulin system [148].
SPRINT was a paper-based protocol developed using the model to optimize recommended insulin
and nutrition delivery based on measured BG and previous interventions [101]. However, in use,
SPRINT could not explicitly calculate SI , or forward-predict the outcomes of interventions although
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it implicitly uses a crude surrogate [265]. In contrast, STAR implements the glucose-insulin model on
tablet computer and therefore identifies SI , allowing forward prediction of interventions to optimize
treatments, directly manage the risk of hypoglycaemia and personalize care [128].
For both protocols in the Christchurch Hospital ICU, patients received a similar nutrition type.
SPRINT patients are typically fed enterally with either GlucernaTM 1 Cal. (34.3% Carbohydrate,
16.7% Protein, 14.4 g/L Fibre, Abbott Labs, Illinois, USA) or Diabetic Resource (36% Carbohydrate,
24% Protein, 12 g/L Fibre, Nestle Health Science, Epalinges, Switzerland). Similarly, STAR patients
are typically fed GlucernaTM Select (31% Carbohydrate, 20% Protein,21.1 g/L Fibre, Abbott Labs,
Illinois, USA). Note all carbohydrate concentrations exclude indigestible fibre. All the formulas used
are within 2-8% of total carbohydrate and protein content and thus provide very similar nutrition
content and composition for the patients over all of the years. For both protocols, parenteral nutrition
is used occasionally to supplement enteral nutrition when necessary.
For both protocols, the same ACCP guidelines are used to determine the patients daily calorific goal
intake of 25 kcal/kg/day [156] and enteral nutrition is advised between 30% and 100% of this calorific
goal [101], [128], although fixed nutrition rates and rates up to 120% of calorific goal were included
in this study. The main difference between the SPRINT and STAR feeding regime was SPRINT
modulated feeding in steps up to +/- 10% and effectively targeted 60-70% of calorific goal [101],
whereas STAR modulated feeding in steps up to +/- 30% and targeted 100% of calorific goal [128].
Note, In Christchurch ICU patients are not weighed so ACCP caloric goal feed is approximated by
first assuming an 80 kg individual and then modifying this value based on frame size (subjective),
age and sex, see Section 7.2.1.2 Christchurch Clinical Implementation.
5.2.3.2 Gyula Hospital ICU, Hungary
Kálmán Pándy County Hospital (Gyula, Hungary), which is also a mixed medical ICU, has been
using STAR since December 2011. This ICU is markedly different from Christchurch in terms of
clinical GC practices. IV insulin is delivered via continuous infusion, and local nutrition guidelines
specify aggressive early parenteral nutrition to supplement enteral nutrition to a similar goal feed
rate of 25 kcal/kg/day. Patients are transitioned from parenteral to enteral nutrition as their stay
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progresses, and STAR modulates both rates to obtain total delivery values between 30% and 100%
of the daily goal.
Starting criteria for STAR in Gyula is also two successive BG measurements over 8.0 mmol/L within
a 4-hour period, but is subject to the clinician’s choice, depending on expected length of stay and
severity of illness of the patient. This difference in patient selection can be seen in Table 5.3, with
the Gyula cohort having much higher Acute Physiology And Chronic Health Evaluation (APACHE)
II scores and ICU length of stay. BG is measured using the E77 Elektronika Dcont Optimum or
Dcont Personal Glucometers (E77, Budapest, Hungary) with blood taken directly from an arterial
line. It should be noted that only one STAR tablet is available for use in the Kálmán Pándy County
Hospital, thus limiting the patient numbers and increasing the severity of illness of selected patients
as it was typically used for the most ill patients.
5.2.4 Analysis and statistics
Mortality on GC was calculated by working out the number of patients that died while on the GC
protocol or within 5 hours of the GC protocol ending. This statistic is used to identify patients for
whom GC might have impacted their ICU mortality.
BG performance statistics are presented as median and IQR of individual patient mean and standard
deviation values of BG, as per Finfer et. al. 2013 [137]. All hypoglycaemia and other rare occurrences
were manually verified. Due to irregular sampling intervals, patient episode BG data was also
analysed after linear interpolation at 60 min intervals, see Chapter 2 Interpretation of Retrospective
BG Measurements. Note, minutely sampling was not used as this analysis was done before the prior
chapter’s analysis had been performed. Therefore, the interpolated BG performance statistics are
also presented in median and IQR of individual episode’s mean and standard deviations of BG, as
above.
Mean hourly nutrition rates of glucose are reported, but exclude hours in which patients were not
fed, as occasionally patients could not be fed due to clinical reasons irrespective of the GC protocol.
The standardized mortality ratio (SMR) calculated in Table 5.2 was calculated using the APACHE
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II Risk of Death prediction and the recorded hospital mortality. As the number of patients in the
Gyula cohort (N=47) is significantly less than the Christchurch cohort (N=267) a p-test power
calculation is performed to assess the comparison of raw ICU mortality.
Non-parametric statistics are used exclusively for all the comparative tests due to the typically
skewed distributions of BG, insulin dose and other data. P-values were computed using the Mann
-Whitney rank-sum test for all continuous data and the chi-squared test for categorical data.
P-values <0.025 are considered statistically significant after Bonferroni correction [224] for multiple
comparisons.
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5.3 Results
5.3.1 STAR vs SPRINT Christchurch
The cohort demographics in Table 5.2 show the SPRINT and STAR Christchurch cohorts have no
significant difference in gender, age, operative status, or ICU length of stay. However, the STAR
cohort had higher APACHE II scores and ICU mortality rates than the SPRINT cohort.
Table 5.4 presents the cohort results of GC safety and performance for STAR and SPRINT in
Christchurch. In targeting the 4.4-8.0 mmol/L range using model-predictive methods to personalize
treatment, STAR reduced clinical workload in the same ICU (13.6 measurements per day per patient
compared to 15.8, P < 0.001, Table 5.4) and increased nutrition delivery per-episode compared to
SPRINT (Achieving 86% of ACCP calorific goal feed compared to 73%, P < 0.001, Table 5.5), when
allowed to feed. It did so while maintaining consistent GC for a more critically ill cohort.
Table 5.5 presents the per-patient and per-episode GC safety and performance of STAR and SPRINT
in Christchurch. These results show both STAR and SPRINT protocols resulted in over 86% time
in the BG band of 4.4-8.0 mmol/L per-episode (86.6% and 93.0% respectively), while maintaining
safe control of severe hypoglycaemia (BG < 2.2 mmol/L, 1.5% vs. 0.3% of patients respectively).
SPRINT’s lower and tighter BG target range (4.4-6.1 mmol/L), resulted in an increased incidence
of moderate hypoglycaemia (BG < 4.0 mmol/L, 62.0% vs 26.3% of patients for SPRINT and STAR,
respectively) compared to STAR.
5.3.2 STAR Christchurch vs STAR Gyula
The cohort demographics in Table 5.3 show the STAR Christchurch and Gyula cohorts have no
significant difference in gender or age. However, STAR Gyula had much higher APACHE II scores
(32 vs 21, P < 0.001), ICU length of stay (14 days vs 5.7 days, P < 0.001), and ICU mortality
(38.3% vs 24.3, P = 0.05) than the STAR Christchurch cohort. All of these results are consistent
with each other.
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Despite a significant increase in the severity of illness, STAR demonstrated consistent effective
GC performance over the Gyula cohort. Table 5.5 shows both Christchurch and Gyula STAR
cohorts achieved over 86% of time in its target range (4.4–8.0 mmol/l) per-episode (86.6% and
87.1% respectively, P = 0.81), while maintaining very safe control of hypoglycaemia per-episode,
BG < 4.4 mmol/L (0.0% and 0.9% of time respectively, P = 0.003).
Fig. 5.1 shows the STAR BG CDF in these two ICUs are almost identical, although P < 0.001
due to very large number of measurements. The per-patient BG mean and standard deviation was
also very similar for both of the cohorts (7.0 vs. 6.9 and 1.5 vs. 1.6, respectively). Thus, this
evidence suggests that STAR is able to deliver consistent GC to different cohorts with significantly
different clinical practices and illness severity. The ability for the STAR controller stochastic model
to capture both the variability seen in the Gyula and Christchurch cohort Chapter 3 Evaluation and
simplification of STAR’s stochastic model may largely account for why such similar GC performance
and safety could be achieved in these two cohorts.
Table 5.4 presents the cohort GC safety and performance results of STAR in Christchurch and Gyula.
Compared to Christchurch, the Gyula clinical staff chose to use longer intervention intervals (11.7 vs.
13.6 measurements per day, P < 0.001) and fed a significantly higher amount of glucose per-episode
(5.1 vs 7.4 g/hr, P < 0.001, Table 5.5), largely due to their higher carbohydrate parenteral and
enteral feed regime and/or composition. Thus, they required higher insulin dosing per-episode (2.7
vs 3.2 U/hr, P = 0.01, Table 5.5), amplifying the effects of SI variations [123]. This difference
ultimately resulted in the Gyula cohort having a higher occurrence of moderate hypoglycaemia



















































Table 5.4: Cohort Glycemic Control (GC) results for the STAR and SPRINT cohorts in Christchurch and Gyula Hospital Intensive Care Unit (ICU).




Number Patients 292 267 47 - -
Number Episodes 355 336 47 - -
Total Hours 40931 22948 6244 - -
Number of BG Measurements 26530 12363 3050 - -
Median [IQR] Days on protocol 3.0 [1.3 : 6.3] 1.9 [0.9 : 3.5] 3.9 [1.9 : 6.9] <0.001 <0.001
Median [IQR] Measures/day per-patient 15.8 [14.1 : 18.0] 13.6 [11.5 : 16.2] 11.7 [10.9- 13.3] <0.001 <0.001
Glycaemic Performance – Cohort Raw Data
BG Mean 5.8 7 6.8 - -
BG SD 1.3 1.3 1.3 - -
BG Median [IQR] 5.7 [5.0 - 6.6] 6.8 [6.0 - 7.9] 6.7 [5.8 – 7.8] <0.001 <0.001
Glycaemic Performance -Cohort Hourly Interpolated
BG Mean 5.7 6.7 6.6 - -
BG SD 1.2 1.2 1.2 - -
BG Median [IQR] 5.6 [5.0 - 6.4] 6.6 [6.0 - 7.4] 6.5 [5.9 - 7.2] <0.001 <0.001
% time >10.0 mmol/l 1.5 4.4 3 - -
% time 4-6.1 mmol/l (SPRINT Target) 71.4 43.9 46.5 - -
% time 4.4-8.0 mmol/l (STAR Target) 87.2 82.6 85.7 - -
% time <4.4 mmol/l 7.4 1.4 1.9 - -
% time <4.0 mmol/l 2.5 0.6 0.9 - -
% time <2.22 mmol/l 0.002 0.004 0 - -







Table 5.5: Per-patient and Per-episode Glycemic Control (GC) results for the STAR and SPRINT cohorts in Christchurch and Gyula Hospital Intensive
Care Unit (ICU).




Number Patients 292 267 47 - -
Number Episodes 355 336 47 - -
Glycaemic Performance - Per-Patient Raw Data
Median [IQR] BG mean 5.9 [5.5 - 6.3] 7.0 [6.6 - 7.6] 6.9 [6.6 - 7.4] <0.001 0.60
Median [IQR] BG SD 1.2 [1.0 - 1.6] 1.5 [1.2 - 2.1] 1.6 [1.3 - 1.9] <0.001 0.50
Median [IQR] BG median 5.7 [5.3 - 6.1] 6.7 [6.3 - 7.3] 6.6 [6.3 - 7.1] <0.001 0.28
# (%) Patients <4.0 mmol/l 181 (62.0%) 70 (26.3%) 25 (53.2%) <0.001 <0.001
# (%) Patients <2.22 mmol/l 1 (0.3%) 4 (1.5%) 2 (4.3%) 0.20 0.22
Glycaemic Performance – Per-Episode Hourly Interpolated
Median [IQR] BG mean 5.8 [5.4 - 6.2] 6.7 [6.4 - 7.3] 6.7 [6.5 - 7.1] <0.001 0.60
Median [IQR] BG SD 1.1 [0.8 - 1.5] 1.2 [0.9 - 1.7] 1.3 [1.04 - 1.5] 0.002 0.23
Median [IQR] BG median 5.6 [5.2 - 6.0] 6.5 [6.2 - 7.0] 6.5 [6.3 - 6.7] <0.001 0.61
% time >10.0 mmol/l 0.0 [0.0 - 1.6] 1.6 [0.0 - 6.5] 2.4 [0.7 - 5.4] <0.001 0.16
% time 4-6.1 mmol/l (SPRINT Target) 65.6 [52.4 - 77.9] 29.8 [12.4 – 45.9] 33.3 [21.5 - 40.9] <0.001 0.49
% time 4.4-8.0 mmol/l (STAR Target) 93.0 [85.0 - 97.5] 86.6 [75.0 - 94.1] 87.1 [79.3 - 91.1] <0.001 0.81
% time <4.4 mmol/l 7.3 [2.1 - 16.1] 0.0 [0.0 - 1.8] 0.9 [0.0 - 2.8] <0.001 0.003
% time <4.0 mmol/l 1.4 [0.0 - 5.71] 0.0 [0.0 - 0.0] 0.0 [0.0 - 1.8] <0.001 <0.001
% time <2.22 mmol/l 0.0 [0.0 - 0.0] 0.0 [0.0 - 0.0] 0.0 [0.0 - 0.0] 0.97 0.71
Intervention Performance – Per-Episode (Excluding not fed)
Median [IQR] Mean Insulin (U/hr) 2.2 [0.0 - 2.8] 2.7 [1.9 - 3.5] 3.2 [2.4 - 4.6] <0.001 0.01
Total Hours not fed (%) 16430 (40.1%) 2305 (10.0%) 0 (0.0 %) - -
Median [IQR] Mean Goal Feed (%) 73 [52 - 86] 86 [64 - 97] 80 [74 - 88] <0.001 0.28
Median[IQR] Mean Total Glucose (g/hr) 4.2 [3.1 - 5.4] 5.1 [4.0 - 6.2] 7.4 [6.2 - 8.9] <0.001 <0.001
Median [IQR] Mean Enteral Glucose (g/hr) 4.1 [3.0 - 5.3] 4.5 [2.6 - 5.6] 3.04 [1.48 - 5.40] 0.74 0.09
Median [IQR] Mean Parenteral Glucose (g/hr) 0.0 [0.0 - 0.0] 0.0 [0.0 - 1.1] 4.05 [2.84 - 5.69] <0.001 <0.001
*blood glucose (BG), standard deviation (SD). Data presented in Median [inter-quartile range (IQR)] where appropriate.
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Figure 5.1: CDF plots comparing the STAR Christchurch, STAR Gyula, SPRINT Christchurch
cohorts hourly resampled blood glucose (BG). The target BG band 4.4–8.0 mmol/L is shown in




Table 5.2 suggests a shift in severity of illness in the Christchurch ICU over the past 7 years, with the
patients on STAR being more critically ill on average than those on SPRINT and a lower surgical rate
indicating more acute cases. This phenomenon is not wholly unexpected. Increasing economic and
demographic stress worldwide has placed greater demand on limited bed spaces. In highly occupied
units like Christchurch (2.2 beds/1000 people) admission may be limited to the more critically ill
[266].
The increase in ICU mortality in patients on STAR compared to SPRINT is likely a result of the
increase in severity of illness in the STAR cohort. The hospital SMR reported in Table 5.2, shows
an increase between the SPRINT and STAR Christchurch cohorts (0.76 vs 0.86, respectively). This
result suggests the APACHE II risk of death scores are slightly more representative of the cohort’s
illness in the STAR cohort compared to the SPRINT cohort. The significant difference in the severity
of illness between the STAR Gyula and Christchurch cohorts is largely due to the different entrance
criteria, as only one STAR tablet computer is available and STAR is thus reserved for the more
critically ill patients, as clinically selected.
5.4.2 STAR versus SPRINT
Compared to SPRINT, both STAR cohorts had slightly lower time in the 4.4-8.0 mmol/L band
per-episode (86.6% and 87.1% vs. 93.0%). SPRINT targeted a lower and tighter range (4.4-6.1
mmol/L), resulting in an increased incidence of moderate hypoglycaemia (BG < 4.0 mmol/L, 62.0%
vs 26.3% and 53.2% of patients having at least one occurrence) compared to STAR. In addition,
SPRINT measured more frequently However, recent studies have shown that time in the essentially
same band, 3.9-7.8 mmol/L, is associated with improved outcomes [61], [142], [261], supporting this
slightly higher upper target limit of 8.0 mmol/L.
Flexibility to patient specific requirements is a critical aspect of the STAR model-based protocol, as
the tablet application allows nursing staff to enter any information that may change the patient’s
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insulin or nutrition requirements. This approach allows STAR to adapt to patient-specific needs and
provide appropriate recommendations that take into account all necessary considerations. However,
the effect this has had on protocol compliance has not yet been investigated.
SPRINT was deliberately designed to target nutrition to 60-70% or lower for control, which reduced
insulin requirements and thus risk of hypoglycaemia [31], [265]. SPRINT had a maximum 2-hourly
measurement rate for the same reasons of risk mitigation which increased workload relative to
STAR’s 3-hourly maximum. In addition, the tighter SPRINT target (4.4-6.1 mmol/L) is also part
of the reason for this increased nurse workload and lower feeding on SPRINT. For STAR, the use of
stochastic risk models [145], [149] and virtual patient design in-silico [154], [230] enabled the lower
workload, and also play a role in making possible the higher nutrition delivery, although a wider
overlapping target band also enables some of this increased nutrition
Both STAR and SPRINT Christchurch have the same starting and stopping criteria. However,
patients on STAR Christchurch required insulin therapy for 36.7% fewer days than SPRINT (P <
0.001, Table 5.4). Differences that could account for this significant reduction in length of treatment
for a more critically ill cohort include:
• Significantly reduced incidence of moderate hypoglycaemia (BG < 4.0 mmol/L) with STAR.
• Slightly higher median BG with STAR, with similar BG in the 4.4-8.0 mmol/L range.
• Increased mortality on the STAR protocol.
• Increased amount of carbohydrate, protein, fibre and nutrition content delivered by STAR.
The number of patients experiencing moderate hypoglycaemia are not enough to account for the
size of this change. Prior analyses have suggested that a high percentage of time, per-patient, in
target bands very similar to STAR is beneficial [61], [142], [261]. Despite the lower median BG for
SPRINT, the time in the 4.4-8.0 mmol/L band is very similar for both protocols. ICU and hospital
mortality were higher for STAR due to changes in the illness severity and demographic factors,
as seen in Table 5.2. However, the percentage mortality while on the respective GC protocol is
very similar (5.5% vs 6.4%, P = 0.72, Table 5.2), suggesting that the reduction in period of GC is
less likely to be attributed to the cohorts respective mortality. This outcome leaves the increased
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carbohydrate, protein, fibre and overall nutrition intake as a potential reason for the reduced length
of GC. However, there is significant debate about the role of energy and protein delivery in critical
illness [136], with some literature showing increased calorific intake levels that are still below the
100% calorific goal have beneficial effects [267] and others showing no effect [134]. In this study, the
median per-episode feed for the STAR Christchurch cohort was 86% of calorific goal feed, shown by
Heyland et al. [135] to be a region of reduced risk of death.
5.4.3 STAR Christchurch versus STAR Gyula
STAR entry criteria were the same in both units based on hyperglycaemia (BG > 8.0 mmol/L) or
clinician choice. STAR was used for a patient through their entire stay or multiple episodes of stay
in Gyula, and is the standard of care for the Christchurch ICU for all GC. Hence, the study, while
a retrospective analysis, is run essentially prospectively in that all patients who had STAR with the
same target band were included from each unit.
One difference between Gyula and Christchurch cohorts is that with a single tablet to run STAR
in Gyula, clinician’s chose the more ill patients they thought would benefit. This choice could
likely have biased the severity of illness upwards, as well as the length of stay (Table 5.3). It may
have similarly affected the difference in ICU mortality in Table 5.3, although this comparison is
significantly underpowered given the low patient numbers in Gyula and could thus also be due
to statistical variation. Hence, variation in these cohorts is biased by this choice and the results
in Table 5.3 could be due to one or a combination of these factors. However, a recent study by
Uyttendale et. al [255] has shown that mortality is independent of patient variability, thus does not
effect a protocol’s ability to provide GC. Therefore, this difference is not as relevant to showing that
STAR can provide safe, effective GC results across very different patients and clinical practices.
In the STAR Christchurch cohort, 4 patients experienced severe hypoglycaemia and in the Gyula
cohort 2 patients experienced severe hypoglycaemia. STAR’s model-based predictive GC forward
predicts potential patient-specific behaviour using the 5th and 95th percentile, choosing an intervention
to optimize the placement of these stochastic bounds [128], [145]. Therefore, all of the hypoglycaemic
cases occurred outside of STAR’s cohort based model-predictive bounds. Each of these patients had
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a 99th percentile (outlier) patient-specific model-based insulin sensitivity during their hypoglycaemic
episode and the number of events suggest this is a 1 in 100 event, which broadly matches the cohort
results observed in Table 5.5.
It is worth noting that all of the severe hypoglycaemic events on STAR, in Christchurch, occurred
at high fixed nutrition rates over 100% of ACCP goal feed, but < 120%. High fixed nutrition
rates raise BG all else equal, resulting in the need for higher or maximum insulin rates to control
hyperglycaemia. The large amount of insulin in the patient then amplifies any small changes in the
patient’s SI due to changes in condition, significantly reducing the ability to control BG safely and
effectively [123]. Despite high fixed nutrition inputs, up to 120% goal feed in some cases, making
GC more difficult, it also is an important feature of the STAR application allowing it to be more
flexible to specific clinical needs. However, in these specific cases lower (100% or less) and/or variable
nutrition would have allowed greater safety [128].
5.4.4 Limitations
A total of 19 patients were excluded from the STAR Christchurch (15) and Gyula (4) analysis as
they received more than 120% of ACCP recommended caloric target on average. In some instances
the high level of nutrition may be clinically specified. However, in most cases the high level of
nutrition is due to nursing staff choosing to fix enteral and/or parenteral feed on STAR.
The discrepancy in patient numbers between the two STAR cohorts, over approximately the same
time period, is due to only one of STAR tablet being available in Gyula, compared to 10 in
Christchurch. The number of patients in the Gyula cohort is low. Therefore, there is not yet have
enough power (52%, p-test) for comparison to the Christchurch cohort in relation to raw mortality
on the STAR GC protocol in Gyula, or morbidity and per-patient BG statistics (e.g. per-patient
TIB, mean/median BG). Sufficiently more patients would be required for a well powered outcome
study on mortality or morbidity.
It should be noted that there was also patient selection bias for STAR Gyula, creating significantly
different cohorts in terms of ICU length of stay and severity of illness (P < 0.001, Table 5.3). The
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difference in the cohorts could result in GC being more complex or simpler in the Gyula cohort
relative to the Christchurch cohort due to more severely ill patients having more complications or
possibly longer length of stay patients being more stable. However, it also enables generalisability
and repeatability of STAR to be shown over very different cohorts.
As mentioned previously, STAR and SPRINT target different BG bands (4.4-8.0 mmol/L and 4.4-6.1
mmol/L, respectively). These BG targets overlap, but vary in width and level of BG. Therefore, the
comparison of these two protocols in terms of percentage of time in 4.4-8.0 mmol/L BG band may
be an unfair statistic considering that only one the protocols actually targeted this band. The only
way to fully and fairly compare the two protocols performance would be if they both targeted the
same BG target.
To compare the STAR GC protocol to other ICU GC protocols is difficult as the cohorts need to
be similar and the same statistics need to be reported, as seen in Section 1.2.3 Glycaemic Control
Protocols. Considering performance, safety and workload to achieve them, that other studies have
shown similar performance based on time in band [129], [138], [214], [268]. STAR achieved these
performance and safety results with a lower relative clinical workload over a much larger, more
diverse and relatively very ill cohort. With the data available, it appears STAR performs very well
in comparison to other current ICU GC protocols with better safety and lower workload. However,
a best protocol cannot be determined without the same statistics being reported and the cohorts
being much more similar.
Sensor error can affect the quality of control [269], particularly in target to value protocols [270].
SPRINT was designed in silico to be robust to these errors for the Arkray Super GlucocardTM II
glucometers used (CV approximately 9.35 % [256], [257]). STAR is more robust to this error due to
its target to range approach, using the 5th and 95th percentile of the SI stochastic model, to guide
robust control. In addition, Christchurch Hospital ICU changed to the more reliable Accu-Chek Infor
II glucometer in 2012 (CV approximately 6.0% [258], [259]). The Gyula unit used a E77 Elektronika
Dcont Optimum or Dcont Personal Glucometers (CV < 4.6%).
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As seen previously in Chapter 2 Interpretation of Retrospective BG Measurements, minutely interpolation
resulted in the best representation of a GC protocols BG performance statistics. However, minutely
interpolation was not used in this analysis as the research into interpolation occurred after this
research had been completed. As a consequence the BG percentage of time out of the targeted band
statistics may be slightly conservative, although very unlikely to be significant, see Chapter 2.
By using model-based predictive GC tailored to patient-specific metabolic response, through identifying
their respective time variant SI , safe and effective GC can be offered. With the stochastic models
of SI variability used, Chapter 3 Evaluation and simplification of STAR’s stochastic model, STAR
thus directly manages inter- and intra- patient variability to improve safety. Other protocols could
have failed in the past due to their inability to adjust for this inter- and intra- patient variability
via model-based GC on a computer. Considering this study is a retrospective analysis, as opposed
to a randomized control trial, we cannot explicitly link the outcomes to GC. Hence, the main focus
of this study is to demonstrate that safe, effective and generalizable GC is possible. To this end,
STAR is also currently undergoing a clinical trial at the International Medical University Medical
Centre, Kuala Lumpur, Malaysia, furthering investigating it’s generalisability across ICUs.
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5.5 Summary
This retrospective, observational study analysed the GC safety, performance and generalizability
of the STAR protocol in Christchurch, NZ and Gyula, Hungary. Results of STAR’s predecessor,
SPRINT, were presented for comparison. Patients on the STAR protocol spend over 86% of all
time on protocol within the goal 4.4-8.0 mmol/L BG band, with very few occurrences of severe
or moderate hypoglycaemia. STAR outperformed SPRINT by providing higher nutrition and safe,
effective control for all days of stay, as well as reducing time on protocol and workload.
Overall, in Christchurch, the STAR framework has shown an ability to adapt well to a wide range of
situations, and provide safe and effective treatment at all times. It has also reduced clinical burden
in the ICU, by lowering the number of measurements and interventions needed to achieve equivalent
control to SPRINT, while improving safety.
A key criteria for success in any protocol is the ability to demonstrate high performance and high
safety across patient types, time, clinical practice culture, and clinical resources. The results of
the STAR protocol in Gyula, Hungary are used to analyse this criteria. The results show STAR
comprehensively meets these criteria, with the BG distributions of the two cohorts being almost
identical even though the clinical practices are significantly different. Thus, this research shows how
a model-based and personalized approach to GC can safely improve care and reduce workload across
differing clinical practices.
The retrospective results prove STAR is a promising GC protocol clinically, with greater generalisability
than other published protocols. However, further investigation into protocol compliance is required
to ensure this outcome is a result of the protocol and not clinical staff involved. In addition, further
investigation into nutrition feeding protocols is required, as fixed feeding was consistently present
when hypoglycaemia occurred, counter to STAR’s normal use, and is an area of concern for clinicians.
Chapter 6
Compliance of the STAR Glycaemic
Control Protocol
6.1 Background
As discussed previously in Section 1.2 Glycaemic Control in the Intensive Care Unit, the benefit of
GC is still heavily debated, with mixed evidence shown for both cases [264]. Before the physiological
benefits and/or consequences of GC can be assessed, effective GC needs to be achieved clinically,
reducing both hyper- and hypo- glycaemia [260] . Some previous attempts of GC have failed
due to increased occurrence of hypoglycaemia and/or not effectively reducing the prevalence of
hyperglycaemia [103], [105], [107], [108], [110], [111], [213]. These issues hinder the ability to see
the potential physiological benefit of GC. The poor performance of these previous attempts at GC
may not necessarily be due to the theoretical implementation of the GC protocol, but the clinical
impracticality of the GC protocol and resulting poor clinical staff compliance to the protocol [151],
[271], [272].
GC protocol adherence can be very protocol specific, depending on the clinical demands and
flexibility of the protocol, and has been shown to be directly related to the resulting GC performance
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[138], [273]. Therefore, for a GC protocol to be clinically effective it must both be practically
implementable, in terms of workload and clinical flexibility, while still being able to provide safe and
effective GC. Only once this outcome is achieved can the potential physiological benefits of GC be
investigated.
The tablet-based STAR GC protocol has been designed to be clinically flexible and still provide
patient-specific GC [128], [147]. STAR uses a clinically evaluated pharmaco- kinetic and dynamic
model of the insulin-glucose system [31], [148] and a cohort based model of SI variability [145],
[149] to compute the optimal patient-specific insulin and nutrition interventions which maximize
time in targeted band, and nutrition, while maintaining a maximum 5% risk of BG < 4.4 mmol/L
[128], [147]. STAR adapts to nurse workload by allowing variable 1-3 hourly BG measurement
frequencies, selected (largely) by nurses. In addition, if clinical circumstances arise, resulting in
STAR’s GC intervention not being able to be followed, STAR is able to adapt future treatments to
this limitation, furthering its clinical flexibility. As seen in Chapter 5 Clinical performance review
of the STAR Glycaemic Control protocol, STAR is able to provide patient-specific, safe and effective
GC. However, an investigation into protocol compliance is required to ensure this outcome is a result
of the protocol and not clinical staff involved.
The aim of this retrospective analysis is to review the compliance of STAR data input, and recommendations.
Clinical bedside sheets are reviewed for data input reference and the recommendations recorded by
STAR are used to assess recommendation compliance. The results of this analysis will assess the
clinical practicability of the STAR protocol and allow clinically impractical areas to be addressed.
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6.2 Methods
6.2.1 STAR Tablet Protocol
Starting criteria for STAR in the Christchurch Hospital ICU, NZ is two successive BG measurements
over 8.0 mmol/L within a 4 hour period. IV insulin is delivered in hourly bolus form, with added
background infusions of up to 3.0 U/h when insulin requirements are high and sustained [128], [147].
EN interventions are changed by STAR, in maximum steps of ±30% of the patients daily caloric goal
[128]. ACCP guidelines are used to determine the patients daily caloric goal intake of 25 kcal/kg/day
[156] and EN is advised between 30% and 100% of this caloric goal [128]. PN interventions are not
changed by STAR, and are only changed at the clinical staff’s discretion. However, PN interventions
are still required to be recorded by STAR. Blood for BG measurement is typically taken directly
from an arterial line and measured using a PoC BG meter.
STAR makes recommendations to clinical staff based on a patient’s, model identified, current and
predicted future metabolic state captured by SI . If a patient’s BG is currently within the targeted
BG band (typically 4.4-8.0 mmol/L), clinical staff have the flexibility to choose between 1-3 hour
measurement intervals. However, if a patient’s BG is outside the targeted BG band, clinical staff are
limited to hourly measurements. After every BG measurement, clinical staff are required to enter BG
information, and enter/confirm insulin and nutrition information. The STAR software framework
is designed to be very flexible allowing clinical staff to modify and/or add historical information,
and also change the intervention given from what STAR recommended due to interfering clinical
circumstances [274], [275].
6.2.2 Patient Data
Clinical data for compliance analysis was obtained from 221 patients treated with the STAR GC
protocol in Christchurch Hospital ICU, NZ [215]. A randomly chosen subset of 20 patients was
chosen from this cohort for data entry compliance assessment. A smaller cohort was chosen due
to the labour involved with manually checking paper-based records. The entire cohort was used
for assessment of recommendation compliance. The Patient demographics for both cohorts can be
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seen in Table 6.1. The Upper South Regional Ethics Committee, New Zealand granted approval for
the retrospective audit, analysis and publication of the Christchurch patient data. Note, a single
patient may be treated by the protocol on several distinct occasions separated by significant breaks.
Therefore, a distinction is made between a patient and an episode of GC, see Section 5.2.2.3 Episodes
of GC.
Table 6.1: Demographic data of the cohorts used for STAR protocol compliance assessment.
STAR Chch Cohort STAR Sub-cohort P-Value
Patient Demographics
Num Episodes: 286 33 -
Num Patients: 221 20 -
Age [IQR]: 64.00 [54.00 - 72.00] 67.50 [53.50 - 76.00] 0.54
Gender (% Male): 66.1 60.0 0.63
ICU Length of Stay (Days) [IQR]: 8.43 [3.14 - 15.33] 9.49 [3.04 - 12.22] 0.89
Days on Protocol [IQR]: 2.67 [1.50 - 5.67] 6.67 [1.77 - 9.67] -
Percent Operative: 29.0 35.0 0.61
APACHE II Score [IQR]: 21.00 [16.00 - 27.00] 20.00 [14.00 - 22.00] 0.25
Overall ICU Mortality (%): 28.1 5.0 0.03
Overall Hospital Mortality (%): 33.0 10.0 0.04
Mortality on GC (%): 7.7 0 0.37
GC Performance Statistics per patient
BG mean (mmol/L): 6.66 [6.36 - 7.21] 6.86 [6.57 - 7.49] 0.04
BG SD (mmol/L): 1.17 [0.85 - 1.65] 0.96 [0.74 - 1.44] 0.07
% time BG >10.0 mmol/L 1.22 [0.00 - 5.56] 0.00 [0.00 - 6.25] 0.85
% time BG within 4.0-8.0 mmol/L 88.42 [77.42 - 94.44] 89.86 [73.94 - 95.54] 0.89
% time BG <4.4 mmol/L 0.00 [0.00 - 1.79] 0.00 [0.00 - 0.00] 0.02
% time BG <2.22 mmol/L 0.00 [0.00 - 0.00] 0.00 [0.00 - 0.00] 0.74
*inter-quartile range (IQR), Acute Physiology And Chronic Health Evaluation (APACHE),
Glycemic Control (GC), blood glucose (BG), standard deviation (SD). Data presented in Median
[IQR] where appropriate.
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6.2.3 Compliance Assessment
The manner in which data is recorded by the STAR tablet and the flexibility integrated into the
STAR software creates two areas of compliance:
Data entry compliance: Tablet data entry matches what was recorded on the bedside
sheet. Note, this is the ’official’/’legal’ record for the ICU
patient.
Recommendation compliance: STAR’s recommendations matches what was recorded by
STAR as having been given.
6.2.3.1 Data entry compliance
Bedside sheets were collected for 20 randomly chosen patients from Christchurch Hospital ICU, NZ.
The data collected from the bedside sheets was then directly compared to the information collected
from the STAR tablets (BG, insulin, and nutrition values). Cross referencing these two records can
result in 3 different cases:
Case 1: Both records have a value present at a similar point in time:
(tST AR − 60) ≤ tBedside ≤ (tST AR + 30)
Therefore, the recorded values can be directly compared.
Case 2: STAR has a recorded data point, but no bedside sheet data exists around this point
in time.
Case 3: The bedside sheet has a recorded data point, but no STAR data exists around this
point in time.
Note, the STAR tablet records interventions to the nearest minute and you can typically expect
around ±10-15 minutes delay between recording and the actual intervention [276]. In contrast, the
bedside sheet only records interventions to the nearest hour. To account for this difference, a timing
tolerance was added when matching up interventions. A STAR tablet data point was considered to
match a bedside sheet data slot if it occurred up to an hour after the bedside data slot to account
for truncation of time, where for example the STAR recorded time of 13:42 → bedside sheet slot of
13:00. Equally, a STAR tablet data point was considered to match a bedside sheet data slot if it
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occurred up to half an hour before the bedside data slot to account for rounding up of time, where
for example the STAR recorded time of 13:42 → bedside sheet slot of 14:00.
All of the cases mentioned above can occur in BG measurements and interventions given (Insulin,
EN, and PN). As it is difficult to state whether absence or presence of data is non-compliant (Case
2 and 3), the main focus of this analysis will be on matched measurements (Case 1). However, the
absence and presence of data will still also be reported. When comparing nutrition interventions
a tolerance of ±0.05 mmol/min was used to allow for small discrepancies in the nutrition content
given. No tolerance was given for the BG measurements and insulin interventions.
This analysis assumes all the data recorded on the bedside sheets is correct. Any absence of data
on the bedside sheet was assumed to be zero for lack of better knowledge. Note, this may limit
the validity of some of the intervention compliance results, such as in interventions that are held
constant i.e. insulin infusions and/or nutrition interventions.
6.2.3.2 Recommendation compliance
STAR tablet data was recorded for 221 patients in Christchurch Hospital ICU. The recommendations
provided by STAR at each intervention is recorded by the tablet. These recommendations can then
be directly compared to the data input into the STAR tablets (BG, insulin and nutrition values).
Using this information a compliance to the STAR GC protocol recommendations can be determined.
It should be noted that a deviation from STAR’s recommendation may not represent non-compliance,
but could be a result of clinical circumstances resulting in the intervention unable to be undertaken.
CHAPTER 6. COMPLIANCE OF THE STAR GLYCAEMIC CONTROL PROTOCOL 108
6.3 Results
6.3.1 Data entry compliance
The 20 bedside sheet review showed high compliance in all interventions, with both BG and
insulin interventions approximately 94% compliant. Both nutrition interventions had slightly lower
compliance of approximately 87%, and a large spread per-patient with an IQR of 20.6% and 47.2%,
for EN and PN respectively. In addition, when non-compliance did occur in any intervention,
particularly BG measures and EN interventions (+0.2 mmol/L and +0.05 mmol/L), it was only a
small difference. Percentages of missing data in STAR or on the bedside was approximately none,
median differences for all cases being 0.0%, with the largest discrepancy being in the EN intervention
information (0.5%).
109 6.3. RESULTS
Table 6.2: STAR protocol data entry compliance results of the 20 patient STAR sub-cohort.
Matched Data Compliance
Number Bedside Sheets 20
Number Hours 3634
Number Measurements 1557
Percentage input compliance per-patient
BG Measures (%) 94.7 [93.3 : 96.2]
Insulin Doses (%) 94.8 [93.8 : 98.2]
EN Interventions (%) 86.5 [76.8 : 97.4]
PN Interventions (%) 88.2 [52.6 : 99.8]





Non-compliant intervention differences (= STAR Data−Bedside Data)**
BG Measurement (mmol/L) 0.2 [-0.1 : 0.7]
Insulin Dose (mU/min) 500.0 [-16.7 : 3016.7] (18.5 [-0.6 : 111.8] %)
EN Intervention (mmol/min) 0.05 [-0.14 : 0.13] (13.2 [-36.8 : 34.2] %)
PN Intervention (mmol/min) -0.20 [-0.26 : -0.15] (-50.0 [-65.0 : -37.5] %)
Percentage on Bedside and NOT on STAR
BG Measures (%) 0.0 [0.0 : 1.8]
Insulin Doses (%) 0.0 [0.0 : 0.6]
EN Interventions (%) 0.5 [0.0 : 1.5]
PN Interventions (%) 0.0 [0.0 : 2.9]
Percentage on STAR and NOT on Bedside
BG Measures (%) 0.0 [0.0 : 1.8]
Insulin Doses (%) 0.0 [0.0 : 0.3]
EN Interventions (%) 0.0 [0.0 : 0.8]
PN Interventions (%) 0.0 [0.0 : 0.0]
*blood glucose (BG), enteral nutrition (EN), parenteral nutrition (PN). Data presented in Median
[inter-quartile range (IQR)] where appropriate. **Relative differences based on median values in
Chapter 5 Clinical performance review of the STAR Glycaemic Control protocol.
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6.3.2 Recommendation compliance
Both cohorts had extremely good recommendation compliance, with all of STAR’s recommendations
being changed very infrequently, as shown in Table 6.3. In addition, when interventions were changed
it was either to decrease the insulin bolus given by 1.0 U, increase the insulin infusion by 1.0 U
or increase the EN and PN feed rate by approximately (20 mL/hr). Similar to the data entry
compliance, both nutrition recommendations had a lower, lower quartile compliance. The median
and IQR for all interventions of both cohorts is similar, suggesting the STAR sub-cohort represents
the compliance of the entire STAR cohort relatively well.
Table 6.3: STAR protocol recommendation compliance results for the entire STAR cohort and
sub-cohort.
STAR Chch cohort STAR Sub-cohort
Number of Patients 221 20
Hours 16,834 3,837
Number Measurements 8,833 1,836
Per-patient percentage recommendation compliance
Insulin Bolus (%) 100.0 [100.0 : 100.0] 100.0 [100.0 : 100.0]
Insulin Infusion (%) 100.0 [100.0 : 100.0] 100.0 [100.0 : 100.0]
EN (%) 100.0 [96.3 : 100.0] 99.0 [97.1 : 100.0]
PN (%) 100.0 [98.8 : 100.0] 100.0 [99.0 : 100.0]
Total number of recommendations changed
Insulin Bolus 22 3
Insulin Infusion 10 1
EN 120 37
PN 6 2
Changed interventions differences (= Recommended−Given)
Insulin Bolus (U/hr) 1.0 [-1.0 : 2.0] 1.0 [-2.8 : 1.7]
Insulin Infusion (U/hr) -1.0 [-2.0 : 1.0] -1.0 [-1.0 : -1.0]
EN (ml/hr) -20.0 [-24.0 : -7.7] -16.0 [-20.0 : 1.8]
PN (ml/hr) -15.0 [-80.0 : 20.0] -20.0 [-20.0 : -20.0]




6.4.1 Data entry compliance
All matched interventions had a median patient compliance greater than 86% (Table 6.2), with both
insulin and BG interventions being greater than 94.7%. In addition, when non-compliance did occur
in any intervention, it was likely to be very small. Equally, there was approximately no bedside
sheet information not entered into the STAR tablet, and vice-versa, with the median patient for all
cases being approximately 0.0%. Therefore, the information entered into STAR by clinical staff was
extremely good, and the large majority of recorded data can be considered true and accurate.
The lowest and largest range of data entry compliance was seen in both EN and PN interventions
(Median patient 86.5% and 88.2%, Table 6.2). This suggests there may be issues around the recording
of all nutritional interventions. However, as only EN interventions are changed by STAR, and PN
interventions are up to the clinical staff’s discretion, only poor EN compliance can be a result of GC
protocol non-compliance. The lower compliance on the EN interventions could be due to:
1. Changing feed frequently is difficult and/or impractical to do in the clinical setting. Resulting
in clinical staff finding it easier to leave the feed rate constant, while the STAR tablet believes
it is changing, as evidenced by the variable EN intervention differences, Table 6.2. In addition,
during the normal practice of ICU patient care, a patient’s feed rate is usually kept constant,
infrequently being stopped or reduced due to clinical circumstances or gastric tolerance. Thus,
frequent changing of feed rate for GC is foreign practice.
2. There is a negative stigma around changing/lowering a patient’s feed rate due to not receiving
their prescribed ACCP caloric goal. Although, the lowering of feed rate by STAR is usually
for a very short time period (Typically 3-5 hours), and the feed rates achieved overall are a
median of 86%, per-patient [215]. However, if this were true the EN intervention differences
would be consistently negative, Table 6.2, which they are not.
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3. Data entry for nutritional interventions is often forgotten. As the feed rate given to a patient
may be changed due to other clinical circumstances other than GC, it may be not updated
within the STAR tablet. As evidenced by the consistently negative PN intervention differences,
implying that the STAR tablet was not updated about the nutrition intervention change.
All of these are valid reasons for the low EN compliance, and could contribute to the higher
non-compliance seen in EN interventions. In addition, the lower, lower quartile PN compliance
may be due to PN interventions requiring a clinician to enter this information into STAR, rather
than STAR prompting the clinician about its value. Hence, making data entry of PN more easily
forgotten.
As the BG and insulin data entry compliance was relatively high, and the measurement discrepancies
when non-compliant were very low (median BG measure +0.2 mmol/L on STAR and median insulin
dose +500 mU/min on STAR, Table 6.2), non-compliance is likely due to accidental data entry error
by the clinician. The differences in BG values entered are not large enough to imply purposeful
modification of the resulting recommendation offered by STAR. In addition, as the insulin dose
non-compliance differences are commonly only different by 0.5 U and/or 16.67 mU/min (1 U/hr
infusion), implying accidental data entry error or STAR not being notified about the starting or
stopping of a 1 U/hr insulin infusion. Thus, the slight reduction in both the BG and Insulin data
entry compliance is most likely due to accidental data entry error by the clinician and STAR not
being updated about insulin infusion changes.
It should be noted, if information is entered incorrectly into the STAR tablet it will result in the
identified patient-specific SI to be either higher or lower than its actual value. Resulting in the
recommendation given by STAR being either too aggressive or conservative. Thus, directly effecting
GC performance. However, as STAR recommends interventions based on a 90% confidence interval
the impact of incorrect data entry is minimised, as seen by the GC results in Table 6.1.
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6.4.2 Recommendation compliance
The compliance of clinical staff following STAR’s recommendations was extremely high, with approximately
100% of interventions followed in both cohorts (Table 6.3). In addition, given the total number of
measurements and the total number of recommendation changes, a recommendation change is a
very rare occurrence, occurring approximately once every 43-56 measurements. Thus, showing the
strong compliance, and, as a result, trust of the STAR protocol.
Again, a minor discrepancy in the nutrition interventions was seen in the IQR in Table 6.3, consistent
with the previous observations of data entry compliance. In addition, EN recommendations had the
highest numbers of non-compliant cases in both cohorts (120 and 37, Table 6.3), emphasising the
non-compliance of STAR’s feed recommendations. The discrepancies in nutrition recommendations
were consistently negative, suggesting that clinicians would consistently increase the nutrition interventions
from what STAR recommended by approximately 20 mL/hr Table 6.3, emphasising point 2 of the
reasons discussed in the previous section. However, these discrepancies could be due to all of the
reasons discussed in the previous section. Equally, nutrition interventions are the most likely of the
GC interventions to be altered by clinical circumstances, due to factors such as medical imaging,
surgery, gastric tolerances etc. Therefore, making this discrepancy in the nutrition interventions less
significant.
The number of non-compliant cases for both insulin bolus and infusion recommendations was very
small in both cohorts. However, when an insulin intervention was changed, it was commonly to
decrease the insulin bolus given by 1.0 U or increase the insulin infusion by 1.0 U/hr. This suggests
that both less and more aggressive interventions were desired from the clinicians. However, the IQR
of differences in Table 6.3, implies this is not consistent in all non-compliant insulin interventions.
Overall, showing that the insulin interventions recommendations of STAR offer a good balance
aggressive and safe GC.
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6.4.3 Limitations
This analysis assumes all the data recorded on the bedside sheets is correct. In addition, any
absence of data on the bedside sheet was assumed to be zero. However, from assessing trends in
recorded insulin and nutrition data this assumption may be incorrect. In particular, the bedside
sheet nutrition data (both enteral and parenteral) occasionally had a delay (1-2 hours) in the value
being recorded by the STAR tablet, thus appearing as poor data entry compliance in this analysis.
This may be due to the clinical staff not immediately updating STAR when the feed is stopped or
started due to clinical circumstances. As a result, this may be one of the reasons for the poorer
nutrition intervention compliance seen in Table 6.2.
The STAR sub-cohort only gives an approximate representation of the entire STAR Christchurch
cohort, having similar demographic statistics of Age, Gender, ICU Length of stay and APACHE II
Score (Table 6.1). However, there is a significant discrepancy in both ICU and Hospital mortality
(P = 0.04, Table 6.1), although, this should not effect the compliance to the STAR protocol.
In addition, the GC achieved and recommendation compliance in both cohorts was similar, both
spending approximately 89% of time in the targeted 4.4-8.0 mmol/L band (P = 0.89, Table 6.1), and
having almost identical recommendation compliance statistics. These results suggest the sub-cohort
is a representative sample of the entire STAR cohort in terms of protocol compliance, and that
future studies could use a similar, smaller group.
Overall, the high compliance seen by the STAR protocol suggests it is clinically practical and
implementable, with enough flexibility to handle unexpected clinical circumstances and workload.
This result suggests that the GC performance achieved by STAR seen in Chapter 5 Clinical performance
review of the STAR Glycaemic Control protocol, is a function of the GC protocol and not the clinical
staff involved. In addition, this analysis has shown that STAR’s clinical usability may be improved
by adjusting the nutrition intervention protocol and tablet recording.
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6.5 Summary
This chapter investigated the compliance of the STAR GC protocol in terms of data entry and
following STAR’s recommendations. The information recorded by the STAR tablet was compared
to bedside sheet information and STAR’s recommendations. Data entry compliance was very high,
with all intervention having over 86% of data entered correctly. Recommendation compliance was
approximately 100%, with 1 in every 43-56 recommendations being changed, largely due to nutrition
recommendation changes. In both the data entry and and recommendation compliance, the nutrition
interventions (EN and PN) compliance was consistently lower than other interventions. This gap is
likely due to either to the difficulty associated with changing the feed rate or clinical circumstances
changing the feed rate and STAR not being updated.
This analysis supports the argument that STAR is a safe and effective GC protocol which clinical
staff trust, and is flexible enough for the clinical environment to allow for very high compliance.
However, it also shows that there is a slight room for improvement in terms of the way in which
nutrition interventions are handled. Further investigation to the benefits of variable nutrition and
potential simplification should be investigated.
Chapter 7
Clinical nutrition delivery of STAR
7.1 Background
The STAR GC protocol is unique in maintaining normal BG levels by changing both insulin and
nutrition interventions [128], [147]. Changing nutrition interventions differentiates STAR all from
other ICU GC protocols, which only change insulin interventions (e.g. [109], [126], [129], [214],
[277]). STAR maximises nutrition in the context of GC to the targeted 4.4-8.0 mmol/L BG range
[128], [147]. Hence, the level of nutrition it provides is a patient-specific, time-varying estimate of
the ability to take-up glucose, and is only reduced in the face of significant insulin resistance.
Currently, there is also significant debate over the appropriate amount to feed an ICU patient. Many
studies have shown mixed results in reviewing caloric intake, route, and timing, and their relation
to outcome [100], [131], [134]–[136], [278]–[284]. Cahill et al. [263] surveyed the overall nutrition
performance of 158 ICUs, from 20 countries, finding significant variation in nutrition delivery. This
study also found the largest improvement for mortality outcomes to be at 85% of the caloric goal
nutrition rate set by the respective ICU [135].
1Stewart KW, Chase JG, Pretty CG, Shaw GM. Nutrition delivery of a model-based ICU glycaemic control
system. Ann. Intensive Care. 2018;8:4.Stewart KW, Chase JG, Pretty CG, Shaw GM. Nutrition delivery of a
model-based ICU glycaemic control system. Ann. Intensive Care. 2018;8:4.
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This ideal value, and the best performing unit surveyed, are used in this chapter as benchmarks for
assessing the clinical performance of STAR’s nutrition delivery.
This chapter first evaluates STAR’s clinical provision of nutrition, to a cohort of hyperglycaemic
ICU patients, compared to reports including all ICU patients in other ICUs from the survey of [263].
This comparison assesses if safe, effective GC precludes or limits high nutrition delivery, as well as
determining if nutrition restriction to obtain effective GC limits total nutritional intake. Second,
the inter- and intra- patient variation of nutritional delivery, while maintaining normo-glycaemia,
is assessed to evaluate the range of glucose/nutrition tolerance in ICU patients on GC. Third, the
relationship between morbidity and mortality, and nutrition delivery is retrospectively assessed to
determine if nutrition restriction from GC affects outcome. The main outcomes assess, at a cohort
level, the nutrition clinically provided by using STAR, in an international context, and whether or
not a ’best’ nutrition rate is patient-specific, when considering patients requiring GC.
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7.2 Methods
7.2.1 STAR GC Protocol
7.2.1.1 GC Protocol Overview
STAR modifies nutrition rate depending on the bounds of predicted potential behaviour, with a
preference to increase insulin before reducing nutrition, and to raise nutrition whenever possible
[128], [147]. Full details of protocol methodology can be seen in Section 1.2.4 Stochastic Targeted
(STAR) Glycaemic Control. STAR modulates this nutrition rate between 30-100% of the caloric
goal, with a maximum step change of ±30% of caloric goal per hour [128]. ACCP guidelines are
used to determine patient-specific daily caloric goal based on 25 kcal/kg/day [156].
Overall, STAR attempts to provide the maximum nutrition rate a patient can tolerate, while keeping
BG in the targeted 4.4-8.0 mmol/L range. However, in some patients, insulin saturation limits the
ability of insulin to lower BG on its own [285]–[287], thus requiring nutrition restriction to assist
in the lowering of BG. If the provision of excess carbohydrates, above this saturation limit, results
in excess BG, the nutrition rate achieved by STAR represents an ‘ideal’ patient-specific nutrition
rate that does not result in hyperglycaemia, based on their current ability to tolerate glucose. It is
thus a surrogate for a patient, and time specific maximum tolerable feed in the context of safe and
effective GC.
7.2.1.2 Christchurch Clinical Implementation
Clinical data from 221 hyperglycaemic ICU patients treated with STAR (2011-2015) [215] in the
Christchurch Hospital ICU (mixed medical ICU) was used to assess the performance of its variable
nutrition delivery. BG, insulin and nutrition data is automatically collected by the STAR tablets
when patients are on GC. The Upper South Regional Ethics Committee, New Zealand granted
approval for the audit, analysis and publication of the retrospective data. Cohort demographics are
given in Table 7.1.
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Table 7.1: STAR cohort patient demographics and GC performance statistics
Patient Demographics
Number of Patients 221
Number Hours of GC 21,769
Age 64.0 [54.0 - 72.0]
Sex (% Male) 66.1
ICU length of stay (Days) 8.4 [3.1 - 15.3]
Days on GC 2.67 [1.50 - 5.67]
Admission to GC Start (Hours) 17.5 [7.3 – 53.8]
Operative (%) 29.0
APACHE II Score 21.0 [16.0 - 27.0]
ICU Mortality (%) 28.0
GC Performance Statistics
BG mean per-patient 6.66 [6.36 - 7.21]
BG SD per-patient 1.17 [0.85 - 1.65]
% time BG 4.4-8.0 mmol/L, per-patient 88.42 [77.42 - 94.44]
% time BG 4.4-8.0 mmol/L, cohort 83.2
% time BG <4.4 mmol/L, cohort 1.35
# Patients <2.2 mmol/L 4
*Acute Physiology And Chronic Health Evaluation (APACHE), Glycemic Control (GC), blood
glucose (BG), standard deviation (SD). Data presented in Median [inter-quartile range (IQR)]
where appropriate.
STAR has proven to provide excellent GC in this cohort, spending over 88% time, per-patient, in the
targeted 4.4-8.0 mmol/L range, Table 7.1. STAR patients in Christchurch are typically fed enterally
with low carbohydrate GlucernaTM Select (74.6 g/L Carbohydrate, 50 g/L Protein, 21.1 g/L Fibre,
Abbott Labs, Illinois, USA), where these carbohydrate concentrations exclude indigestible fibre. PN
is used occasionally, at clinicians discretion, to supplement EN. While STAR knows the PN value,
it does not regulate it, enabling the possibility of nutrition delivery over 100% of the caloric goal.
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Patients are not weighed in the Christchurch ICU so ACCP caloric goal feed is approximated by
first estimating the patient weight. This estimation first assumes an 80 kg individual, and then
modifies this value based on frame size (subjective assessment; small, medium, large), age and sex.
The process uses Table 7.2 and Eq. (7.1) [112].
Table 7.2: Coefficients used to determine an ICU patient’s estimated weight in Christchurch
Hospital ICU.
Frame Size (F) Small Medium Large
0.9 1.0 1.1
Age (A) ≤39 40-59 60-79 ≥80
1.1 1.0 0.9 0.8
Gender (G) Male Female
1.0 0.8
A× F ×G× 80 = estimated weight kg (7.1)
Eq. (7.1) modifies the estimated weight of 80 kg into a maximum range of 46.1-96.8 kg. In this
cohort, the median and IQR of estimated weight was 72.0 [64.3 - 79.7] kg. This value is multiplied
by the 25 kcal/kg/day ACCP caloric goal to find the patient’s daily caloric goal. Due to clinical
circumstances a patient’s nutrition may be stopped or reduced significantly, for short periods, not
reflective of the STAR feeding algorithm. Therefore, in this analysis, all occurrences of feeding less
than the minimum specified by STAR, which is 30% of caloric goal, are ignored (3,135 hours, 14.4%
of the time).
7.2.2 Analysis
7.2.2.1 Overall Clinical Performance of STAR Nutrition Protocol
The mean cohort caloric goal achieved per day in the ICU by STAR, considering only hyperglycaemic
ICU patients on STAR, is calculated and compared to the entire ICU patient cohorts reviewed by
Cahill et al. [263]. For STAR, information only exists for periods of GC, which are aligned to the
appropriate day of ICU stay to ensure that comparisons to Cahill et al. [263] are valid. Note, as
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data was only taken from the STAR tablet, this may not be what was actually given/recorded on
the bedside sheet. However, the analysis in Chapter 6 Compliance of the STAR Glycaemic Control
Protocol shows the STAR records to be largely representative of the bedside sheet information.
This comparison helps answer whether caloric restriction to obtain safe and effective GC, or if safe,
effective GC in general, preclude or limit nutrition delivery when compared to that achieved by an
entire ICU patient cohort.
7.2.2.2 Per-patient Clinical Performance of STAR Nutrition Protocol
The distribution, per-patient (median, IQR, 5th – 95th range), of caloric goal achieved per day on
STAR is calculated. The per-day distribution is compared to the best performing ICU surveyed
in [263] and the 85% optimum caloric goal of [135] to evaluate the percentage of patients who
can tolerate more, or less, nutrition than these levels. This comparison delineates the range and
distribution of glucose and nutrition tolerance for these mixed medical ICU patients, and assesses
how well STAR performs, per-patient, compared to other ICUs and a ’best’ level, with respect to
outcome.
The mean and SD of caloric goal achieved over a patient’s entire stay is assessed in terms of median
and IQR between patients, and to the overall variation seen per day across the entire cohort. This
analysis assesses if the overall variability seen per day is due to variable patients or different and
variable patient and time specific tolerance of nutritional uptake.
The relationship between mortality and morbidity, and caloric goal achieved, is also investigated
in relation to the optimum caloric goal of 85% goal feed presented in [135]. This analysis assesses
whether glucose restriction to obtain GC, due to limited patient-specific glucose tolerance, is associated
with increased morbidity and mortality. The outcome may also delineate a potential limit in this
regard.
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7.3 Results
7.3.1 Overall Clinical Performance of STAR Nutrition Protocol
The percentage caloric goal clinically achieved by STAR, each day in ICU, was compared to the
survey results in Cahill et al. [263]. Fig. 7.1 shows the mean nutrition delivered to hyperglycaemic
ICU patients by the STAR nutrition protocol performs very well compared to all ICU patients in
the best performing ICU reviewed in Cahill et al., only slightly under-performing after day 3. It is
well above the mean ICU surveyed in [263] on all days. In addition, the mean percentage caloric
goal nutrition exceeds the ideal 85% caloric goal [135] from day 4 onwards, and is within 5% after
day 1.
Figure 7.1: Comparison of mean percentage caloric goal achieved for each day in the ICU between
the clinical STAR Christchurch results and the results published in Cahill et al. [263]. The ideal
85% caloric goal, to minimise mortality, presented in Heyland et al. [135] is also indicated for
comparison.
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7.3.2 Per-patient Clinical Performance of STAR Nutrition Protocol
Fig. 7.2 shows the distribution of per-patient mean caloric goal achieved per day by STAR, including
IQR and 5th – 95th percentile values. It clearly shows large variation in patient-specific nutrition
rates on the first day of ICU stay, which narrows as patient-specific metabolic state stabilises [122].
Over 56.2% of patients reach or exceed the ideal 85% caloric goal in [135] after day 2, reaching 73.5%
on day 7. The percentage of patients over the mean ICU result in [263] are also shown ranging from
100% on day 1 to 85.7% on day 7. Overall, in comparison to Fig. 7.1, the per-patient results clearly
show some patients cannot achieve this cohort mean rate or the ideal 100% caloric goal.
Figure 7.2: Comparison of STAR Christchurch’s percentage caloric goal distribution achieved
clinically (N = 221 Patients) and the best, and mean performing unit reviewed in Cahill et al.
[263]. The percentage of patients per day ≥ the mean of the units surveyed in in Cahill et al. [263]
is provided for comparison (Above mean unit trace). The ideal 85% caloric goal, to minimise
mortality, presented in Heyland et al. [135] is also indicated for comparison in conjunction with
the percentage of patients per day ≥ 85% caloric goal (Along top of figure).
As noted, the rates in Fig. 7.2 are an estimate of the ‘ideal’ time-varying patient-specific nutrition
uptake in the context of GC to the targeted 4.4-8.0 mmol/L BG range. Equally, some variability is
due to patients starting or finishing GC. Hence, the results of Fig. 7.2 are a conservative or worst-case
analysis.
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Table 7.3 shows the median of the mean per-patient feed rates achieved is relatively high at 89.8%
caloric goal, but has a large IQR of 23.9% ([74.3 - 98.2]). However, the relatively small median
of the per-patient feed rate SD, over a patient’s stay, of 12.9% shows individual patients are less
variable than the cohort. Thus, the overall ability to tolerate glucose is patient-specific. Therefore, it
is clear the ability to take up, and thus to deliver, nutrition varies significantly between GC patients.
Table 7.3: Per-patient feed rate characteristics.
Number of Patients 221
Mean caloric goal achieved over entire stay (%) 89.8 [74.3 - 98.2]
SD of caloric goal achieved over entire stay (%) 12.9 [4.6 - 20.4]
*standard deviation (SD). Data presented in Median [inter-quartile range (IQR)] where
appropriate.
The relationship between mean percentage caloric goal achieved over a patient’s entire stay and
APACHE II Score, and ICU mortality are shown in Fig. 7.3. Both figures show the mean feed
rate achieved appears unrelated to APACHE II Score and ICU mortality (P = 0.68). In addition,
logistic regression suggests the probability of mortality, given the mean percentage caloric goal
achieved, might not differ statistically from a constant model. This data suggests STAR feeds all
patients ‘equally’, independent of morbidity or mortality, and thus the patient-specific ability to
tolerate glucose is not associated with APACHE II Score or ICU mortality in this mixed medical
ICU cohort. Alternatively, the low number of feed rates below the mean ICU in [263] may indicate
that the nutrition rates obtained are well above any clear limit to show a trend in morbidity or
mortality.
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Figure 7.3: Left Panel: Comparison of mean percentage caloric goal achieved vs Acute Physiology
And Chronic Health Evaluation (APACHE) II Score. Logistic regression results shown in bottom
right corner. Right Panel: Comparison of mean percentage caloric goal achieved vs ICU mortality.
P-value shown in the bottom right corner to show significance of relationship.
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7.4 Discussion
7.4.1 Overall Clinical Performance of STAR Nutrition Protocol
Fig. 7.1 shows STAR’s nutrition protocol, on hyperglycaemic ICU patients, performs equal to or
better than, the average of all the ICU patients in the best ICU surveyed by Cahill et al. [263] over
the first 3 days of ICU stay. After day 3, the best ICU performs slightly better. However, as seen
in Table 7.1, the median patient spends 2.67 days on protocol and starts GC within 17.5 hours of
ICU admission, indicating the majority of patients are finished GC after ICU day 3. This outcome
makes the relevance of nutrition performance less significant after this time.
Overall, these outcomes show the current STAR nutrition protocol delivers clinical nutrition, for
hyperglycaemic patients, equal to, or better than, those reported in the Cahill et al. survey for all
ICU patients in 158 ICUs from 20 countries [263]. It is clear that high nutritional delivery and safe,
effective GC are not mutually exclusive. Therefore, STAR’s modulation of nutrition to achieve GC
does not reduce total nutrition intake when compared to an entire ICU cohort.
7.4.2 Per-patient Clinical Performance of STAR Nutrition Protocol
Fig. 7.2 shows a large variation in nutrition rates achieved per day, per-patient, narrowing and rising
as the patient-specific metabolic state stabilises [122]. However, the median variation per-patient
was only 12.9 [4.6 - 20.4] % (Table 7.3), suggesting patients do not deviate significantly from their
mean nutrition rate. This result and the large IQR of the mean feed rates achieved (74.3% - 98.2%,
Table 7.3) suggest the lower nutritional delivery to the 5th and 25th percentile are a result of a few
patients who had a lower ability to tolerate glucose intake.
Considering STAR feeds the maximum possible nutrition, while maintaining normo-glycaemia, the
nutrition rates achieved give a good indication of the patient-specific ability to tolerate glucose and
thus their ‘ideal’ nutrition rate. In essence, every patient is fed the maximum they can achieve
with added insulin. Therefore, the spread of nutrition rates per-patient in Fig. 7.2 infer this ‘ideal’
nutrition rate is very patient-specific, and evolves with time.
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This maximum/‘ideal’ nutrition rate achieved by STAR was less than the 100% caloric goal for
more than 50% of patients, over all days. In addition, the best unit surveyed in Cahill et al.
[263] was still considerably lower than their predetermined caloric goal, suggesting these generalised
approximations do not represent all ICU patients well, as seen in Fig. 7.2 for STAR in Christchurch.
Fig. 7.3 showed no apparent relationship between the nutrition delivered to hyperglycaemic ICU
patients and either APACHE II Score or ICU mortality. A value of P = 0.68 suggests ICU mortality
and mean percentage goal feed achieved on GC are not significantly different, contrary to the results
seen in [100], [131], [135], [267], [282]. However, the number of patient’s which died are low, and
therefore we do not have enough power (38% t2 test) to assess the relationship between ICU mortality
and mean percentage goal feed achieved. Equally, this is an unadjusted analysis and doesn’t account
for other known factors related to ICU mortality. However, of note, none of the studies which were
assessing feed in relation to ICU mortality particularly considered GC or glycaemic levels.
In this study, glycaemia was well-controlled for virtually all patients to an intermediate BG band
associated with improved outcomes [61], [142], where it has recently been shown that the patient-specific
metabolic variability is independent of patient outcome [288]. In addition, over 56% of patients
exceeded the lower 85% optimum of [135] by day 3. Thus, the lack of a trend in this data may be
due to any number of factors including: very low numbers of patients who were ‘underfed’ or in
the lowest tertile of goal feed, the impact of GC and outcome glycaemia not considered in other
analyses, and/or other factors.
In addition, the median duration on STAR was 2.67 days, while the relationship presented in Heyland
et al. [135] is over the first 12 days in the ICU, and it considered all days of stay whereas this study
only has data for days on GC. This difference is a possible study limitation. However, after STAR
GC, when patients are stable enough to stop GC (>5 hours in target BG band), nutrition rates
remain the same or rise, so this result is likely to still hold. Overall, these results suggest the,
generally high, nutrition rates achieved by STAR were independent of morbidity and mortality,
although there was no clear lower limit or optimal value.
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The STAR GC protocol, uses model-based, patient-specific control in conjunction with a stochastic
model to predict the best treatment for a patient. As shown by Table 7.1 and Chapters 5 and 6, STAR
is able to achieve very good GC with a compliance of over 86.5% in all interventions and near identical
results across multiple ICUs [215]. However, in many clinical practices, the idea of protocol-driven
changes in the nutrition given to a patient for GC is foreign, and thus clinically unacceptable. Thus,
the main focus of this study is to show that protocol-driven changes in nutrition rate do not preclude
achieving better nutrition delivery rates than those of 158 ICUs from 20 different countries. This
study shows that high nutrition delivery and safe, effective GC are not exclusive. Equally, these
results show nutrition restriction to obtain GC does not necessarily reduce total nutrition intake in
an international context. Hence, nutrition restriction for GC should be considered more directly as
a part of GC protocols.
7.4.3 Limitations
Cahill et al. [263] provides the percentage caloric goal nutrition achieved by each ICU. However,
caloric goals may vary across ICUs. As a result, some ICUs may achieve caloric goal nutrition targets
’more easily’ than others, making comparison difficult. Additionally, the estimation of a patient’s
body weight used by the Christchurch ICU [112], Table 7.2 and Eq. (7.1), may also bias the caloric
goal feed estimated for a patient. However, the 25 kcal/kg/day ACCP guideline [156] used in the
Christchurch ICU, or a similar value guideline (25-30 kcal/kg/day SCCM/ASPEN [289], and 20-25
kcal/kgBW/day initial phase and recovery phase 25-30 kcal/kgBW/day ESPEN [290]), is commonly
used, and these cover the range used with STAR patients.
The mean nutrition rate achieved by the best unit surveyed by Cahill et al. [263] was still considerably
lower than the predetermined ACCP caloric goal over the first 3 days, suggesting these generalised
approximations do not represent all patients well, as seen in Fig. 7.2. This reduction is likely due
to patients being unable to tolerate the 100% feeding, resulting in high gastric residuals and other
negative effects. In addition, the patient-specific nutrition rates presented in Fig. 7.2 are dependent
on the carbohydrate content of the feed type given. Hence, considering that the nutrition rate is
in relation to a patient’s glucose tolerance, and the glucose content of feed types used vary across
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ICUs, the percentage caloric goal a cohort can tolerate is likely ICU specific. However, this value
could be easily changed to be in terms of only glucose concentration to allow better integration into
other ICUs, with varying feed types.
Moreover, Cahill et al. surveys the nutrition given to ’all’ ICU patients, where this study only
considers patients who required GC. The approximately 25-35% of patients who require GC in
the ICU [107] are the most metabolically stressed, and, as a result, have reduced glucose uptake
capacity. They are thus often harder to deliver the target nutrition rates [280], [291]. Therefore,
providing excellent GC and achieving nutrition rates similar to that achieved for all ICU patients,
normo-glycaemic and hyperglycaemic, in the best ICU reviewed in [263] is a significant outcome.
Other factors, such as mechanical ventilation, neurologic injury, gastric emptying, and paresis
patients are well known to influence the nutritional requirements of ICU patients. This study is
only a retrospective analysis, for which this detailed information is not available, and thus cannot
be accounted for. However, the cohort was typical of a mixed medical ICU.
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7.5 Summary
The STAR GC protocol clinical provision of nutrition to hyperglycaemic patients was compared to
nutrition rates of entire ICU cohorts surveyed in 158 ICUs in Cahill et al. [263]. Mean nutrition
rates clinically achieved by the STAR nutrition protocol were significantly higher than the mean
and best ICU surveyed, for the first 3 days of ICU stay. Overall, STAR’s protocol-driven changes in
nutrition rate provide on average nutrition rates for hyperglycaemic patients which are equal to, or
better than, the mean of all ICU patients in 158 ICUs from 20 different countries. More importantly,
these outcomes show high nutrition delivery and safe, effective GC are not mutually exclusive, and
that restricting nutrition for GC does not limit overall nutritional intake when compared to other
ICUs.
The inter- and intra- patient variation of nutritional delivery was assessed in the STAR cohort.
There was large inter-patient variation in nutrition rates achieved per day, which reduced overtime
as patient-specific metabolic state stabilised. Median intra-patient variation was 12.9%, however
the IQR of the mean per-patient nutrition rates achieved was 74.3% - 98.2%, suggesting patients do
not deviate much from their mean patient-specific nutrition rate and the ability to tolerate glucose
intake varies significantly between, rather than within, patients. There is significant inter-patient
variability between patients to tolerate and uptake glucose, where intra-patient variability over stay
is much lower. Therefore, a best nutrition rate is likely patient-specific for patients requiring GC.
The relationship between mean nutrition rate achieved and morbidity, and mortality was investigated.
The nutrition rates delivered by STAR showed no association between nutrition delivery to hyper-
glycaemic patients and morbidity or mortality. This result/outcome may have been due to no or
very few ‘underfed’ patients or the patients receiving safe and effective GC. Overall, these results
suggest the generally high nutrition rates achieved by STAR were independent of morbidity and
mortality, although there was no clear lower limit or optimal value.
From the results seen in Chapter 6 Compliance of the STAR Glycaemic Control Protocol and
this chapter it can be inferred the slightly poorer nutrition intervention compliance should not
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be the result of STAR feeding too low, but rather the frequency of feed changes. Therefore,
further investigation into the simplification of the STAR feeding protocol should be undertaken
to improve STAR’s nutrition intervention compliance. This chapter’s analysis provides a good basis
and reference for what is currently achieved with the current variable STAR feeding protocol.
Chapter 8
Simpler STAR nutrition protocols
8.1 Background
The STAR GC protocol is unique in maintaining normal BG levels by changing both insulin and
nutrition interventions [128], [147]. Changing nutrition interventions differentiates STAR all from
other ICU GC protocols, which only change insulin interventions [108], [109], [126], [129], [214],
[268], [277]. However, the clinical workload and complexity of GC may be increased due to the
nutrition changes required by STAR, in turn affecting compliance and control quality for some
ICUs, as discussed in Chapter 6 Compliance of the STAR Glycaemic Control Protocol [101], [151],
[272]. Thus, simplifying the STAR nutrition protocol, while maintaining its safe and effective GC,
could decrease clinical workload and complexity, and increase its clinical suitability.
Currently, there is also significant debate over the appropriate amount to feed an ICU patient. Many
studies have shown mixed results in reviewing caloric intake, route, and timing, and their relation to
outcome [100], [131], [134]–[136], [278]–[284]. Cahill et al. [263] surveyed the nutrition performance
1Stewart, K. W. , Chase, J. G., Pretty, C. G., and Shaw, G. M. (2017) ’Nutrition delivery, workload and
performance in a model-based ICU glycaemic control system’, Computer Methods and Programs in Biomedicine.
(Under Review)
2K. W. Stewart, C. Pretty, J. G. Chase, and G. M. Shaw, “The Effect of Variable vs Fixed Feeding on
Glycaemic Control in the Adult ICU: Virtual Trial Evaluation,” in 20th World Congress The International Federation
of Automatic Control, 2017.
3K. W. Stewart, J. G. Chase, J. Dickson, C. Pretty, and G. Shaw, “Can we fix it? Yes we can! Simplifying
nutrition in STAR Glycemic Control.,” in 16th Annual Diabetes Technology Meeting, 2016.
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of 158 ICUs, from 20 countries, finding significant variation in nutrition delivery. This study also
found the ideal relation to improved mortality outcomes to be at 85% of the caloric goal nutrition
rate set by the respective ICU [135]. This ideal value, and the best unit surveyed, are used in this
chapter as benchmarks for assessing the alternative, reduced workload nutrition protocols for STAR.
This chapter evaluates three simpler, reduced workload, alternative nutrition protocols for STAR
using clinically evaluated virtual trials [154], [230]. The results are then compared to the current
nutrition protocol and the survey in [263]. Each protocol is assessed in terms of GC performance,
safety and workload.
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8.2 Methods
8.2.1 Current nutrition protocol
8.2.1.1 STAR Variable nutrition
STAR currently modifies the nutrition rate depending on the stochastic prediction bounds of potential
patient behaviour, with a preference to modulate insulin before reducing nutrition, and to raise
nutrition if possible [128], [147]. ACCP guidelines are used to estimate the patient’s daily caloric
goal [156]. STAR modulates nutrition rate between 30-100% of caloric goal, with a maximum step
change of ±30% caloric goal per hour [128]. STAR attempts to provide the maximum nutrition
rate a patient can tolerate, while keeping BG in the 4.4-8.0 mmol/L range. The complete GC
protocol details can be seen in Section 1.2.4 Stochastic Targeted (STAR) Glycaemic Control. Thus,
the nutrition rate achieved by STAR gives a good indication of the patient and time specific ‘ideal’
nutrition rate that does not result in hyperglycaemia, in regard to their current ability to tolerate
glucose, as discussed in Chapter 7 Clinical nutrition delivery of STAR.
STAR patients in the Christchurch Hospital, ICU are typically fed enterally with the low carbohydrate
GlucernaTM Select (95.7 g/L Carbohydrate, 50 g/L Protein, 21.1 g/L Fibre, Abbott Labs, Illinois,
USA), where these carbohydrate concentrations exclude indigestible fibre. PN is used occasionally,
at the discretion of clinical staff, to supplement EN. STAR accounts for, but does not regulate, this
added PN. This original nutrition protocol is referred to as the variable nutrition protocol.
This variable nutrition protocol changes nutrition rate every 1-2 interventions, significantly increasing
total workload and the apparent protocol complexity [101], [151], [272]. In addition, varying
nutrition, even if patient-specific, is also unusual in GC and ICU clinical practice in general. Hence,
a fixed or semi-fixed approach could significantly reduce complexity and workload.
8.2.2 Alternative nutrition protocols
Three simpler, lower workload alternatives are investigated. All three protocols are set in terms of
the percentage of ACCP caloric goal achieved [156], as in STAR currently. Their performance is
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compared to the current variable nutrition STAR protocol using clinically evaluated virtual trials
[154], [230]. Each alternative nutrition protocol is designed to reduce clinical workload by fixing
nutrition rates for all patients, either for their entire stay or per day of stay, leaving STAR to only
modulate insulin.
8.2.2.1 Fixed nutrition rate
As noted, most GC protocols do not change the nutrition rate a patient receives, at least not per
protocol. As a result, nutrition rates are fixed, or relatively so, at the caloric goal set for that
patient, with changes only being made ad-hoc by clinical staff. Therefore, a 100% caloric goal fixed
nutrition protocol, Fig. 8.1, is investigated, even though it is not typically achieved in even the best
performing ICUs [263].
Figure 8.1: Fixed nutrition protocol.
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8.2.2.2 Stepped nutrition rates (by day)
As an ICU patient is most stressed immediately post-surgery or traumatic event [73], they are the
most likely to require GC at the beginning of their ICU stay [78], [85], [86]. In this study, 59.3%
of patients started GC within 24 hours of being admitted to the ICU (Median 15.5 hours after
admission, Table 8.1). In particular, prior studies have shown a patient’s metabolic state (SI) is
lowest and most variable during their first 2-3 days of ICU stay [125], [228], [254], [288], [292], making
GC more difficult and dynamic over this period.
If less nutrition is given to a patient over these first few days, less insulin is required to lower BG,
and ultimately, the risk due to any potentially large variations in SI during this more volatile period
are reduced. This reduction in nutrition thus enables safer, and more effective GC over this period.
In addition, the median length of time on GC, for each STAR patient, is 2.2 days, Table 8.1. Thus,
a stepped nutrition protocol, which varies nutrition by day over this period, will have the largest
influence on the GC quality and safety.
ICU patient metabolism can vary significantly [122], [123], [292] and as a result, their nutritional
uptake can also vary significantly, as seen in Fig. 8.3 and Chapter 7. Thus, any fixed/stepped
nutrition protocol will result in some patients being overfed or underfed, relative to their ability to
tolerate glucose. Although both of cases are not ideal, the consequences of each vary.
If patients are overfed, it may result in higher insulin doses being required to lower BG, emphasising
any variability in the patient-specific metabolic state, SI [122], [123], [292]. Especially considering
that SI is most variable over the first 3 days of ICU stay [122], [254], [288], [292]. Ultimately,
overfeeding patients would increase insulin requirements, and thus BG variability, and the risk of
hypoglycaemia, and, as a result, clinical workload to maintain patient safety. However, if patients
were underfed, it would result in lower/no insulin doses being required to lower BG, and thus likely
achieving safer, less variable, more effective, and more workload efficient GC, at the expense of
potential complications due to not meeting nutritional requirements. Although, if not underfed
substantially, these complications may not arise as shown by previous studies [134], [284], [293].
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Cahill et al. best (CB) [263] stepped nutrition rate:
One goal of a stepped nutrition protocol could be to provide nutrition delivery equivalent to or
better than the best unit surveyed by Cahill et al. [263]. Therefore, a stepped nutrition protocol of
60, 80 and 100% caloric goal, by day, over the first 3 days of GC, and 100% thereafter, is selected
to match the beginning and the end of the best unit surveyed, over a 3 day period, Fig. 8.2. It thus
under feeds most STAR patients, over the first 2 days, compared to the patient-specific variability
shown in Fig. 8.3.
Figure 8.2: Cahill et al. best (CB) stepped nutrition protocol in comparison to the best performing
unit surveyed in Cahill et al. [263].
STAR lower quartile (SLQ) stepped nutrition rate:
As noted, the nutrition rate achieved by STAR’s variable nutrition protocol gives a good indication
of the patient’s ‘ideal’ nutrition rate that doesn’t result in hyperglycaemia, based on their current
ability to tolerate glucose. Therefore, if patients were fed the lower quartile nutrition rate achieved
clinically by the variable nutrition protocol, as shown in Fig. 8.3, 75% of patients would be fed less
than what was achieved clinically with STAR. Hence, 75% of patients would be underfed, promoting
further safety by lowering the required insulin doses. In addition, having a final fixed caloric goal
CHAPTER 8. SIMPLER STAR NUTRITION PROTOCOLS 138
of 85% matches the minimum feed rate associated with the best mortality outcome, as reported in
[135]. Therefore, a stepped nutrition protocol of 65, 75 and 85% caloric goal, by day, over the first
3 days of GC, and 85% thereafter, is selected based, Fig. 8.3.
Figure 8.3: STAR lower quartile (SLQ) stepped nutrition protocol in comparison to the clinical
results achieved by the STAR variable nutrition protocol.
Fig. 8.3 clearly shows large variation in nutrition rates achieved clinically, per-patient, on the first
day of GC, which narrows as patient-specific metabolic state stabilises. Note, the nutrition rate
may exceed the 100% caloric goal when extra clinical interventions are given, such as PN. Hence,
as noted, the rates in Fig. 8.3 are an estimate of the ‘ideal’ patient-specific nutrition uptake in the
context of GC to the 4.4-8.0 mmol/L BG range, and a minimum value given.
8.2.3 Patient Data and Virtual Trials
Virtual patients are created by fitting the time varying model-based SI parameter to each patient’s
clinical data [154], [230], where model-based SI is a marker of patient-specific metabolic state [122],
[294]. The SI profile is then used with a GC protocol, which specifies insulin and nutrition, to
simulate the BG response [154], [230]. The clinically determined ACCP caloric goal and typically
used GlucernaTM Select (Section 7.2.1.2) is used in each patient’s GC simulation. Each of the
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alternative STAR nutrition protocols is simulated on the virtual STAR cohort and their GC safety,
performance and workload are assessed.
Clinical data from 221 patients treated with STAR (2011-2015) [215] in the Christchurch Hospital,
ICU was used to create virtual patients. The cohort demographics are given in Table 8.1. The
Upper South Regional Ethics Committee, New Zealand granted approval for the audit, analysis and
publication of this data.
Table 8.1: STAR cohort patient demographics.
Number of Patients 221
Number Hours 21,1769
Age 64.0 [54.0 - 72.0]
Sex (% Male) 66.1
ICU length of stay (Days) 8.4 [3.1 - 15.3]
Days on GC 2.2 [1.2 - 3.9]
Admission to GC Start (Hours) 15.5 [6.7 – 46.7]
Operative (%) 29.0
APACHE II Score 21.0 [16.0 - 27.0]
ICU Mortality (%) 28.0
*Intensive Care Unit (ICU), Glycemic Control (GC), Acute Physiology And Chronic Health
Evaluation (APACHE). Data presented in Median [inter-quartile range (IQR)] where appropriate.
ACCP caloric goal of 25 kcal/kg/day [156] is used for all the nutrition protocols investigated. In
the ICU the patient-specific caloric goals are recorded for all patients, and thus, are used as the
patient-specific caloric goal in this study. For full details on the calculation of caloric goal in
Christchurch Hospital ICU, NZ, see Section 7.2.1.2.
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8.2.4 Analysis and statistics
Each of the proposed STAR nutrition protocols are assessed in terms of GC performance, safety,
and workload. An analysis of the first 3 days of GC, in terms of performance and workload, is also
performed to assess where the largest impact is achieved. The first 3 days are specifically chosen for
assessment due to the median time on GC being 2.2 days, Table 8.1, and 67% of patients having
finished GC by day 3. The metrics assessed comprise of:
Performance: • Percentage of time in targeted BG band (4.4-8.0 mmol/L) [61], [142].
• Percentage of time hyperglycaemia occurs (BG > 10 mmol/L).
Safety: • Number of mild and severe hypoglycaemia patients (Number of patients
with BG < 4.0 mmol/L and BG < 2.2 mmol/L, respectively) [35] [34].
Workload: • Number of BG measurements per day, per-patient.
• Number of intervention changes (insulin and nutrition) per day, per-patient.
• Summed total of the number of intervention changes (insulin and nutrition
rate changes) and BG measurements over the entire cohort.
Due to the irregular 1-3 hourly measurement intervals in STAR [128], [147], patient BG data was
analysed with linear interpolation at 60 min intervals to enable fair comparisons [246], per Chapter 2
Interpretation of Retrospective BG Measurements. BG performance statistics are presented as
median and IQR of the mean and SD of BG for individual patients per the consensus recommendations
in Finfer et al. 2013 [137].
Non-parametric statistics are used exclusively due to the typically skewed distributions of BG,
insulin dose and other data. P-values were computed using the Mann-Whitney rank-sum test for
all continuous data and the chi-squared test for categorical data. P-values <0.016 are considered
statistically significant after Bonferroni correction [224] for multiple comparisons.
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8.3 Results
8.3.1 Nutrition protocol simulations
The three alternative nutrition protocols and the current variable nutrition protocol were simulated
on the virtual STAR cohort. Fig. 8.4 compares the mean percentage of the caloric goal per day
achieved in virtual trial simulation for each nutrition protocol to the best unit surveyed in Cahill et
al. [263]. All three alternative nutrition protocols deliver more nutrition over the first 3 days of ICU
stay than the best unit surveyed in Cahill et al. [263].
Figure 8.4: Comparison of mean percentage caloric goal achieved for each day on Glycemic Control
(GC) between each of the simulated nutrition protocols (Variable, Fixed, Cahill et al. best (CB)
stepped, and STAR lower quartile (SLQ) stepped) and the best unit surveyed in Cahill et al. [263].
These nutrition rates are fixed for all alternative nutrition protocols, for all patients.
CHAPTER 8. SIMPLER STAR NUTRITION PROTOCOLS 142
8.3.2 Glycaemic performance and safety
The GC performance and safety for each simulated nutrition protocol is shown in Table 8.2. The
current variable nutrition protocol and both stepped nutrition protocols had very similar GC perform-
ance, with very similar percentages of time in the targeted 4.4-8.0 mmol/L BG band (89.0% Var.
vs. 88.3% CB and 89.5% SLQ, P=0.88 and P=0.64 respectively). In contrast, the fixed nutrition
protocol resulted in significantly less time in the targeted 4.4-8.0 mmol/L BG band (85.6% Fixed vs.
89.0% Var., P = 0.018), and more hyperglycaemia (1.6% Fixed vs. 0.7% Var., P = 0.07), although
these differences may not be clinically significant.
The current variable nutrition protocol and the CB stepped nutrition protocols had very similar GC
safety, with similar numbers of patients who experienced mild hypoglycaemia (BG < 4.0 mmol/L)
(77 vs. 78, P = 1.00). Whereas, the fixed and SLQ stepped nutrition protocols resulted in slightly
more cases of mild hypoglycaemia (82 vs. 77, P = 0.71 for both). However, the SLQ stepped
nutrition protocol almost halved the number of severe hypoglycaemic (BG < 2.22 mmol/L) cases (9
vs. 5, P = 0.42). In all cases, these results were measurable, but not statistically significant due to







Table 8.2: Comparison of the per-patient virtual trial GC performance results for the 4 simulated nutrition protocols.









BG median (mmol/L) 6.2 [6.0 - 6.7] 6.3 [6.0 - 6.9] 6.3 [6.0 - 6.7] 6.2 [6.0 - 6.7] 0.24 0.89 0.61
BG mean (mmol/L): 6.4 [6.20 - 6.9] 6.5 [6.2 - 7.2] 6.4 [6.2 - 6.9] 6.4 [6.2 - 6.9] 0.17 0.75 0.57
BG SD (mmol/L): 1.2 [0.9 - 1.7] 1.3 [0.9 - 1.9] 1.2 [0.9 - 1.7] 1.2 [0.9 - 1.7] 0.05 0.89 0.84
% BG <2.22 mmol/L 0.0 [0.0 - 0.0] 0.0 [0.0 - 0.0] 0.0 [0.0 - 0.0] 0.0 [0.0 - 0.0] 0.81 0.65 0.28
% BG <4.4 mmol/L 0.0 [0.0 - 3.6] 0.0 [0.0 – 4.0] 0.0 [0.0 - 3.8] 0.0 [0.0 – 4.0] 0.80 0.90 0.82
% BG 4.4-8.0 mmol/L 89.0 [75.8 - 94.7] 85.6 [68.8 - 94.4] 88.3 [76.2 - 95.7] 89.5 [75.0 - 96.1] 0.018 0.88 0.64
% BG >10.0 mmol/L 0.7 [0.0 - 5.3] 1.6 [0.0 - 7.1] 0.6 [0.0 - 5.6] 0.6 [0.0 - 5.4] 0.07 0.93 0.98
Mean hourly insulin (U/hr) 3.4 [2.1 - 4.6] 3.7 [2.3 - 5.1] 3.0 [1.8 - 4.4] 3.0 [1.7 - 4.1] 0.019 0.06 0.022
Safety
# patients BG <4.0 mmol/L 77 82 78 82 0.71 1.00 0.71
# patients BG <2.22 mmol/L 9 10 11 5 1.00 0.82 0.42
*Cahill et al. best (CB), STAR lower quartile (SLQ), Glycemic Control (GC), blood glucose (BG), standard deviation (SD). Data presented in Median
[inter-quartile range (IQR)] where appropriate.
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The hourly resampled BG CDF for the first 3 days of ICU stay and overall are plotted in Fig. 8.5.
The variable and both stepped nutrition protocols had very similar performance over the first 2
days of ICU stay. However, at day 3, where the CB stepped nutrition protocol exceeds the average
achieved clinically in Fig. 8.4, the CB protocol experiences slightly more hyperglycaemia, as might
be expected. The fixed nutrition protocol consistently under performs the other simulated nutrition
protocols on all days.
Figure 8.5: Resampled hourly BG cumulative distribution function (CDF) for each of the
simulated nutrition protocols (Variable, Fixed, Cahill et al. best (CB) stepped, and STAR lower
quartile (SLQ) stepped) on the first 3 days of Glycemic Control (GC) and for all time.
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8.3.3 Workload
GC workload for each of the simulated nutrition protocols is given in Table 8.3. The fixed nutrition
protocol and both stepped nutrition protocols had slightly higher numbers of BG measurements per
day compared to the variable nutrition protocol (11.4 Var. vs. 13.4 Fixed, 12.0 CB and 12.0 SLQ, P
< 0.001, P = 0.004, and P = 0.011 respectively), with an overall increase of total BG measurements
required of 17.8% for fixed, 9.4% for CB stepped, and 7.0% for SLQ stepped. All four nutrition
protocols had very similar numbers of insulin changes per day. However, as expected, the fixed and
stepped nutrition protocols had significantly lower numbers of nutrition changes per day compared
to the variable nutrition protocol (6.4 Var. vs. 0.0 Fixed and 0.5 for both CB and SLQ, P < 0.001
for all cases).
Overall, all 3 alternative nutrition protocols largely reduced the total number of clinical interventions
(BG measurements, and insulin and nutrition rate changes) required (-14.6% Fixed, -18.3% CB and
-19.8% SLQ), and thus GC workload. Note, the expected number of nutrition rate changes per day
for the stepped nutrition protocols is 1. However, if a patient ends GC part way through a day,


























Table 8.3: Comparison of the virtual trial GC workload results for the 4 simulated nutrition protocols.









Num. BG measurements 10,237 12,060 (+17.8%) 11,196 (+9.4%) 10,956 (+7.0%) - - -
Num. insulin changes 6,759 6,964 6,626 6,542 - - -
Num. nutrition changes 5,270 0 370 370 - - -
Total interventions 22,266 19,024 (-14.6%) 18,192 (-18.3%) 17,868 (-19.8%) - - -
Per-patient treatment statistics
Num. BG measures/day: 11.4 [10.1 - 13.7] 13.4 [11.6 - 16.8] 12.0 [10.6 - 14.7] 12.0 [10.5 - 14.5] <0.001 0.004 0.011
Num. insulin changes/day 7.5 [6.4 - 8.3] 7.8 [6.5 - 8.9] 7.4 [6.0 - 8.4] 7.2 [6.1 - 8.4] 0.026 0.31 0.21
Num. nutrition changes/day: 6.4 [4.4 - 8.0] 0.0 [0.0 - 0.0] 0.5 [0.2 - 0.7] 0.5 [0.2 - 0.7] <0.001 <0.001 <0.001
Total Num. interventions/day: 25.5 [21.7 - 30.0] 21.5 [18.9 - 24.8] 19.9 [17.7 - 23.1] 19.8 [17.5 - 23.1] <0.001 <0.001 <0.001
*Cahill et al. best (CB), STAR lower quartile (SLQ), blood glucose (BG). Data presented in Median [inter-quartile range (IQR)] where appropriate.
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CDFs of the number of BG measurements per day, per patient, for the first 3 days of ICU stay
and all time are plotted in Fig. 8.6. CDFs of BG measurements were plotted as opposed to overall
workload, as they have the largest impact on clinical workload [272]. Initially, the variable nutrition
and both stepped nutrition protocols had very similar BG measurement workload. However, as the
days on GC progress, the fixed nutrition rate given to all patients increases, and, as a result, BG
measurement workload for both stepped nutrition protocols increases. The fixed nutrition protocol
consistently has higher BG measurement workload than all the other simulated nutrition protocols,
and with respect to Fig. 8.3, is also overfeeding the greatest number of patients.
Figure 8.6: The cumulative distribution function (CDF) of the mean number of blood glucose
(BG) measurements per day, per patient, for each of the simulated nutrition protocols (Variable,
Fixed, Cahill et al. best (CB) stepped and STAR lower quartile (SLQ) stepped) on the first 3 days
of Glycemic Control (GC) and for all time.
CHAPTER 8. SIMPLER STAR NUTRITION PROTOCOLS 148
8.4 Discussion
From Fig. 8.4, the difference in the nutrition protocols simulated on the virtual STAR cohort is
evident. All the alternative nutrition protocols proposed deliver considerably more nutrition, over
the first 3 days of ICU stay, and thus the majority of patients, than the best ICU surveyed by Cahill
et al. [263].
8.4.1 Variable vs Fixed nutrition
The fixed nutrition protocol (100% caloric goal) had slightly worse GC performance compared
to the variable nutrition protocol in Table 8.2 (P = 0.018) and Fig. 8.5, with considerably more
hyperglycaemia (P = 0.07, Table 8.2). This result can be largely attributed to the higher nutrition
rate overfeeding a greater number of patients, based on Fig. 8.3. These issues result in increased BG
and increased insulin dose (3.7 vs. 3.4 U/hr, P = 0.019), which in some cases saturates the maximum
’safe’ insulin dose allowed (≤ 9 Units/hour) by STAR. At this point, only lowering nutrition given
would enable reductions to intermediate BG levels in the 4.4-8.0 mmol/L range, due to the saturation
of insulin action [225], [287]. In addition, as the fixed nutrition protocol required more insulin, it
thus created a greater risk of hypoglycaemia in response to patient variability. Thus, 5 (6.5%) more
patients experienced mild hypoglycaemia than the variable nutrition protocol (P = 0.71, Table 8.2),
illustrating the reduced safety with the high fixed nutrition protocol.
The fixed nutrition protocol also resulted in 2 more BG measurements required per day (P<0.001,
Table 8.3), with a 17.8% increase overall in total number of BG measurements required. This result
can again be attributed to overfeeding most or all patients, resulting in more BG measurements
above the targeted 4.4-8.0 mmol/L BG band and thus more hourly measurements being required
by STAR [128], [147]. The changes in insulin interventions were very similar between protocols (P
= 0.026, > 0.016, Table 8.3), and, as expected, the number of nutrition changes were significantly
lower (P < 0.001, Table 8.3). Therefore, overall, compared to variable nutrition protocol the total
number of interventions required is reduced by 14.6%, largely reducing clinical staff workload, but
with a consequent decrease in GC performance and safety.
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8.4.2 Variable vs CB Stepped nutrition
The CB stepped nutrition protocol provided very similar GC performance to the variable nutrition
protocol in Table 8.2 (P = 0.88) and Fig. 8.5. The largest loss in GC performance in Fig. 8.5 occurs
during day 3, which is most likely due to the CB stepped nutrition protocol feeding 100% caloric
goal on this day, to all patients, compared to the variable nutrition protocol, feeding on average 87%
caloric goal (Fig. 8.4), with a wide variability across patients (Fig. 8.3). Thus, there are increasing
numbers of overfed patients as days on GC progress with the CB protocol.
Safety was also very similar in Table 8.2, but there were 2 more cases (0.7%) of severe hypoglycaemia
(P=0.82). Both episodes occurred when the CB protocol was delivering 100% caloric goal. This
outcome clearly emphasises the strong trade-off between achieving high nutrition targets and achieving
safe, and effective GC.
The CB stepped nutrition protocol resulted in 0.6 more BG measurements required per day (P =
0.004, Table 8.3), with a 9.4% increase overall in total number of BG measurements required. The
slight increase in BG measurements is consistent in each of the CDFs presented in Fig. 8.6. This
increase in BG measurements may be due to the intra-day inflexibility of the CB stepped nutrition
protocol resulting in less effective treatment options being offered to some patients, given the clinical
patient-specific nutrition variability seen in Fig. 8.3.
In general, the difference in workload occurs where an insulin increase and nutrition lowering was
offered previously by variable nutrition protocol, but now only an insulin increase was able to be
offered by the CB stepped nutrition protocol, limiting STAR’s ability to effectively lower BG. This
limitation results in patients spending a slightly greater duration outside the targeted 4.4-8.0 mmol/L
BG band, thus requiring more 1-hourly measurements per the STAR protocol.
In contrast, the number of insulin changes per day was very similar between the two nutrition
protocols (P = 0.31, Table 8.3). However, again, there was a significant reduction in the number of
nutrition changes required per day (P<0.001, Table 8.3). Therefore, overall, compared to variable
nutrition protocol, the total number of interventions required is reduced by 18.3%, further reducing
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clinical staff workload, while maintaining a similar GC performance. However, due to overfeeding
still occurring for many patients, based on Fig. 8.3, especially after day 3 at 100% goal feed rate, a
slight decrease in safety occurs.
8.4.3 Variable vs SLQ Stepped nutrition
The SLQ stepped nutrition protocol provided very similar GC performance to the variable nutrition
protocol in Table 8.2 (P=0.64) and Fig. 8.5. From Fig. 8.5 a small loss in GC performance occurs
during day 3, which is, again, most likely due to the intra-day inflexibility of the stepped nutrition
protocols, as mentioned above. The SLQ stepped nutrition protocol resulted in 5 more patients
who experienced mild hypoglycaemia (P = 0.71, Table 8.2). However, it largely reduced insulin
requirements (3.0 vs. 3.4 U/hr, P = 0.022 Table 8.2), and as a result, almost halved the number
of severe hypoglycaemia cases (5 vs. 9, P = 0.42 Table 8.2), greatly improving patient safety. In
essence, severe hypoglycaemic events were improved to mild events. This outcome further illustrates
the fine balance between achieving nutrition targets, not under or over feeding individual patients,
and achieving safe, and effective GC.
The SLQ stepped nutrition protocol resulted in 0.6 more BG measurements required per day (P
= 0.011, Table 8.3), with a 7.0% increase overall in total number of BG measurements required.
This slight increase is again consistent in each of the CDFs presented in Fig. 8.6, although the SLQ
stepped protocol at least slightlyunder feeds approximately 75% of patients each day by definition
compared to the maximum possible uptake. Thus, the increased BG measurements again may be
due to the intra-day inflexibility of the SLQ stepped nutrition protocol.
In contrast, the number of insulin changes per day was very similar between the two nutrition
protocols (P = 0.21, Table 8.3). However, again, there was a significant reduction in the number of
nutrition changes required per day (P<0.001, Table 8.3). Therefore, overall, compared to variable
nutrition protocol the total number of interventions required is reduced by 19.8%, the largest




The mean nutrition rate achieved by the best unit surveyed by Cahill et al. [263] was still considerably
lower than the predetermined ACCP caloric goal over the first 3 days, suggesting these generalised
approximations do not represent all patients well, as seen in Fig. 8.3 and Chapter 7. This reduction is
likely due to patients being unable to tolerate the 100% feeding, resulting in high gastric residuals and
other negative effects. In addition, the patient-specific ’ideal’ nutrition rates presented in Fig. 8.3
are dependent on the carbohydrate content of the feed type given. Hence, considering that the
’ideal’ nutrition rate is in relation to a patient’s glucose tolerance, and the glucose content of feed
types used vary across ICUs, the percentage caloric goal a cohort can tolerate is likely ICU specific.
However, this value could be easily changed to be in terms of only glucose concentration to allow
better integration into other ICUs, with varying feed types.
Virtual trials have been shown to give a good indication of expected clinical performance [230], [295]
and be generalizable across ICUs [154]. However, they do not allow for unforeseen clinical exceptions,
such as the gastric residuals or malnutrition of a patient, and the likely associated increased workload
with these effects. In addition, this analysis did not consider the clinical feed stoppages that occurred
clinically for each patient. However, considering this analysis was not comparing to other clinical
protocols and only between virtual trials, it was deemed not necessary. Therefore, the results only
represent an ‘ideal’ situation and remain to be confirmed, and a prospective clinical trial should be
undertaken. However, the rates of nutrition given here do suggest malnutrition is not occurring, as
all rates were in the optimal middle tertile of the work in [100]. Overall, the virtual in silico design
analysis presented has improved the likelihood of a successful clinical implementation. The STAR
GC protocol, uses model-based, patient-specific control in conjunction with a stochastic model to
predict the best treatment for a patient. As shown by the GC results, irrespective of the nutrition
protocol, STAR is able to achieve very good GC. However, in many clinical practices protocolised
changes in the nutrition rate given to a patient for GC is foreign, and thus clinically unacceptable.
Thus, the main focus of this study is to suggest alternative nutrition protocol options that may be
more clinically acceptable, and show the associated consequences for each. However, as this study
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is only strictly a virtual trial, a clinical trial of these different nutrition protocols would be required
to further confirm these results in the face of real-life, clinical compliance.
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8.5 Summary
STAR is a model-based GC protocol that uniquely maintains normo-glycaemia by changing both
insulin and nutrition interventions, and has been proven effective in controlling BG in the ICU.
However, most ICU GC protocols only change insulin interventions, making the variable nutrition
aspect of STAR less clinically desirable. Therefore, three alternative, simpler and lower workload
nutrition protocols were investigated using clinically evaluated virtual trials.
All the alternative nutrition protocols reduced the total intervention workload considerably (14.6 -
19.8%). However, only the stepped (by day) nutrition protocols achieved similar GC performance
to the current variable nutrition protocol. Of the two stepped nutrition protocols, the SLQ stepped
nutrition protocol also improved GC safety, almost halving the number of severe hypoglycaemic
cases (5 vs. 9, P = 0.42), while still providing nutrition delivery near equal to the best ICU in an
international context. Overall, the SLQ stepped nutrition protocol was the best alternative to the
current variable nutrition protocol, but either of the stepped nutrition protocols could be adapted
by STAR to reduce workload and make it more clinically acceptable. Overall, these virtual trials
indicate a strong 3 sided trade-off between high nutrition rate, safe, effective GC and total workload.
While virtual trials have shown to be very good in part, a clinical trial should be undertaken to
confirm the results of this study. The overall results of this study should further the clinical flexibility
of STAR for differing clinical practices. However, the existing STAR implementation needs to be
developed to better allow changes to be made within the framework.
Chapter 9
Design of a STOMP controller
9.1 Background
The STAR GC protocol recommends interventions based on a clinically specified maximum risk of
light hypoglycaemia (BG < 4.4 mmol/L), derived from stochastic model predictions of future SI , as
detailed in Section 1.2.4 and Chapter 3 [145], [149]. With the ability to quantify the probability of
hypoglycaemia, STAR allows aggressive yet safe control of BG within a target band. STAR is flexible
to different BG targets [229], [296] and clinical staff intervention frequency, and thus addresses many
of the areas required for clinical implementation.
However, the heuristic intervention selection algorithm used by STAR is fixed and does not allow for
dynamic tuning [128], limiting the capacity for the controller to be further optimized in real time.
In particular, it uses multi-layered condition statements to select the desired intervention from a
pool of allowed interventions. Overall, the multiple conditions and layers are conceptually complex,
making tuning of the controller response difficult.
1K. W. Stewart, C. G. Pretty, H. Tomlinson, L. Fisk, G. M. Shaw, and J. G. Chase, “Stochastic Model Predictive
(STOMP) glycaemic control for the intensive care unit: Development and virtual trial validation,” Biomed. Signal
Process. Control, vol. 16, pp. 61–67, Feb. 2015.
2K. W. Stewart, C. G. Pretty, H. Tomlinson, L. Fisk, G. M. Shaw, and J. G. Chase, “Stochastic Model Predictive
Glycemic Control for the Intensive Care Unit: Development and virtual trial validation,” in 14th Annual Diabetes
Technology Meeting, 2014, pp. 342–485.
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MPC is an alternative control approach that allows the dynamic response of the controller to be
easily tuned through a series of clinically pre-defined cost functions. MPC utilizes a mathematical
model of a system to forecast the response to a given input, and control interventions are chosen to
produce optimal forecasted results. Commonly, optimization will involve specifying cost functions to
key input and output performance metrics, and choosing an intervention that minimizes the overall
summed total cost. Thus, cost functions provide a mathematical alternative to what is currently
done with multiple condition statements.
The benefit of such a system is that the cost functions can be easily optimized to produce robust and
consistent control outcomes from an intuitively and easily understood clinical specification. This
type of controller is thus investigated due to the flexibility of cost functions, allowing the dynamic
response of the controller to be easily tuned, improving on the clinical flexibility that can be offered
by STAR. More specifically, the relative weighting of insulin minimization for safety, and nutrition
maximisation for recovery, can be modified more easily via cost functions. MPC is also a proven
effective technique for GC, with many implementations of different models already [214], [232],
[297]–[301].
This chapter presents a Stochastic Model Predictive (STOMP) GC protocol that uses an infrequently
measured BG signal to control the BG levels of adult ICU patients, while providing greater flexibility
than the STAR GC protocol. This chapter presents the STOMP protocol design and optimization
for an adult ICU using clinically evaluated virtual trials [154], [230] to amend safety and efficacy
before clinical utilization.
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9.2 Methods
9.2.1 Control methodology overview
STOMP is designed to combine the methodology of MPC with the stochastic prediction used within
the STAR framework. Similar to STAR, STOMP initially requires 2 BG measurements [128]. After
2 BG measurements are taken, integral based parameter fitting [153] is used to identify the current
model-based SI , per Section 4.2.1 Identification of insulin sensitivity (SI) [31], [148], [154]. This
value is then used with the stochastic model in Chapter 3 Evaluation and simplification of STAR’s
stochastic model [128], [145], [149], to find the 5th and 95th percentile potential future SI values.
These 5th and 95th percentile SI values, and a potential insulin and nutrition intervention, are then
used to forward-simulate the likely resulting 5th and 95th percentile BG values, for that potential
intervention. The potential intervention and associated forward simulated BG outcome are then
evaluated in a series of cost functions, and a cost assigned to that intervention. This process is
repeated over all the possible interventions to find the intervention with the lowest evaluated cost,
the optimal intervention. These steps are summarised in Fig. 9.1.




ACCP guidelines are used to estimate the patient’s daily caloric goal [156]. STOMP modulates
nutrition rate between 30-120% of caloric goal in steps of 5%, with a maximum change of ±30%
caloric goal per hour. Insulin is administered by infusion, rather than bolus, and is modulated
between 0-9 U/hr (0-150 mU/hr) in steps of 0.5 U/hr, with a maximum increase of 2 U/hr.
Similar to the current version of STAR, if a patient’s BG is currently within the targeted BG
band (4.4-8.0 mmol/L), clinical staff have the flexibility to choose between 1-3 hour measurement
intervals. However, if a patient’s BG is outside the targeted BG band, clinical staff are limited
to hourly measurements. In this studies simulation the maximum measurement interval offered by
either STAR or STOMP was always selected. In addition, a 4 hour measurement interval, while
patients were in the targeted band, was also investigated with the STOMP protocol.
9.2.2 Model prediction
9.2.2.1 Glucose-Insulin model
A modified version of the ICING model, Section 1.2.4.1 ICING Model, was used to describe and
predict the glucose-insulin metabolic system dynamics in the STOMP GC protocol. This model
requires the future model-based SI and given interventions to forward-simulate the future BG
trajectory. The future model-based SI is provided by the stochastic model of Fig. 9.2, and given
interventions are iteratively selected from the pool of all possible interventions.
9.2.2.2 Stochastic prediction
A conditional probability density function (PDF) of SI , based on historical patient data [145], [149],
is used to predict expected future SI range (the stochastic model). Given a value of SI at hour n, the
probability of future SI values at hour n+1 can be estimated, see Fig. 9.2. The stochastic model used
by STOMP is the same stochastic model currently used by STAR, generated using kernel-density
methodology in combination with the model-based SI data from a large cohort of patients (>23,000
hours) [145], as described in Chapter 3. The stochastic model covers a broad medical ICU cohort
over all the days of stay, and, if required, can be made specific to unique cohorts [122], [262].
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Figure 9.2: The stochastic model of insulin sensitivity (SI) used by the Stochastic Model
Predictive (STOMP) Glycemic Control (GC) protocol.
The future SI PDF obtained from Fig. 9.2 can then be used to find the future BG PDF, for a specific
insulin and nutrition intervention, by forward solving the Glucose-Insulin model, as illustrated in
Fig. 9.3 [145]. Like STAR, STOMP focusses on the 5th and 95th percentile values of the stochastic
model, as these values can be used to impose a 5% risk limit on hypoglycaemia for a given insulin
and nutrition intervention. Note, the 5th percentile SI corresponds to the 95th percentile BG value
and the 95th percentile SI corresponds to the 5th percentile BG value.
Figure 9.3: Using the stochastic model of insulin sensitivity (SI) to find the probability density
function (PDF) of blood glucose (BG), for a given insulin and nutrition intervention.
9.2.2.3 Prediction horizon
Prediction horizons of 1 to 10 hours were initially investigated. The nutrition and insulin interventions
chosen are kept constant over the prediction horizon to encourage minimal intervention changes, and
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thus encourage reduced clinical workload. In addition, the 5th and 95th percentile SI values are kept
constant over the prediction horizon as the previously identified SI value is most likely to stay
approximately at its current value, as seen by the mode in Fig. 9.2 being at no change in value.
Note, the model was evaluated up to the prediction horizon for treatment assessment, but BG
measurements occurred every 1-4 hours, during which the model prediction was re-evaluated.
Initial simulations highlighted two factors that limited the prediction horizon. Insulin and nutrition
changes have differing time scales, with insulin changes having a rapidly observable effect (<10
minutes), while EN changes act over 1-2 hours due to the slower, more complex absorption dynamics
through the stomach and gut [220], [302]. Thus, the predicted BG outcomes over longer prediction
horizons include a greater contribution from intervention changes in EN.
In addition,SI fluctuates each hour. Thus, the current fitted SI value becomes more inaccurate
as the prediction horizon increases. Equally, constant insulin and nutrition over the prediction
interval means the model eventually reaches a steady-state. Typically, steady-state was reached
after approximately 6 hours, thus limiting the maximum horizon to this maximum value.
9.2.3 Cost functions
The cost functions used to evaluate the multiple different interventions can be seen in Fig. 9.4.
These cost functions were chosen iteratively using virtual trials to optimize the likely GC results.
They are also strongly based on clinical and physiological literature, and clinical experience with
prior protocols. The functions are designed to manage risk trade-offs between BG outcomes, and
the insulin and nutrition interventions given.
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Figure 9.4: Cost functions used with the Stochastic Model Predictive (STOMP) Glycemic Control
(GC) protocol to evaluate the optimal insulin and nutrition intervention.
The 5th and 95th percentile BG cost functions were designed to severely penalize both hyper- and
hypo- glycaemia, and thus keep the predicted 5th and 95th percentile BG range within the desirable
targeted band [34]. The 5th percentile BG cost function was generated by combining an exponential
and 2nd order polynomial function, severely penalizing BG < 4.0 mmol/L, ensuring hypoglycaemia
was very unlikely to occur, while not forcing the controller to be too aggressive in lowering BG. The
95th percentile BG cost function is a 2nd order polynomial with a strong emphasis on reducing the
incidence of hyperglycaemia. The equations for these two cost functions are defined:
CostBG 5th = 1.875×BG5th2 − 16.5×BG5th + 36.3 + exp−10×BG5th+42 (9.1)
CostBG 95th = 0.1×BG95th2 (9.2)
Where: BG5th = 5th Percentile predicted blood glucose value (mmol/L),
BG95th = 95th Percentile predicted blood glucose value (mmol/L)
161 9.2. METHODS
The insulin and nutrition cost functions were designed to maximize nutrition and minimize insulin
use. This choice ensures the patient is getting as much of the desired caloric goal nutrition rate
as possible, while minimizing the chance of BG falling dramatically due to the large insulin doses,
amplifying the effects of SI variability [122], [254], [288], [292]. Hence, it is a balance of maintaining
maximum nutrition intake and patient safety, as discussed previously in Chapter 8 Simpler STAR
nutrition protocols. The equations for these two cost functions are defined:
CostInsulin = 0.001× Uex2 − 0.078× Uex + 1.255 (9.3)
CostNutrition = 7.292×10−6×GF 4−2.469×10−3×GF 3 +0.3158×GF 2−18.26×GF+407.8; (9.4)
Where: Uex = Insulin dose prescribed (mU/hr),
GF = Percentage of goal feed/hour prescribed (%/hr)
Pancreatic insulin secretion in the critically ill can be highly variable and unpredictable. Thus,
maintaining a low insulin dose can dominate pancreatic insulin secretion [122] and provide greater
certainty around circulating plasma insulin for model-based predictions. Hence, the minimum of the
insulin cost function is placed at 2 U/hr (33 mU/min) to increase this predictability.
The mathematical equations for the insulin and nutrition cost functions were derived by fitting a
2nd and 4th order polynomials to the shape desired by clinical staff consultation. The cost function
polynomials were designed to have a clear global minima in the range at which the functions would
be applied. The use of polynomials means the cost functions are smooth, and thus continuously
differentiable in optimization with a unique global minimum, due to their convex definition.
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9.2.4 Blood glucose cost function weightings
In addition to the 1, 2, 3, 4, 5, and 6 hour forward predicted BG 5th and 95th each being evaluated
in the BG cost functions, weightings were also placed on each of the hourly BG prediction costs,
increasing the relative importance of BG outcome timing. Each of the evaluated costs were increasingly
weighted as the BG prediction time increased, see Eq. (9.5). Therefore, more importance was placed
on the far future BG outcome, near the end of the prediction horizon, rather than the immediate BG
response to encourage treatments which don’t require future modification. A normalized weighting









i.e. W2 = 2×W1, W3 = 3×W1 etc.
N∑
i=1
Wi = 1 (9.6)
Where: Wi = Normalized increasing weight, i = BG prediction hour (1-N hours),
N = Prediction window period
In addition to the time dependent weighting on hourly BG predictions, an additional weighting was
placed on the overall summed BG prediction costs. This weighting ranks the evaluated BG prediction
costs higher than the insulin and nutrition cost. Iteratively, it was found that a weighting of 6 on
the BG prediction costs gave the best glycaemic performance, while still maintaining reasonable
nutrition and insulin levels within virtual trial simulations. The final cost calculation can be seen
below:
Intervention Cost = 6×(
N∑
i=1
Wi×(CostBG 5th,i+CostBG 95th,i))+CostInsulin+CostNutrition (9.7)
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9.2.5 Patient cohort and virtual trials
Clinical data from 149 patients treated with the STAR protocol (2011-2014) [128], [229], in Christchurch
Hospital ICU, NZ were used to generate virtual patients. Details of these patients are shown in
Table 9.1. The Upper South Regional Ethics Committee, New Zealand granted approval for the
audit, analysis and publication of this data. Note, this controller was developed before assessment
of the larger STAR cohort in Chapter 5 Clinical performance review of the STAR Glycaemic Control
protocol, and thus was not used for virtual trials.
Table 9.1: Demographic details of the STAR cohort used for virtual trials.
Number of Patients 149
Age 64 [54 - 72]
Gender (% Male) 66.7
Length of ICU Stay (Days) 8.4 [3.5 - 16.0]
# Operative/Non-operative 49/100
APACHE II score 21.0 [15.0 – 25.0]
Length of GC (hours) 73.4 [43.2 - 135.7]
Cohort total GC (hours) 17,610
*Acute Physiology And Chronic Health Evaluation (APACHE), Glycemic Control (GC). Data
presented as median [inter-quartile range (IQR)] where appropriate.
Virtual patients were created from the patient-specific time varying model-based SI profiles [153].
This model-based SI can be used as a critical marker of a patient’s metabolic state [112], [145], [230].
These virtual patients allow robust protocols to be safely designed and rigorously tested prior to
clinical implementation, improving patient safety and minimising the need for protocol alterations
post- implementation [154], [230].
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9.2.6 Analysis and statistics
STOMP was compared to STAR in terms of GC safety, performance, and workload. The metrics
assessed comprise of:
Safety: • Number of severe hypoglycaemia patients (Number of patients with BG
< 2.2 mmol/L) [35] [34].
Performance: • Percentage of time in targeted BG band (4.4-8.0 mmol/L) [61], [142].
• Percentage of time hyperglycaemia occurs (BG > 10 mmol/L).
Workload: • Mean number of BG measurements per day.
Due to the irregular 1-3 hourly measurement intervals, used in both STAR and STOMP, patient BG
data was analysed with linear interpolation at 60 min intervals to enable fair comparisons [246], per
Chapter 2 Interpretation of Retrospective BG Measurements. Note, minutely sampling was not used
as this analysis was done before the analysis of Chapter 2 had been performed. As a consequence
the BG percentage of time out of the targeted band statistics may be slightly conservative, although
very unlikely to be significant, see Chapter 2.
STAR clinical data is presented for comparison with the virtual trial results of STAR. As the
current implementation of STOMP only provides insulin via infusion, an infusion-based virtual trial
of STAR is also presented for direct comparison. As noted, both STAR and STOMP allow variable
measurement intervals, based on the BG history, and the maximum allowed measurement interval
was always selected in these virtual trials. Both 3 and 4 hour maximum measurement intervals are
shown for the STOMP protocol. Clinically, STAR uses a 3-hour maximum measurement interval.
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9.3 Results
GC safety, performance, and workload for STAR clinical, and simulated STAR and STOMP protocols
are shown in Table 9.2. Both STOMP and STAR provided very good GC performance, with
very similar percentages of time in the targeted 4.4-8.0 mmol/L BG band (approximately 87.0%
for both protocols), in all cases. Equally, the safety of both protocols was very high with less
than 3.4% of patients experiencing a severe hypoglycaemic episode (BG < 2.2 mmol/L). However,
because STOMP optimises treatment and performance over a 6 hour prediction window, the selected
treatment options have better foresight. As a result, STOMP was able to maintain excellent GC
performance and safety with both 3 and 4 hour measurement intervals, while largely reducing the
average number of measurements required per day (approximately 13 vs. 10.0 and 8.4 measures per
day, respectively), which represent significant workload reductions [101], [151], [272].
A randomly selected virtual patient was chosen to show how STAR and STOMP respond to
fluctuating SI in Fig. 9.5. The total cost associated with each chosen STOMP intervention can
be seen to be constantly minimized, targeting the optimum balance of BG outcome and intervention
cost for the patient, based on the pre-selected weights and cost functions. While, overall, the
BG is largely similar between protocols, the insulin and nutrition interventions vary significantly,

























Table 9.2: Clinical and virtual trial cohort performance of the STAR and STOMP Glycaemic controllers on STAR Cohort. STAR Clinical (Bolus) shows
actual clinical performance of STAR. The other columns indicate virtual trial performance on this same cohort using bolus or infused insulin, with













Mean num. measures/day 13.4 13.2 12.7 10.0 8.4
Safety
% time BG <4.4 mmol/L 1.7 2.7 3.2 1.9 2.8
% time BG <2.2 mmol/L 0.006 0.01 0.05 0.04 0.06
Number of patients BG (%) <2.2 3 (2.0%) 2 (1.3%) 4 (2.7%) 4 (2.7%) 5 (3.4%)
Performance
% time BG 4.4 - 7 mmol/L 61.0 75.4 73.2 76.8 73.5
% time BG 4.4 - 8.0 mmol/L 80.6 87.5 86.3 87.7 86.2
% time BG 8.0 - 10 mmol/L 12.6 7.9 8.6 7.7 8.2
% time BG >10 mmol/L 5.1 2.5 2.6 3.2 3.2
Goal feed median [IQR] (%) 75.9 [36.4 - 99.4] 90.2 [30.7-100.0] 84.8 [30.5- 100.0] 80.0 [65.0 - 95.0] 80.0 [65.0 - 95.0]
Insulin rate median [IQR] (U/hr) 2.5 [1.0 - 4.0] 3.0 [1.5 - 5.5] 4.0 [1.5 - 6.0] 4.0 [2.0 - 5.5] 4.0 [2.0 - 5.5]
*Stochastic TARgeted (STAR), Stochastic Model Predictive (STOMP), blood glucose (BG), inter-quartile range (IQR).
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Figure 9.5: An example virtual patient showing the performance of Stochastic Model Predictive
(STOMP) and Stochastic TARgeted (STAR) GC protocols. The STAR targeted blood glucose
(BG) band (4.4-8.0 mmol/L) is also shown for comparison of performance.
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9.4 Discussion
Table 9.2 shows STOMP performed very well providing safe and effective GC approximately equal
to that of both STAR controllers, infusion and bolus. Both STAR and STOMP protocols provided
a high percentage of time in the targeted BG (approximately 87%), while also ensuring patient
safety (< 0.06% time of BG < 2.2 mmol/L). Equally, the number of patients who experienced severe
hypoglycaemia (4-5 or 2.7-3.4% of patients BG < 2.2 mmol/L) were very low compared to other
reported GC protocols [105], [109], [213].
In addition, STOMP provided approximately equivalent GC performance and safety as STAR, while
also largely reducing the clinical workload (12.7 vs. 10.0 and 8.4 measures/day). This large reduction
in the number of measures required per day is likely due to long prediction horizon (N=6) used with
STOMP enabling better foresight of treatment options offered, encouraging long term BG goals of
the controller. This behaviour is well illustrated in Fig. 9.5, with STOMP offering more gradual
changes in nutrition and insulin compared to STAR’s relatively rapid changes. Hence, STOMP
was able to maintain excellent GC performance and safety, while offering the hour longer 4 hour
measurement intervals and, as a result, reducing clinical staff GC workload by approximately 35%,
which is critical to clinical uptake and compliance [101], [151], [272].
Interesting to note, in Fig. 9.5, STOMP allowed the predicted 5th percentile BG to go below 4.0
mmol/L. This is likely due to the earlier BG prediction costs (1 and 2 hour) being outweighed by
other factors such as more desirable future BG predictions (4, 5, and 6 hour) and their associated
interventions. Emphasising how STOMP’s intervention cost calculation, Eq. (9.7), weights the long
term outcome of interventions higher than the immediate predicted BG response. STAR is unable
provide this type of behaviour. As a result, STOMP is able to provide more effective GC, especially
for patients whose wide prediction bounds, and immediate predicted BG response limit the treatment
options able to be offered by STAR.
The method of combining MPC with the stochastic prediction behaviour used by STAR to implement
a GC protocol has proven very effective. This approach formalizes the STAR GC algorithm, making
169 9.4. DISCUSSION
optimization easier for different clinical practices and requirements. Using a series of cost functions,
to set the behaviour of the controller means modifications to the controller behaviour can be easily
made, which thus allows clinical staff or specific ICUs to put a higher priority on any of the desired
performance metrics. Clinical staff could choose the weighting for each performance metric, based
on the specific patient’s condition or local practice, making the protocol more patient-specific or
hospital-specific. For example, if a patient was hyperglycaemic, but the clinicians wanted to continue
giving the patient a high amount of nutrition, the cost functions could be adapted so there was a
larger penalty for having low nutrition. Thus, the controller would have to choose an intervention
with a higher nutrition input, while also trying to maintain a desirable BG.
Additional cost functions, based on other aspects of GC, could also be easily added to STOMP.
This level of flexibility is not currently available with the STAR protocol. For example, adding a
cost function to reduce large changes in insulin interventions would make the controller less likely
to over respond and suit a more cautious clinical practice. The MPC cost functions enabled this
added flexibility in implementing a stochastic-predictive controller. Therefore, STOMP is potentially
better suited for a more diverse range of clinical practice cultures and cohort-specific approaches
than STAR.
It is important to note this MPC form of STAR is different from other MPC GC protocols [214],
[232], [297]–[301]. Beyond a different model, STOMP uses stochastic model forecasting [145], [149]
to manage intra-patient metabolic variability and risk [123], [124]. In contrast, these other MPC
GC protocols commonly use auto-regressive models that are more patient-specific but require more
data to adapt to changes, and do not manage variability in any way. As a result, STOMP’s MPC
approach , as with STAR, can safely predict further ahead because it does not rely on external black-
or grey- box machine learning models to manage intra-patient variability.
Virtual trials have been shown to give a good indication of expected clinical performance [230],
[295] and be generalizable across ICUs [154]. However, they do not allow for unforeseen clinical
exceptions. Therefore, the results only represent an ‘ideal’ situation and remain to be confirmed. A
clinical pilot trial should be undertaken to validate these results on real patients prior to full clinical
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implementation. However, the virtual in-silico design analysis presented has improved the likelihood
of a successful clinical implementation. Note, the STOMP controller is currently in development for
a clinical trial implementation.
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9.5 Summary
An MPC GC protocol was developed and optimised for GC in the adult ICU using virtual trials. The
STOMP protocol was designed as a model-predictive evolution of STAR, permitting the controller
response to be easily tuned to specific, clinically relevant, performance metrics. It has the additional
benefit of formalising the heuristic control algorithm of STAR, and providing a much more generalisable
approach. The results indicate STOMP retains the performance and safety of STAR, spending
approximately 87% of time in the 4.4-8.0 mmol/L BG band and 0.06% of time BG < 2.2 mmol/L,
while considerably reducing clinical workload, requiring 35% fewer BG measurements. The GC
performance and reduced workload of STOMP can be largely attributed to the 6 hour prediction
horizon used, giving the controller better foresight into the interventions given. Overall, the STOMP
protocol is a promising to development to the STAR protocol, enabling easy customization to a more
diverse range of clinical practice cultures, cohort-specific approaches, and patient-specific conditions.
Overall, the virtual trial results of STOMP show the clinical flexibility of STAR has been considerably
improved. However, a clinical pilot trial should be undertaken to confirm the results of this study.
The combination of MPC and stochastic prediction presented in this chapter is a unique and effective
GC methodology, which could be adapted to multiple scenarios.
Part III:
Development of the ICING
model for Type 2 diabetic ward
patients




Design of an interventional subcutaneous
insulin trial
10.1 Background
Currently in NZ, the initial suggested treatment of type 2 diabetes is generally a significant change
in lifestyle (diet and exercise) to try and lower the individual’s HbA1c concentration [162], [181]. An
HbA1c measurement provides a weighted measure of the mean BG over the previous 120 days [174].
If the targeted HbA1c is not met after 3 months, assistive oral medication is recommended. The
initial recommended medication is Metformin (Apotex NZ Ltd., New Zealand) [186]. Metformin acts
by increasing the biological efficiency of available insulin, increasing glucose uptake and effectively
increasing a patient’s sensitivity to insulin [181], [187] and has been proven effective in improving
patient outcomes [188]. If the individual’s condition still deteriorates they are prescribed Sulphonylurea
[186], which acts as a steroid to increase pancreatic insulin output, increasing endogenous insulin
secretion [181], [189]. However, it has been shown that 9 years after the prescription of sulphonylurea,
approximately 80% of patients will still require insulin treatment [25], [190], where insulin is currently
considered the last available treatment option [183], [186], [191].
Many studies have discussed and compared the treatment options for type 2 diabetes, specifically
with regard to GC and beta cell degradation leading to reduced endogenous insulin secretion. It has
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been shown in many cases that insulin treatment is more effective in preserving beta cells [25], [168],
[195], [196], improving lipid metabolism [197]–[200], and achieving GC targets [25], [164], [190], [201]
compared to other offered treatments. This result may be due to those receiving oral medication
still requiring relatively high endogenous insulin secretion rates from the pancreas, leading to the
eventual ’fatigue’ of the pancreas [161], [202]–[205]. Therefore, treating type 2 diabetes with basal
insulin, much earlier, may allow the pancreas to ’rest’, reducing endogenous insulin secretion [206],
[207], between meals and thus allowing it to act more appropriately during meals [208]. Ultimately,
this approach suggests ’early’ basal insulin therapy may improve GC and reduce the degradation of
an individual’s pancreatic functionality. However, if basal insulin suppresses endogenous insulin
secretion entirely, including when patient’s have meals, or has no effect on endogenous insulin
secretion very limited benefit will be observed. As there is limited literature available in this area a
clinical trial is needed to test the potential benefits of basal insulin therapy.
Although basal insulin therapy may have potential benefits, it increases the risk of hypoglycaemia if
not taken correctly [64], [66], [164], [180], [201], [209]–[211]. Use of insulin is thus avoided clinically
due to human variability [124] making dosing riskier [191], [201]. In addition, there is also a negative
stigma around starting insulin therapy, as individuals and the physician feel they have failed [183].
Therefore, before early basal insulin therapy can be offered, a very safe and effective dosing protocol
needs to be developed. Only then can any potential benefits of early basal insulin therapy be realized.
The trial designed in this chapter investigates the idea of insulin being used as an initial treatment
option for type 2 diabetics. Specifically, whether or not basal insulin supports or suppresses
endogenous insulin production and improves GC. In addition, the data gathered from this trial
will allow a comprehensive insulin-glucose model to be developed for the type 2 diabetes cohort.
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10.2 Aims
Primary aims: • Determine if basal insulin supports or suppresses endogenous insulin
secretion.
• Gather data to develop a model of a type 2 diabetic and pre-diabetic
patient’s insulin-glucose response, with and without exogenous basal
insulin support.
Secondary aims: • Determine the inter-patient variability in the appearance kinetics of
the basal insulin analog Detemir (Levemir, Novo Nordisk, Bagsvaerd,
Denmark).
• Determine if basal insulin support improves a patient’s endogenous
GC.
10.3 Study design
Non-randomised, uncontrolled pilot trial investigating the effects of subcutaneous basal insulin
treatment for people with type 2 diabetes and pre-diabetes.
10.3.1 Patient overview
Patients receiving elective cardiac surgery are targeted because they have a high chance of meeting
the type 2 diabetic or pre-diabetic eligibility criteria of this study [165], [167] and commonly stay
2-3 days in the ward, post-surgery, for recovery. The typical cardiac surgery patients time-line at St
George’s Hospital in relation to the trial can be seen in Fig. 10.1.
10.3.1.1 Locality
The trial will be undertaken at the Sir George Seymour Ward of St George’s Hospital, Christchurch,
NZ.
10.3.1.2 Entry criteria
Cardiac surgery patients who are considered to have type 2 diabetes or pre-diabetes (HbA1c > 40
mmol/mol or > 5.8%, and fasting BG > 6.0 mmol/L [173]), and have an expected length of stay in
the Sir George Seymour Ward equal to or greater than 2 complete days.
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Figure 10.1: Flow chart of patient time-line from eligibility test to commencement of the trial at St
George’s Hospital, New Zealand.
10.3.1.3 Exclusion criteria
Patients < 18 years of age; Inability to gain consent; Lack of equipoise (for any reason) on the part
of the treating clinician.
10.3.1.4 Informed consent
All patients who are receiving cardiac surgery at St George’s Hospital will be provided with a trial
information sheet in their pre-surgery information packs. Written, informed consent will be obtained
from eligible patients by Dr. Geoff Shaw or the Intensivist on at St George’s either in the morning
or night before the patient’s cardiac surgery. Patients can withdraw from the study at any time.
However, if a basal insulin dose has been given within the last 24 hours the patients BG will need
to be monitored relatively strictly (approximately every 3 hours). Should a patient be withdrawn
during the trial, consent will be sought after to use any data collected up to that point in time,
otherwise it will be destroyed.
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10.3.2 Trial protocol
The trial commences the morning after the patient has moved from the ICU to Sir George Seymour
Ward, approximately 44 hours on average after surgery. For the next 2 complete days measurements
for the trial are taken around the patient’s meals. Patient demographic data, such as age, weight,
height, gender, and patients prior diabetes related history will be recorded once consent is received.
10.3.2.1 Meal monitoring
Before and after each patient’s meal (Breakfast, Lunch, and Dinner), 4.0 mL blood samples are
taken to measure BG, plasma insulin, and C-peptide concentrations. C-peptide concentrations are
used to estimate the patients endogenous insulin secretion rate, per Section 11.2.2.1. The 4 blood
samples taken around each patient’s meal are shown in Fig. 10.2.
Figure 10.2: Blood sampling time-line around each patient’s meal. The shaded orange region
indicates the region in time where the measurement can be taken.The dashed green region
indicates the time in which the patient has the meal tray.
The measurement prior to each meal is designed to capture the patient’s initial state before a meal.
This state is assumed to be relatively constant if no food has been consumed in the past 3 hours,
as illustrated in Fig. 10.3. The 2 measurements immediately post-meal are designed to capture
the patient’s response around the postprandial peak in BG and plasma insulin, as illustrated in
Fig. 10.3. The final measurement is designed to capture the standard 2 hour postprandial BG and
plasma insulin level in the second phase of typical response [303]. The timing of all 4 measurements
are compared to the BG and plasma insulin levels published in Jacobs et al. [236] for hospitalised
non-diabetic subjects, as illustrated in Fig. 10.3.
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Figure 10.3: The proposed blood sampling time-line (orange region) in comparison to a modified
plot from Jacobs et al. [236]. Mean ± standard error (SE) of blood glucose (BG) and plasma
insulin measurements for hospitalised for non-diabetic subjects (Shaded area), and mean ±
standard deviation (SD) of blood glucose (BG) and plasma insulin measurements for hospitalised
diabetic patients treated with lispro (-©-) and human insulin (--) are shown.
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10.3.2.2 Insulin treatment allocation
Patients are split evenly between one of two streams for insulin treatment. Stream A will be
conducted on the first half of patients (5 patients), and Stream B will be conducted on the remaining
half of patients (5 patients).
Stream A: Trial Day 1 patient receives a small basal insulin dose in the morning.
Trial Day 2 patient does NOT receive any insulin.
Stream B: Trial Day 1 patient does NOT receive any insulin.
Trial Day 2 patient receives a small basal insulin dose in the morning.
Measurements are the same for both streams, only the timing of the basal insulin dose varies. Two
streams of insulin dose timing are used to eliminate the scenarios associated with differing patient
response. These scenarios are:
• The patient is more stressed, post-cardiac surgery, on day 1 compared to day 2. As a result, the
patient may have more stress hormones present on day 1, naturally raising BG [39], [85]–[88],
suppressing endogenous insulin secretion [74], [84], and thus conflicting with the potential
influence of basal insulin therapy. Therefore, giving the insulin dose on day 2 should minimise
this influence.
• The benefits of basal insulin support may not occur immediately and require a period for the
body to adjust to the external insulin intervention. Therefore, giving the insulin dose on day
1 should be able to observe this effect.
Hence, having two streams of insulin treatment, one on day 1 and one on day 2 of ward stay,
post-cardiac surgery, allows for both scenarios to be observed.
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10.3.2.3 Insulin Dosing
Levemir (Insulin Detemir analog) from 100 U/mL Levemir FlexTouch pens (Novo Nordisk, Bagsvaerd,
Denmark) is used. Insulin is injected in the lower abdomen, in the morning during the first blood
sample of the day. Insulin is very conservatively dosed based on the patient’s Total Daily Dose
(TDD) insulin requirements [304], as defined:
TDD = 0.5×BW
Basal/Background dose = 50% of TDD
∴ Dose size = 0.25 U/kg/day
(10.1)
Where: TDD = Total Daily Dose (U/day), BW = Body wieght (kg)
For example, an 80 kg patient would receive:
Basal insulin dose = 0.25× 80 = 22 U/day
10.3.3 Sample size
As this trial is an investigative pilot trial, only 10 patients will be included in this trial. This sample
size will provide enough data to address the trial’s primary and secondary aims. More specifically,
this sample size does not provide enough data/power to assess patient outcomes. However, assessing
patient outcomes is not the aim of this first trial.
A total of 10 participants will be recruited. However, if one or more patients do not complete both
trial days, either because they have withdrawn or because they were unable to complete the study,
additional patients will be recruited until 5 patients in each stream have completed both days of the
study.
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10.3.4 Clinical surveillance
10.3.4.1 Blood sampling
At each measurement point, a 4.0 mL whole blood sample will be taken from the patient’s peripheral
IV line. The one blood sample is used for assessment of BG, C-peptide, and plasma insulin. BG
tests will be performed in-situ with an Optium Neo H (Abbott Diabetes Care, Illinois, USA) PoC
BG meter, using approximately 0.1 mL of the IV blood sample. C-peptide and plasma insulin will
be determined by immunometric assays (Elecsys 2010, Roche Diagnostics, Germany) at Canterbury
Health Laboratories (CHL). Only one 4.0 mL blood sample per measurement is used to minimise
daily blood draw from the patient. With 12 blood samples a day the total expected blood draw, per
day, for each patient is 48 mL.
10.3.4.2 Continuous glucose monitoring (CGM)
Two iPro2 continuous glucose monitor (CGM) sensors (Medtronic, MiniMed, Northridge, CA, USA)
will be inserted for retrospective analysis of BG data, enabling assessment of higher frequency BG
dynamics. The CGMs will be inserted into the patient’s lower abdomen by a member of the research
team or a trained clinician, preferably while the patient is in the ICU post-cardiac surgery, but no
later than 12 hours before initiation of the trial to allow calibration of the sensor [305]. The CGMs
will be removed the morning after the trial has concluded. The sensor site will be monitored
frequently by the nursing staff for signs of possible infection or pressure trauma, and the sensors will
be removed if there are any concerns.
10.3.4.3 Nutrition details
For every meal the patient consumes the nutritional information will be recorded. The amount and
type of food consumed will be estimated from meal tray photos pre- and post- meal. The total
nutritional content of each meal is provided by the St George’s Hospital Kitchen. External food
brought will be discouraged, but similarly monitored if consumed.
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10.3.5 Adverse Events
All adverse events will be reported to nursing staff and the research team. Specifically:
Hypoglycaemia: In the rare event the patient experiences mild hypoglycaemia (BG < 4.0
mmol/L), the patient is given an oral 15 g dose of dextrose. The patient’s BG is then checked
approximately 20 minutes later to see if it is > 5.0 mmol/L [306]. If not, the patient will be
given another 15 g dose of dextrose until their BG is measured to be > 5.0 mmol/L.
Hyperglycaemia: If 2 consecutive BG are measured > 10.0 mmol/L, the patient may be
treated with a small bolus of IV rapid acting insulin (Actrapid, Novo Nordisk, Bagsvaerd,
Denmark), as per standard practice.
Post-cardiac surgery complications: If complications arise due to the cardiac surgery,
unrelated to the trial, such as cardiac arrhythmia, the patient will be treated as per standard
practice. Note, this may involve IV infusion of anti-arrhythmic drugs such as Amiodarone
Hydrochloride which is administered with a 5% glucose solution [307]. If more severe complications
arise, such as large internal bleeding requiring resternotomy and tamponade, continuation of
the trial will be up to the clinicians discretion.
If either hyper- or hypo- glycaemia occurs the patient will not be excluded from the study and
normal trial procedure will continue. However, patients are able to opt out of the trial at any time
if they feel uncomfortable.
10.3.5.1 Compensation
Participants in will be covered by the Accident Compensation Corporation (ACC) of NZ should any
harm occur from trial participation.
10.3.6 Data Management
Every patient will be assigned a unique study number. All data will be collected using specific case
report forms labelled with the allocated study number. Collected data will be entered into a secure
database. All records will be secured in a locked drawer or password-protected computer database.
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10.3.7 Trial Identification
The trial is reviewed and approved with the Southern Health and Disability Ethics Committee
(HDEC). Ref: 16/STH/152, 26th September 2016.
10.4 Discussion
It has been shown if type 2 diabetes is treated early and ’effectively’, its progression can be stopped
and normo-glycaemia maintained [176]–[178], reducing the associated long term health care costs.
However, if not treated effectively, the individual’s condition may completely degrade, secreting only
negligible amounts of endogenous insulin. At this point their condition becomes very similar to an
individual with type 1 diabetes in terms of treatment [179]–[181], where such treatment is difficult,
costly, and often not robust. As a result, complications and thus costs mount rapidly.
Insulin therapy for type 2 diabetes usually begins with basal insulin support [179]–[181], where basal
insulin is a subcutaneous long acting analogue of insulin which is designed to be released slowly and
steadily into the blood stream over a long period of time (typically 16+ hours). The most common
commercially available forms of long acting insulin are Glargine and Detemir. Basal insulin support is
designed to mimic the normal basal insulin production of the pancreas [179]–[181], [183], leaving the
pancreas free to act around meals. The most common dosing regime is a sliding scale proportional to
the individual’s morning fasted BG week long average [180], [192], [193]. However, if an individual’s
condition deteriorates even further they are prescribed both basal and rapid acting insulin to try and
mimic the entire functionality of the pancreas [179]–[181], [183], similar to type 1 diabetes treatment
[183], [194].
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Problematically, current approaches to care mean basal insulin therapy is usually only offered after
an individual with type 2 diabetes condition has substantially progressed, and beta cell endogenous
insulin production is likely significantly depleted [176]. This approach is taken largely due to the
perception that the trade-off in care quality is out weighed by the significant risks associated with
insulin therapy [64], [66], [164], [180], [201], [209]–[211]. Therefore, paradoxically, starting basal
insulin therapy this late in the progression of type 2 diabetes may not allow the potential benefits
of insulin therapy to be best utilised.
One study in particular looked at prescribing people age 50 and over, with evidence of cardiovascular
disease and newly detected or established diabetes (pre-diabetes or early stage type 2 diabetes), with
standard practice diabetes treatment or one daily injection of Glargine (basal insulin) for 6 years
[212]. The primary outcomes were in regard to cardiovascular events, and no conclusive outcome was
found. However, a 41% reduction in the number of people with newly diagnosed diabetes was seen in
the group which used basal insulin therapy compared to those who were receiving standard treatment
[193], despite having significant numbers who quit this therapy or were not fully compliant. This
outcome strongly emphasises the potential benefits of early basal insulin therapy, which is otherwise
not used clinically, as well as the risks, difficulty, and resulting non-compliance seen when using this
therapy with current dosing protocols and technology.
Hence, because the progression of type 2 diabetes can be slowed or stopped, preventative treatment
is the focus of this study. In particular, this study is designed to observe the effect of intervening
with basal insulin therapy very early on in the development of type 2 diabetes. The data gathered
from this trial will help us better understand an individual’s response to basal insulin therapy and
determine if it is viable preventative treatment option for people with type 2 diabetes. In particular,




Previous literature has highlighted the potential benefits for early basal insulin therapy as an
preventative treatment for individuals with type 2 diabetes. In particular, in regard to preservation
of endogenous insulin secretion and improved GC. However, limited literature exists around whether
or not basal insulin therapy supports or suppresses endogenous insulin secretion. The proposed trial
aims to gather data to investigate the affect of basal insulin therapy on endogenous insulin secretion,
and develop a model to help us better understand and eventually safely, and effectively control the
type 2 diabetes cohort.
If the data from this trial shows basal insulin therapy to be a potentially viable preventative
treatment for type 2 diabetes, it could provide a relatively safe and effective way of reducing/stopping
the progression of type 2 diabetes.
Chapter 11
Initial results of an interventional
subcutaneous insulin trial
11.1 Background
In Chapter 10, an interventional subcutaneous insulin trial was designed to investigate the idea
of using insulin as an initial treatment option for type 2 diabetics. The trial specifically looks at
whether or not basal insulin supports or suppresses endogenous insulin production and thus if it can
improve GC in early type 2 diabetes or pre-diabetes. The data gathered from this trial will also
allow a comprehensive insulin-glucose model to be developed for the out-patient type 2 diabetic and
pre-diabetic cohort.
The trial was designed and ethics granted in September 2016. Once nursing was arranged with St
Georges Hospital, the first patient was enrolled in March 2017. However, after this patient completed
the trial a few issues arose about the trial workload for the St George’s Hospital nursing staff. As
a result, external research nurses were required to be organised before the trial could be continued.
Therefore, the next trial patient was delayed until December 2017. This chapter provides the initial





Two patients have currently been enrolled in this study. Patient 1 had no prior history of diabetes
and Patient 2 was a well controlled type 2 diabetic. The patient demographics can be seen in
Table 11.1. Notably, their HbA1c levels are similar and are just within the currently considered
pre-diabetic status for NZ (40-50 mmol/mol) [173].
Table 11.1: Demographic data for the two trial patients who have completed the study.
Patient Trial ID 1 2
Age 73 74
Gender Male Female
Weight (kg) 88 72
Height (cm) 180 163
HbA1c (mmol/mol) 41 43
Prior History of Diabetes No Yes, 10 years on Metformin
11.2.2 Raw Measurement Analysis
11.2.2.1 Endogenous insulin secretion
Plasma insulin and C-peptide is measured from whole blood samples 4 times around each meal the
patient receives. By using the population parameters and pharmaco-kinetic model described by
Van Cauter et al. [308] endogenous insulin secretion rates can be deconvolved from the measured
C-peptide data. The pharmaco-kinetic model presented in Van Cauter et al. [308] can be seen in
Eqs. (11.1) and (11.2).
dC(t)
dt
= Uen(t)− (k1 + k3)× C(t) + k2 × Y (t) (11.1)
dY (t)
dt
= k1 × C(t)− k2 × Y (t) (11.2)
Where: C = C-peptide in central compartment (pmol/L)
Y = C-peptide in peripheral compartment (pmol/L)
Uen(t) = Endogenous insulin secretion rate (pmol/min)
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Given the Van Cauter et al. [308] dynamic parameters:
k2 =
















And substituting Eq. (11.8) into Eq. (11.3) gives:
k2 = Fraction× (b− a) + a (11.9)
Given this information each of the kinetic patient-specific parameters (k1, k2, k3, and Volume of
distribution) can be derived from Table 11.2 and Equations (11.10) to (11.12).
Table 11.2: Van Cauter et al. population parameters [308].
Normal Obese NIDDM
Short half-life (min) 4.95 4.55 4.52
Fraction 0.76 0.78 0.78
*Non-insulin dependent diabetes mellitus (NIDDM)
LongHalfLife = 0.14×Age+ 29.2 (11.10)
V ol. Distribution =

Male 1.11× (BSA) + 2.04
Female 1.92× (BSA) + 0.64
(11.11)
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By using discrete deconvolution of Eqs. (11.1) and (11.2) the endogenous insulin secretion rate,
Uen, can be solved for, Eq. (11.13). Tikhonov 2nd order regulation [310] was used with a λ = 50,
estimated by the L-curve approach [311], to ensure a smooth solution of endogenous insulin secretion
rate was found, restricting non-physiological stepwise jumps in Uen.
Uen(t) = (XTX + (λL2)T (λL2))−1XT (Cimp − Cinit) (11.13)
Where: Uen(t) = Endogenous insulin secretion rate (pmol/min), X = Toeplitz matrix of Cimp
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1 −2 1

Cimp = Impulse response of Van Cauter Eqns, as seen in Fig. 11.1.
Cinit = Initial condition response of Van Cauter Eqns, defined by Eqs. (11.14) and (11.15) [308].
C(t0) = Cmeas(t0) (11.14)
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Figure 11.1: Impulse response of Van Cauter et al. [308] endogenous insulin secretion model
equations.
11.2.2.2 CGM Retrospective Calibration
Two CGM sensors were inserted into the abdomen of each patient to provide retrospective information
of BG trends. Two CGMs were inserted to increase the reliability of the observed trend. Retrospective
calibration was performed by forcing the raw signal received from each CGM sensor through each of
the measured BG points. This recalibration ensured the CGM signal captured the BGmeasurements,
while still giving an indication of intermediate trends in BG.
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11.2.2.3 Meal monitoring
Patient meals were monitored by recording the time a patient was given a meal tray and the time the
meal tray was taken back. Photos were taken at each of these times to allow an estimation of initial
meal size and the proportions of each part of the meal the patient consumed. Nutritional information
given by the packaged food or St George’s kitchen was used to estimate the macro nutrients of each
meal (Energy, Protein, Carbohydrates, Sugar, Fibre, Fat, and Saturated Fat). An example of the
photos taken before and after each meal can be seen in Fig. 11.2. For lack of better knowledge, all
meals were assumed to be consumed equally over the entire period in which the patient had the
meal tray. Any other snack food brought in was also monitored.
(a) Pre-Lunch (b) Post-Lunch
Figure 11.2: Example of meal photos taken pre and post each meal used to estimate the amount of
each food type consumed.
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11.3 Results
Each of the patient’s fasted pre-surgery measurements are shown in Tables 11.3 and 11.4. Notably
Patient 2, the established type 2 diabetic, had a much higher fasted C-peptide and plasma insulin
level, suggesting the pancreatic ’stress’ mentioned in Chapter 10. The measurements taken throughout
each of patient’s trial days are presented in Figs. 11.3 and 11.4, where the endogenous insulin
secretion rate is derived from the C-peptide measurements, as described in Section 11.2.2.1. Note,
although all of the macro nutrients were recorded, as stated in Section 11.2.2.3, only carbohydrates
are presented to aid clarity of the figures. Table 11.5 shows there is slight differences between the
day the patient received basal insulin and the day they did not. However, normalisation of these
values to account for meal size and its macro nutrients is required before any relationships can be
observed.
Table 11.3: Patient 1 fasted pre-surgery measurements.
BG (mmol/L) C-peptide (pmol/L) Plasma insulin (pmol/L)
7.8 771 54
Table 11.4: Patient 2 fasted pre-surgery measurements.
BG (mmol/L) C-peptide (pmol/L) Plasma insulin (pmol/L)
7.2 1370 131
Table 11.5: Comparison of the maximum recorded blood glucose (BG), endogenous insulin
secretion (Uen), and plasma insulin (Uplasma) on each of the trial days, with and without basal
insulin support. Both patients were in Stream A.
Insulin day maximum values Non-insulin day maximum values
BG (mmol/L) Uen (mU/hr) Uplasma (mU/L) BG (mmol/L) Uen (mU/hr) Uplasma (mU/L)
Patient 1 9.8 229 229 10.5 250 142




















































Figure 11.4: Summary of the data collected from Patient 2. Insulin given on Day 1 (Stream A).
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11.4 Discussion
After the first patient enrolled in this study issues arose around nurse workload. For the first patient,
trial blood samples were taken by the nurse who was also caring for the patient. This resulted in an
unmanageable workload for this nurse, especially during the morning routine (showering, walking,
cardiogram etc.). In addition, BG measurements were taken using a hand-held iSTAT blood gas
analyser (Abbott Point of Care Inc., Princeton, NJ, America), which required special nurse training.
Overall, these issues resulted in external research nurses being needed, and the replacement of the
hand-held iSTAT blood gas analyser with a standard PoC meter, Accu-Chek Performa II (Roche
Diabetes Care Inc., IN, America), compromising on BG measurement accuracy.
Once these changes were made, prior to Patient 2, the trial appeared to be considerably more
clinically feasible in terms of nurse workload. No major concerns of patient discomfort or safety
arose for either patient. Only minor discomfort from the multiple peripheral IV line blood samples
was reported. No issues arose due to the subcutaneous insulin injection and/or dose given.
The measurements of BG, plasma insulin and C-peptide appear to capture a patients typical meal
response very well, approximately capturing the peak and postprandial decay in BG, plasma insulin
and endogenous insulin production, as seen in Figs. 11.3 and 11.4. This peak and postprandial
decay response is especially prominent during lunch on trial day 2 of patient 1, Fig. 11.3, and during
breakfast on trial day 2 of patient 2,Fig. 11.4. Therefore, the timing of measurements appears to
capture the desired meal response characteristics.
A common issue during both trial patients was the inability to draw blood from the peripheral
IV line. As blood was sampled frequently from the peripheral IV line, commonly in the dorsal
vein (Hand), irritation (Phlebitis) and aspiration resulting in the collapsing of the vein commonly
occurred. When these issues occurred a new IV line was required to be inserted, discomforting the
patient and in some instances resulting in no blood sample being taken. In Patient 1, the IV line
was replaced 2 times, and 4 times in Patient 2. It has been presented in many cases that the use of
peripheral IV lines for frequent and prolonged blood sampling can result in increased complications
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[312]–[314]. Therefore, if possible, keeping the patient’s central venous line in post surgery should
be considered for future patients, as these lines are more suitable for frequent and prolonged blood
sampling [312].
A prominent difference between the patients was the number of haemolysed blood samples in Patient
2. Haemolysis occurs due to the release of haemoglobin and other intracellular components from red
blood cells into the plasma, and, as result, the plasma insulin assays give a lower reading than what
was actually present. Haemolysis can be caused by any process in which the red blood cells could
be damaged. Possible areas where haemolysis could have occurred in this study are:
• Syringe collection of blood exerting pressure on the red blood cells and damaging them.
• Collection through an IV catheter rather than a straight needle.
• Excessive tube shaking damaging the red blood cells.
• A too smaller gauge catheter was used damaging red blood cells on entry to the catheter.
• The blood samples not kept cold enough denaturing the red blood cells.
All of these issues are potentially viable reasons for the frequent haemolysis in the second patient.
However, due to blood draw being more of an issue in Patient 2 relative to Patient 1, considerably
more pressure may have been used to try and draw blood, and, as a result, haemolysis frequently
occurred. Again, a central venous line may allow for better blood draw in these situations, particularity
when the excessive pressure required to draw the blood results in an unreliable plasma insulin
measurement.
Due to frequent missing or unreliable measurements, a method should be developed to recover the
underlying meal response. Once all the patient data is collected a generalised meal response wavelet
or set of wavelets could be formed to approximate the complete meal responses recorded, potentially
using added information from the CGM response. These wavelets could then be fitted to meals
where data is missing or unreliable to approximate the entire meal response. This technique could
provide an innovative way of recovering the meal response characteristics where data is missing or
unreliable.
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In contrast to the ICU, where patients are fed relatively constantly throughout the day, patients
in the ward are fed commonly 3 times per day, with meals of varying nutritional content. Hence,
the modelling of meal dynamics is of relatively high importance in this setting, given the potential
trade-offs to SI . In addition, better modelling of the meal responses will help ‘normalise’ a patient’s
response to a given meal, allowing easier inter-meal comparisons.
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11.5 Summary
An interventional subcutaneous insulin trial was designed in Chapter 10 to investigate the idea of
insulin being used as an initial treatment option for type 2 diabetics. The initial results and raw
data analysis of the first two patients are presented in this chapter. Issues around nurse workload
were identified in the first trial patient, which resulted in the need for external research nurses in
future patients. After arranging external research nurses the clinical implementation of the trial
appeared to provide a much more manageable workload for everyone involved. No issues around
patient discomfort and/or safety arose during either of the patients.
The measurement timing appears to captures the patient’s meal response, peak and postprandial
decay, well through out the day. However, measurements were sometimes missed due to issues with
blood draw from the peripheral IV line. This was a issue common to both patients and could be
remedied by the use of a central venous line. In addition, the difficult blood draw from the peripheral
IV line in Patient 2 may have resulted in increased occurrence of haemolysis, reducing the reliability
of plasma insulin measurements.
Chapter 12
Conclusions
It has been shown, in a range of clinical settings, that BG dysregulation is associated with increased
complications leading to increased morbidity and mortality. These irregularities may be due to
either the influence of stress hormones and external drugs in the critical care setting or a developed
resistance/impairment to glucose regulation as seen in type 2 diabetes. In both situations, safe and
effective external intervention to assist in regulating BG levels has shown benefit. A method that
has proven effective in the ICU is the STAR model-based GC protocol. Therefore, this type of
model-based GC may prove effective for out-patients with type 2 diabetes.
The ICU GC protocol STAR is unique in the respect that it is a tablet-based protocol that uses a
combination of population-based stochastic models and MPC to provide safe and effective risk-based
GC. STAR is developed for the ICU setting, and more specifically the model used, the ICING model,
is developed based on ICU patient characteristics. Thus, for a version of the STAR GC protocol to
be used in an out-patient setting the model and GC methodology need to be adapted.
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The aim of this research was to develop the STAR protocol and associated ICING model for better
suitability in out-patient GC. In-silico and clinical data sets were used to review and develop control
methodologies and technologies, and their impact on GC and outcomes. In addition, a clinical trial
was designed to better understand the metabolic behaviour of type 2 diabetes, to enable improved,
and safer control of this cohort. The main research areas and their rationale include:
Assessment of BG interpolation and resampling Improve approximations of intermediate
BG dynamics in sparse data sets and improve comparison of GC performance statistics,
particularly given the sparser out-patient data available.
Evaluation and simplification of STAR’s stochastic model Determine if patient SI variability
is generalisable across cohorts and if it can be approximated by mathematical functions to
simplify risk-based dosing.
Improving the representation of SI Create a more physiologically realistic representation
of SI that reduces the influence of erroneous BG measures.
Review STAR clinical data Determine GC performance, safety and workload of the STAR
protocol in use to assess its strengths and weakness for use with out-patients.
Assessment of STAR compliance Determine the validity of recorded STAR information
and where areas of compliance could be improved within the protocol, as compliance is a key
issue in protocol success.
Assessment of STAR feeding Determine if STAR GC influences a patient’s ability to
receive nutrition in an international context.
Investigation of simpler STAR nutrition protocols Determine if the same GC performance
and safety can be achieved with a lower workload nutrition protocol, thus also assessing how
much GC relies on nutrition control.
Development of the STOMP GC protocol Develop a MPCGC protocol which was more
clinically flexible, and used longer time frames for determining dose as might be seen in the
less acute scenarios.
Design of subcutaneous basal insulin support trial Create a trial to investigate the
idea of basal insulin support for type 2 diabetics and pre-diabetics.
201
Initial results of basal insulin support trial Present the initial results of the first patients
on the trial.
The method of interpolation used to estimate intermediate BG dynamics was investigated. Piece-wise
functions and B-spline basis functions (1st and 2nd order) were fitted to clinical BG measurements
and their ability to capture removed measurements assessed. Overall a linear piece-wise function
performed the best, providing an estimate of intermediate BG dynamics within measurement error.
Thus, linear interpolation should be used when approximations are required in modelling and
statistical analysis. In addition, the effect of resampling variably sparse BG measurements, common
to ICU GC protocols, on GC performance statistics was investigated. A significant difference in
key GC performance statistics was found when comparing raw to hourly and/or minutely resampled
interpolated BG measurements. Therefore, for fair comparison of a GC protocol’s performance,
minutely or hourly resampled linear interpolation of raw BG measurements should be performed.
Treatment options offered by STAR are very dependent on the 5th and 95th percentile SI bounds
defined in the stochastic model used. Therefore, the current stochastic model bounds were evaluated
in relation to the stochastic bounds of stochastic models made from 3 independent STAR cohorts
(Christchurch (New Zealand), Gyula (Hungary), Kuantan (Malaysia)). The SI variability seen in
both Gyula and Christchurch were well captured by the current STAR controller stochastic model,
with the SI variability being within the controllers current stochastic model bounds consistently
equal to or greater than 90% of the time. The SI variability in the Malaysia cohort was seen to be
much larger than the what was in the currently used STAR controller stochastic model, with the SI
variability being within the controllers current stochastic model bounds approximately 65% of the
time. However, this discrepancy is likely due to the large non-compliance of data entry in Malaysia
and a re-evaluation of the stochastic model is required once compliance is improved. In addition,
piece-wise polynomial approximations of the currently used stochastic models were investigated.
The GC performance and safety was compared with virtual trials on the STAR Christchurch cohort.
The piece-wise polynomials were shown to represent the currently used bounds well (All R2 values >
0.96) and provide approximately equal GC performance (% time in BG band 4.4-8.0 mmol/L, 87.9%
vs. 87.5%, P=0.67) and slightly improved safety, having 19 less cases of mild hypoglycaemia (BG <
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4.0 mmol/L). Overall, the piece-wise polynomial stochastic models provide a promising alternative
to the currently used stochastic model.
2nd order B-spline BFs were investigated as an alternative to the current non -physiologically
representative zeroth order B-spline (KW = 60) BFs used for SI identification in the ICING model.
Various KW 2nd order B-spline BFs were investigated and compared to the current zeroth order
B-spline BF. The BFs were compared in terms physiological relevance, identifiability, robustness
to erroneous measurements, and susceptibility to noise. The 180 minute KW 2nd order B-spline
BF provided the most physiologically realistic fit to the BG measurements, in both the benchmark
cohort and STAR sub-cohort, having very similar fitting error variances to that of the respective BG
meter used, whilst showing significantly less susceptibility to erroneous BG measurements. However,
the ability for this technique to be directly employed in GC needs further investigation before direct
use in the clinical setting.
Clinical data from STAR in Christchurch Hospital ICU, NZ and Kálmán Pándy Hospital ICU, Gyula,
Hungary since 2011 was reviewed in terms of GC performance, safety, and generalizability, using
the linear interpolation and hourly resampling of BG measures for fair comparison, as investigated
earlier. Results of STAR’s predecessor, SPRINT, were presented for comparison. Patients on the
STAR protocol, in both Christchurch and Gyula, spent over 86% of time on protocol within the
targeted 4.4-8.0 mmol/L BG band, with very few occurrences of severe or moderate hypoglycaemia
(patients with BG < 2.22 mmol/L, 4/292 Christchurch, and 2/47 Gyula). Thus, showing how the
model-based and personalized approach to GC can provide safe and effective GC across differing
clinical practices. In addition, in Christchurch STAR outperformed SPRINT by providing higher
nutrition, and safe, effective control for all days of stay, while reducing time on protocol and workload,
and improving patient safety.
The compliance of the STARGC protocol in terms of data entry and following STAR’s recommendations
was investigated. The information recorded by the STAR tablet was compared to bedside sheet
information and STAR’s recommendations. Data entry and recommendation compliance were both
very high, with all intervention having over 86% data entry compliance and approximately 100%
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recommendation compliance. In both the data entry and and recommendation compliance, the
nutrition interventions (EN and PN) compliance was consistently lower than other interventions.
This gap is likely due to either to the difficulty associated with changing the feed rate or clinical
circumstances changing the feed rate and STAR not being updated. This analysis supports the
argument that STAR is a safe and effective GC protocol which clinical staff trust, and is flexible
enough for the clinical environment to allow for very high compliance. However, it also shows that
there is still room for improvement in terms of the way in which nutrition interventions are handled.
The STAR GC protocol clinical provision of nutrition to hyperglycaemic patients was compared to
the nutrition rates of entire ICU cohorts surveyed in 158 ICUs in Cahill et al. [263]. Mean nutrition
rates clinically achieved by the STAR nutrition protocol were significantly higher than the mean
and best ICU surveyed, for the first 3 days of ICU stay. Overall, STAR’s protocol-driven changes
in nutrition rate provide on average nutrition rates for hyperglycaemic patients which are equal to,
or better than, the mean of all ICU patients in 158 ICUs from 20 different countries. In addition,
the inter- and intra- patient variation of nutritional delivery was assessed in the STAR cohort.
Median intra-patient variation was 12.9%, however the IQR of the mean per-patient nutrition rates
achieved was 74.3% - 98.2%, suggesting patients do not deviate much from their mean patient-specific
nutrition rate and the ability to tolerate glucose intake varies significantly between, rather than
within, patients. Therefore, a best nutrition rate is likely patient-specific for patients requiring GC.
Furthermore, the relationship between mean nutrition rate achieved and morbidity, and mortality
was investigated. The nutrition rates delivered by STAR showed no association between nutrition
delivery to hyperglycaemic patients and morbidity or mortality. However, this analysis was significantly
underpowered to asses this relationship. Therefore, it can be inferred the slightly poorer nutrition
intervention compliance shown previously should not be the result of STAR feeding too low, but
rather the frequency of feed changes.
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STAR uniquely maintains normo-glycaemia by changing both insulin and nutrition interventions,
and has been proven effective in controlling BG in the ICU. However, most ICU GC protocols
only change insulin interventions, making the variable nutrition aspect of STAR less clinically
desirable. Three alternative, simpler and lower-workload nutrition protocols were investigated
using clinically evaluated virtual trials. The SLQ stepped nutrition protocol considerably reduced
workload, improved GC safety, almost halving the number of severe hypoglycaemic cases, while still
providing nutrition delivery near equal to the best ICU in an international context. Overall, the
SLQ stepped nutrition protocol was the best alternative to the current variable nutrition protocol,
reducing workload and making STAR more clinically acceptable. However, a clinical trial should be
undertaken to confirm the results of this study.
An MPC GC protocol was developed and optimised for GC in the adult ICU, and potential
future use in the out-patient setting, using virtual trials. The STOMP protocol was designed as a
model-predictive evolution of STAR, permitting the controller response to be easily tuned to specific,
clinically relevant, performance metrics. It has the additional benefit of formalising the heuristic
control algorithm of STAR, and providing a much more generalisable approach. The results indicate
STOMP retains the performance and safety of STAR, spending approximately 87% of time in the
4.4-8.0 mmol/L BG band and 0.06% of time BG < 2.2 mmol/L, while considerably reducing clinical
workload, requiring 35% fewer BG measurements. The GC performance and reduced workload of
STOMP can be largely attributed to the 6-hour prediction horizon used, giving the controller better
foresight into the interventions given. Overall, the STOMP protocol is a promising to development to
the STAR protocol, enabling easy customization to a more diverse range of clinical practice cultures,
cohort-specific approaches, and patient-specific conditions. However, a clinical pilot trial should be
undertaken to confirm the results of this study.
Previous literature has highlighted the potential benefits for early basal insulin therapy as an
preventative treatment for individuals with type 2 diabetes. In particular, in regard to preservation
of endogenous insulin secretion and improved GC. However, limited literature exists around whether
or not basal insulin therapy supports or suppresses endogenous insulin secretion. Therefore, a clinical
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trial was designed which aims to gather data to investigate the affect of basal insulin therapy on
endogenous insulin secretion, and develop a model to help us better understand and eventually
safely, and effectively control the type 2 diabetes out-patient cohort. If the data from this trial
shows basal insulin therapy to be a potentially viable preventative treatment for type 2 diabetes,
it could provide a relatively safe and effective way of reducing/stopping the progression of type 2
diabetes.
An observational subcutaneous insulin trial was designed to investigate the idea of insulin being
used as an initial treatment option for type 2 diabetic out-patients. The initial results and raw data
analysis of the first two patients show no major concerns of patient discomfort and safety occurred.
Issues around nurse workload were identified in the first trial patient, which resulted in the need
for external research nurses in future patients. The measurement timing appears to capture the
patient’s meal response, peak and postprandial decay, well through out the day. Measurements
were sometimes missed due to issues with blood draw from the peripheral IV line. This was a issue
common to both patients and may have resulted in increased occurrence of haemolysis in the second
patient, reducing the reliability of plasma insulin measurements. A solution to the complications
with peripheral IV lines should be considered for future patients.
Overall, the research performed was designed to develop the STAR protocol and associated ICING
model for GC of out-patients with pre-diabetes and type 2 diabetes. Interpolating sparse raw
BG measurements with linear interpolation allows for better interpretation of intermediate BG
dynamics, and thus identification of model-based SI , with minutely or hourly resampling providing
a fair assessment of GC performance statistics. The stochastic models used by STAR were shown
capture patient SI variability well, while being generalizable across independent cohorts, and can be
approximated with piece-wise polynomial functions. A physiologically more realistic representation
of the ICING model’s SI was created, improving the representation of BG measurements and
associated error. The developed representation of SI can more optimally interpolate sparse, variable
data and could be easily used with sparser out-patient data. STOMP, piece-wise polynomial
stochastic models, and a minimal workload stepped feeding protocol provides a simpler and made
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more clinically flexible alternative to the STAR GC protocol, while maintaining GC performance
and safety. Ultimately, STAR is better validated and incrementally simplified for the out-patient
setting. Finally, a clinical trial was designed and implemented to investigate basal insulin therapy for
out-patients with pre-diabetes or type 2 diabetes, and develop our understanding of the metabolic
characteristics of this cohort.
Chapter 13
Future Work
This thesis investigated many issues around the representation of SI , GC provided by STAR, and
understanding the type 2 diabetic out-patient. In many areas solutions were offered which improved
the representation or outcome. However, in some areas a solution was unable to be offered, but
areas of future improvement or development were revealed.
13.1 Stochastic model
The stochastic model was shown to represent the 1, 2, and 3, hourly changes in stepwise SI well.
However, the path of SI to reach its final predicted SI value is not considered. Creating a stochastic
model which provides a 5th and 95th percentile SI future path in time may allow for better forward
prediction of a patient’s BG dynamics. This type of stochastic model could be easily implemented
into the current STOMP control framework. In addition, an investigation into where individual
patient’s lie within the stochastic model may allow for an adaptive stochastic model to be developed.
One which dynamically changes it’s stochastic bounds if patients lie within the same region as they
become metabolically stable, and allowing for tighter GC to be provided.
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Future work should also examine the maximum SI value which causes the STAR controller to offer
the same treatment option regardless of state. This value should be used to define the upper bounds
of the stochastic model used by STAR. Note, physiological limits cannot be used in this instance,
due to SI being mathematically identified.
The creation of wide continuous B-spline basis functions poses an issue for real time identification
of SI . As the current SI value can change depending on the future BG measurements, the currently
used stochastic model cannot be used. Instead, a method needs to be developed which considers a
proportion of past SI values to predict the future SI value or path, minimising the impact of the
current SI value changing. Additionally, creating a stochastic model which considers the past SI
path and the most likely future SI path may again allow for better for prediction of a patient’s BG
dynamics.
13.2 Clinical GC
As the feeding of patients appeared to be major concern of clinical staff, a helpful addition to the
STAR graphical user interface (GUI) may be a display of total calories and the percentage of caloric
goal achieved from all sources, enteral and parenteral, over the last 12-24 hours. This would give the
clinical staff a better indication of a patient’s caloric requirements and what has been achieved, given
clinical feed stoppages and gastric residuals. In addition, the STAR variable feed regime should be
allowed to increase up to 120% goal feed to account for caloric losses during clinical feed stoppages,
as currently implemented in STOMP.
A stepped feeding protocol by day showed promising results in virtual trials. However, a clinical
trial comparing the variable and stepped feeding regime should be carried out to confirm the GC
performance, safety and workload associated with this type of feeding regime. In addition, the clinical
opinion of this type of feeding regime should be assessed to ensure effective clinical implementation.
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STOMP was shown to provide very similar GC safety and performance in virtual trials, and
potentially allowing 4 hour measurement intervals. A clinical trial evaluating the STOMP controller
should be carried out to confirm the results of the virtual trial and determine if 4 hour measurement
intervals can be offered. In addition, the cost functions used by STOMP should be integrated into
the GUI of the tablet, visually showing clinician’s the relative importance of each aspect considered
in control.
Another aspect that became apparent through consultation with clinical staff, was the lack of
understanding of how STAR worked and why it is important to control BG levels. This may
considerably contribute to compliance of STAR when first implemented in new units or used by
new clinical staff, where ’trust’ of the protocol is still in development, as seen in Malaysia. A useful
resource for current and future clinical implementations may be a series of short (approximately 2
minutes) and simple training videos explaining the concepts of STAR and GC in layman’s terms.
Subtitles would aid translation into any language. The ability for these videos to be accessed directly
from the STAR tablet application will allow for very easy nurse training, and help improve clinical
implementation to a foreign clinical practice.
13.3 Type 2 diabetes ward GC
The clinical trial currently under way should be continued until 10 patients have completely finished
the trial. From the clinical data an effective insulin-glucose model should be able to be developed for
this specific out-patient type 2 diabetic or pre-diabetic cohort. From my observations, there appears
to be a difference of endogenous insulin secretion on and off insulin in the ICU cohort, therefore a
robust model of endogenous insulin secretion off insulin should be developed for both the ICU and
out-patient setting. Moreover, the ICU endogenous insulin secretion model should also consider the
suppression of endogenous insulin secretion from exogenous insulin. From these models the question
around basal insulin support for pre-diabetic individuals should be able to be answered.
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From the trial data collected, a robust model of gut dynamics should be investigated. The influence
of macro nutrients on glucose appearance dynamics should be validated and compared to that seen
in the ICU. Ultimately, a predicted glucose response to a given meal should be developed to better
equip GC protocols for dosing around previous and future meals.
If basal insulin support improves an individual’s ability to control BG levels, a larger clinical trial
should be undertaken which evaluates GC performance and safety of this treatment more robustly.
In addition, a basal insulin dosing regime should be developed to be used in this trial, based on the
results and model developed from the initial trial.
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